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AA Arachidonic acid
ATP Adenosine triphosphate
cAMP Cyclic adenosine monophosphate
sn-1,2-DAG - sn-l,2-diacylglycerol 
DMSO dimethylsulphoxide
EGTA ethylene glycol bis (p-amino ethyl ether) tetraacetic acid
GDPpS guanosine 5'-(2-0-thio)diphosphate
GPC glycerophosphatidylcholine
GPI glycerophosphatidylinositol
GTPyS guanosine 5'-(3-0-thio) triphosphate
Hepes 4-(2-hydroxyethyl)-l-piperazine ethanesulphonic acid
HETE hydroxyeicosatetraenoic acid
HPETE hydroperoxyeicosatetraenoic acid
InsPi inositol monophosphate
InsP2 inositol bisphosphate
InsP3 inositol trisphosphate
LTB4 leukotriene B4
LTC leukotriene C
LTD leukotriene D
LTE leukotriene E
LysoPtdCho lysophosphatidylcholine
LysoPtdEtn lysophosphatidylethanolamine
LysoPtdlns lysophosphatidylinositol
LysoPtdOH lysophosphatidic acid
PDBu phorbol dibutyrate
PGBi prostaglandin Bi
PGD2 prostaglandin D2
PGE2 prostaglandin E2
PGF2a prostaglandin F2a
6-K -P G F ia 6-Keto-prostaglandin Fia
PKC protein kinase C
p l a 2 phospholipase A2
PLC phospholipase C
PLD phospholipase D
PMA phorbol 12-myristate 13-acetate
PtdCho phosphatidylcholine
PtdEtn phosphatidylethanolamine
Ptdlns phosphatidylinositol
PtdIns(4,5)P2 phosphatidylinositol(4,5)bisphosphate
PtdOH phosphatidic acid
PtdSer phosphatidylserine
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SUMMARY
A variety of agonists that stimulate inositol phospholipid turnover also 
activate phospholipase A2 (PLA2). This study examines the possibility that 
bombesin, a well-characterised calcium-mobilising peptide mitogen, may fulfil this 
criterion. The profile of arachidonic acid (A A) release, as well as the regulatory 
mechanism(s) behind bombesin-stimulated PLA2 activity, were examined. It was 
found that the AA released upon bombesin stimulation, was composed of two 
phases -  an initial transient phase that is essentially independent of extracellular 
calcium and of PKC activation and a later, sustained phase that is absolutely 
dependent on extracellular calcium and shows a requirement for PKC activation. 
This study focusses on the first of these phases and the regulatory mechanism 
involved in release.
In earlier works it was considered that agonist-induced PLA2 activation was 
simply the consequence of activation of phosphoinositide-hydrolysing PLC i.e. a 
combined effect of calcium mobilisation and PKC activation. More recently, 
arguments have been presented against this notion and work presented in this study 
strongly suggests that the calcium-mobilising peptide bombesin activates a 
phosphatidylcholine-specific PLA2 via a G protein-coupled mechanism that is 
parallel to, but independent of, activation of phosphoinositide-hydrolysing PLC.
The AA released via this pathway was not substantially metabolised via 
either cyclooxygenase or lipoxygenase enzymes. This raised the possibility that 
the fatty acid itself might have an intracellular role. Within this context, the effect 
of exogenously added AA on a short-term response (intracellular calcium 
mobilisation) and a long-term response (DNA synthesis) was studied. The fatty 
acid appeared to enhance both types of response in this system. The possibility 
that AA may be a second messenger within these cells must therefore be 
considered. In this case, at least three main ‘second messengers’ would be 
generated during interaction of bombesin with its receptor, namely inositol (1,4,5) 
trisphosphate, sn-l,2-diacylglycerol and arachidonic acid.
CHAPTER 1 
INTRODUCTION
21 .1  REGULATION OF THE CELL CYCLE
The growth and division of a single cell into daughter cells comprises the 
basic events that constitute the cell cycle. Most animal cells in vivo exist in a non­
proliferating or quiescent state but have the capacity to respond to extracellular signals 
such as growth factors, hormones and neurotransmitters by re-entering the cycle and 
increasing their rate of proliferation (Draetta . 1990,Lewin , 1991)
Most of the work involved in preparing for division occurs during the growth 
phase of the cell cycle which is termed interphase. This occurs after M phase which 
consists of mitosis and cytokinesis. Interphase starts with the Gi phase in which the 
cells, whose biosynthetic activities have been greatly slowed during mitosis, resume a 
high rate of biosynthesis. This S phase begins when DNA synthesis starts and ends 
when the DNA content of the nucleus has doubled and the chromosomes have 
replicated. The cell then enters the G2 phase, which ends when mitosis starts. Cell 
cycle times vary widely in higher eukaryotic cells, with most of the variability being 
in the length of Gi. This may be due to Gi consisting of a series of subphases 
(Pardee, 1989), starting either from G0 non-proliferating state or from the previous 
cell cycle. Cells in vivo can remain healthy for very long periods in the quiescent 
state (G0). Cells in culture can also be made to enter a quiescent state. Fibroblasts 
in culture move out of cycle and into G0 within lh after being placed in suboptimal 
conditions such as in a low serum-containing medium. These cells can be stimulated 
to re-enter the cycle during Gi by adding back serum or defined growth factors to the 
medium (Campisi et al., 1984). It is clear that the cell cycle must be finely regulated. 
The parent cell must pace its division to occur exactly when its mass has doubled. 
Cells must also coordinate events in the cycle. Regulation may occur at two different 
levels -  intracellular and extracellular.
Physiological control of growth initiation is external; it is created by other 
cells as required in a multicellular organism. External controls switch the 
intracellular machinery between G0 and Gi, leading to DNA synthesis and cell
3division. Once the commitment to DNA synthesis has occurred, the subsequent 
events are regulated intrinsically by the cell itself (Pledger et al., 1978). Defined 
mitogens include polypeptide growth factors, hormones and various pharmacological 
agents. These all bind to specific, high affinity receptors, which upon occupancy, 
promote the generation of early signals in the membrane and cytosol which are 
propagated into the nucleus. These early events precede various molecular and 
cellular responses which all lead to a common final pathway of DNA synthesis and 
cell division.
Quiescent cultures of the Swiss 3T3 cells line (Todaro & Green, 1963) have 
provided a useful model system for studies on growth control. Studies conducted 
with combinations of defined growth-promoting molecules have revealed the 
existence of striking synergistic interactions (Rozengurt, 1982). Tumour cell lines, 
which are significantly less dependent on external growth factors and peptides for 
proliferation, often produce growth factors themselves which may act in an autocrine 
manner. A link between production of certain growth-promoting molecules and the 
expression of transformation is well illustrated in the homology between the amino 
acid sequence of the p chain of PDGF and the transforming protein of the simian 
sarcoma virus encoded by the sis oncogene (Doolittle et al., 1983). It therefore 
seems likely that the signals elicited by peptides and growth factors may play a critical 
role in modulating normal and abnormal cell proliferation.
Internal regulation of the cell cycle was initially thought to depend on the 
activity of a protein termed 'maturation promoting factor' (MPF) (Murray & 
Kirschner, 1991). However, other studies conducted by Nurse (1990) on the 
activation of cell division cycle (cdc) genes, showed that one of the key proteins 
regulating cell cycle events is a serine/threonine protein kinase, the cdc2+ gene 
product p34cdc2. This is thought to phosphorylate proteins involved in the control of 
the major events of M phase. The kinase is itself regulated by phosphorylation/
4dephosphorylation reactions with pSO0^ 25, the product of the cdc25+ gene involved 
in activation. It is not entirely clear how the M phase control mechanism is coupled 
to other mechanisms measuring time, cell mass and growth rate, but the requirements 
for several signals may explain why there are a number of different elements involved 
in the mechanism.
1 .2  EARLY MITOGEN-STIMULATED EVENTS IN
QUIESCENT CELLS
1 .2 .1  Ion fluxes
Changes in intracellular ion composition are prominent following cellular 
activation by mitogens. These provide a useful tool for distinguishing responses to 
different types of mitogen.
(a) Changes in intracellular calcium
One of the earliest responses elicited by addition of the mitogens bombesin 
(Hesketh et al., 1985), PDGF (Frantz, 1985) and vasopressin (Nanberg &
Rozengurt, 1988) to quiescent 3T3 cells is mobilisation of Ca^+ from intracellular 
stores. The addition of these mitogens causes a transient rise in cytosolic Ca^+ 
concentration, increases Ca^+ efflux from cells and decreases the total Ca^+ content 
of the cell. A transient acidification also occurs as a result of the initial rise in Ca^+. 
This may result from action of a Ca^+/H+ antiport system involved in re-uptake of 
Ca^+ into intracellular stores (Ives & Daniel, 1987). The mobilisation of 
intracellular Ca^+ has been proposed to be mediated by Ins(l,4,5)P3 which is a 
second messenger in the action of many ligands that induce receptor-mediated 
inositol lipid turnover and calcium mobilisation (Berridge & Irvine, 1984).
A more sustained phase of Ca2+ release may occur later in response to agonist 
stimulation and rather than being dependent on the calcium content of intracellular 
stores, may be dependent on receptor-triggered calcium influx (Meldolesi et al.,
1991). This influx of calcium is physiologically important in a wide range of 
intracellular events. In many secretory cells, exocytosis induced by receptor
5activation has been found to depend on influx and to be eliminated when this is 
blocked ((Stauderman et al., 1990). Other signalling events, such as activation of 
intracellular phospholipases, are largely calcium dependent. In some systems, the 
generation of AA via PLA2 activation may be the consequence of the prolonged 
influx-sustained increases of intracellular calcium rather than of the initial spike 
(Brooks et al., 1989). Calcium influx is also important in cell growth. An increase 
in calcium via Ins(l,4,5)P3 and Ins(l,3,4,5)P4 is obligatory for normal progression 
to DNA synthesis after egg-fertilisation (Irvine & Moor, 1986). Calcium is centrally 
involved in mitosis itself, where it is essential for the disassembly process of the 
spindle fibres that occurs during anaphase.
The cell proliferation response induced by EGF is severely curtailed when 
calcium influx is inhibited by imidazole derivatives (Magni et al., 1991). In addition, 
bombesin-induced mitogenesis in Swiss 3T3 cells is strictly dependent on medium 
calcium concentration. This may be partly due to the involvement of calmodulin. 
Chafouleas et al. (1982) have shown that cellular calmodulin content increases about 
2-fold at late Gi and/or early S phase of the cell cycle. It has also been reported that 
a calmodulin antagonist (Hidaka et al., 1981) or expression of calmodulin anti-sense 
RNA (Rasmussen & Means, 1989) potently inhibits cell proliferation. The 
intracellular calcium concentration is therefore a vitally important regulatory factor 
during the events of the cell cycle.
(b) Cytosolic pH changes
Stimulation of Na+ influx and a rise in cytosolic pH of about 0.2 units 
represent an almost universal response that precedes metabolic activation of quiescent 
cells (Pouyssegur et al., 1985; Grinstein et al., 1989). Mitogenic agents such as 
purified growth factors (Moolenaar et al., 1983), peptides (Hesketh et al., 1988) and 
serum (Schuldiner & Rozengurt, 1982) have all been shown to cause a rapid rise in 
intracellular pH occurring within a few minutes. This alkalinisation results largely 
from activation of a membrane-bound amiloride sensitive Na+/H+ antiporter.
6Activation may occur via a phosphorylation of the protein by protein kinase C (PKC) 
(Vara & Rozengurt, 1985). Schuldiner and Rozengurt (1982) showed that 
incubation of quiescent 3T3 cells with PDGF, vasopressin and insulin increased the 
cellular pH by 0.16 pH units as measured from the uptake of weak acids. The ability 
of these mitogens to cause cytoplasmic alkalinisation suggested that the activation of 
Na+/H+ exchange was a primary effect of the mitogens rather than a secondary 
mechanism for the extrusion of protons resulting from a growth factor induced 
acceleration of cellular metabolism. Prevention of mitogen-stimulated Na+ influx 
and pH rise in a fibroblast mutant lacking Na+/H+ antiport activity (Pouyssegur et al., 
1984) suppressed growth factor induced DNA synthesis at neutral and acidic external 
pHs. More detailed studies have demonstrated that the increased intracellular pH is 
required throughout the Gq/Gi period preceding DNA synthesis. When cells have 
reached the restriction point, they can enter and progress into S phase at a much lower 
pH (Pouyssegur et a l , 1985). Mitogen-stimulated Na+/H+ antiport activity is 
therefore critical in regulating the rate of cell progression from Gq/Gi to S phase. In 
the study by Hesketh et a l  (1988), both calcium and pH responses to mitogens in 
single 3T3 fibroblasts were examined. Although both changes were found necessary 
for progression to DNA synthesis, they were not solely sufficient to commit cells to S 
phase. Elevation of intracellular pH in human fibroblasts in the absence of growth 
factors had little effect on DNA synthesis and an increase in thymidine incorporation 
was only in the presence of serum (Moolenaar et a l , 1986).
In certain cell types, e.g. T lymphocytes, inhibition of Na+/H+ exchange and 
prevention of cytoplasmic alkalinisation by amiloride analogues did not prevent 
mitogen-stimulated DNA synthesis or c-fos expression (Grinstein et a l , 1989).
This may indicate that intracellular pH may be regulated differently in these cells.
The common underlying mechanism between cell types is likely to be an increase in 
the intracellular Na+ concentration and not an alkalinisation. Some controversy 
surrounds the importance of the Na-/H4' antiporter in cell proliferation. It is almost
7always stimulated early in the mitogenic response and may regulate some of the 
reactions that lead to proliferation. However, the involvement of other regulatory 
factors in this process is certainly evident and the importance attached to different 
signals may vary between cell types.
1 . 2 . 2  Protein phosphorylation
Another series of early events that occur in mitogen-stimulated cells during 
the pre-replicative phase of the cell cycle involve the regulation of various protein 
functions through phosphorylation/dephosphorylation reactions. There are a number 
of protein kinases and phosphatases important in signal transmission. Initial 
phosphorylations are often on tyrosine residues as with the autophosphorylation by 
the EGF receptor’s intracellular tyrosine kinase (Yarden & Ullrich, 198S), but 
subsequent phosphorylations are mainly on serine and threonine residues as seen 
with PKC (Kikkawa et al., 1989). PKC plays a pivotal role in signal transmission 
and has a large number of targets, most of which are yet to be determined. One 
important target is the Na+/H+ antiporter, mentioned in 1.2.1. Others may include 
the Ca2+-transport ATPase and the Na+/Ca2+ exchange protein, both of which 
remove calcium from the cytosol (Nishizuka, 1986). PKC also causes inhibition of 
receptor-mediated hydrolysis of inositol phospholipids. Such a negative feedback 
role of PKC may also be extended to long-term responses such as cellular 
proliferation. The EGF receptor can be phosphorylated by PKC, resulting in a rapid 
decrease in high affinity binding of EGF as well as inhibition of ligand-induced 
tyrosine phosphorylation (Schlessinger, 1986). Long-term phorbol myristate acetate 
(PMA) pre-treatment, which causes PKC depletion, relieves the cell from receptor 
down-regulation and may provide useful information regarding the role of PKC in 
the mitogenic action of an agonist. PKC also exhibits a positive forward action.
The kinase may be involved in gene expression, such as induction of the IL2 receptor 
and some proto oncogene activation (Nishizuka, 1986). Studies on fibroblasts 
overproducing PKC suggest a positive action in growth regulation. Overexpression
8of the pi form of PKC leads to increased growth and colony formation in the 
presence of PMA (Housey et al., 1988). This is probably due to increased 
phosphorylation of critical cellular proteins involved in the control of cellular growth 
and morphology. These results suggest that disturbances in the control of PKC 
down-regulation could accentuate the action of tumour promoters and thus potentiate 
the carcinogenic process.
Another kinase that is activated in response to a variety of ligands is the 
protein product of the c-raf-1 gene (the cellular homologue of v-raf, the 
transforming gene of the murine sarcome virus 3611 (Rapp et al., 1988)), designated 
Raf-1 which has intrinsic kinase activity toward serine and threonine residues.
Stimulation of fibroblasts with PDGF, EGF, FGF and PMA causes
hvoerphosphorylation of Raf-1 itself and activation of the protein (Blackshear et al. 1990).
Whether this is a
direct receptor-mediated activation via tyrosine phosphorylation remains uncertain 
and further understanding will require mutational analysis of the phosphorylation 
sites (Ping et al., 1991). It is also unknown whether Raf-1 has a central or 
peripheral role in the signal transduction process. It certainly plays a significant role 
in signalling pathways emanating from the tyrosine kinase class of receptors and 
since Raf-1 can be indirectly activated by PMA, it may also be involved in signalling 
pathways from non-tyrosine kinase receptors. One of the functions of Raf-1 may 
be the integration of signals from a variety of sources. More specifically, it is known 
that constitutively activated forms of Raf-1 can induce transcription of growth factor- 
regulated early response genes including c-fos and (3-actin genes (Siegfried & Ziff,
1990). ‘thus the ultimate role of Raf-1 may be to carry signals to specific 
transcription factors.
During early Gi phase of the cell cycle, the multiple phosphorylation of the 
40S ribosomal protein, S6 has been suggested to facilitate the initiation of protein 
synthesis (Martin-Perez et al., 1984). The S6 kinases that promote this 
phosphorylation have been identified as two groups -the 90kd and 70kd kinases
9(Sturgill & Wu, 1991) which appear to be under separate regulation. The 90kd S6 
kinases are phosphorylated in vitro by p42maPK -  a MAP kinase. MAP kinases 
(mitogen activated protein kinases) are activated by a diverse array of mitogenic 
agents via threonine and tyrosine phosphorylations and have been shown to have 
several correlations with p34cdc2. MAP kinases have been suggested to exert control 
over the G0 to Gi transition, just as p34cdc2 functions at Gi to S phase and G2 to M 
phase transitions. Their importance in mitogenesis has been demonstrated in cells 
defective in MAP kinase activation which show defective mitogenesis (L'Allemain et 
al., 1991). No kinases capable of phosphorylation and activation of the 70kd S6 
kinases have yet been identified, although possibilities include Raf-1 and the 90kd S6 
kinase (Sturgill & Wu, 1991).
The cell cycle protein p34cdc2 is also a kinase that is regulated by 
phosphorylation/dephosphorylation as previously discussed (see Section 1.1). 
Phosphorylation of the cyclin B-p34cdc2 complex causes activation and starts the 
events such as chromosome condensation, nuclear membrane breakdown and 
reorganisation of the microtubule network that characterise mitosis.
The clear importance of phosphorylation/dephosphorylation reactions in cell 
cycle regulation is demonstrated by their involvement throughout various stages.
The regulation of the kinases and phosphatases responsible depends on the activation 
of the signal transduction pathways associated with receptor activation.
1 . 2 . 3  Gene transcription
Abnormal expression of a variety of normal cellular genes (proto-oncogenes) 
can transform a normal cell into a tumour cell. Several of these genes encode protein 
products which are homologous to either a growth factor or a growth factor receptor. 
For example, the sis oncogene of the simian sarcoma virus shows striking homology 
with the (3-chain of PDGF (Waterfield, 1983). Part of the sequence of the EGF 
receptor is almost identical to another oncogene, erb-B, carried by avian 
erythroblastosis virus (Downward, 1984). Several virally encoded transforming
10
proteins have normal cellular homologues that function in cell cycle regulation, 
suggesting that in general, proto-oncogenes might be involved in cell cycle control 
(Greenberg & Ziff, 1984). The c-one genes, especially those encoding nuclear 
antigens, are differentially regulated at the transcriptional level, during cell cycle 
progression.
Stimulation of BALB/c-3T3 cells with defined mitogens induces a rapid, 
transient increase in transcription of c-fos, a nuclear protein, whose function, until 
recently, remained unknown (Greenberg & Ziff, 19S4-). This is followed by a 
more protracted elevation of c-myc gene expression. The increase in c-fos levels 
occurs as 3T3 cells progress from G0 to Gi before S phase. In similar conditions, 
many other c-one genes including c-ki-ras and c-abl show barely detectable levels of 
transcription. An early response gene such as c-fos, whose deregulation can result 
in cell transformation, may be a gene that directly controls normal cell growth. The 
expression of c-fos throughout the cell cycle rather than during a specific stage, may 
be one mechanism of transformation.
It has been reported that expression of the c-myc gene introduced into 3T3 
cells by gene transfer, partly substitutes for PDGF and stimulates DNA synthesis in 
the presence of EGF and platelet-poor plasma (Armelin et al., 19 .). This strongly
suggests that the c-myc gene may play a role of crucial importance in rendering cells 
competent for DNA synthesis.
Bombesin-stimulated induction of c-fos and c-myc has been suggested to 
depend on an increase in intracellular calcium and in PKC activation (Rozengurt & 
Sinnett-Smith, 1987). However, EGF may not depend on PtdIns(4,5)P2 
breakdown or activation of PKC to induce c-fos or c-myc expression (McCaffray et 
al., 1987). This illustrates the fact that gene expression may be activated through 
various pathways.
Another of the genes that is rapidly expressed in response to mitogenic 
stimulation is jun-B. This has been shown to encode a protein related to the human
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transcription factor, AP-1, the product of the protooncogene c-jun. It is now 
known that fos  binds to the AP-1 consensus recognition sequence and this suggests 
there is some connection between fo s ju n  and AP-1. It is possible that fos and juti 
may constitute a class of ligands that interact with genomic receptors containing the 
AP-1 site, thereby modulating gene transcription. As such, they may comprise a 
primordial signalling system adopted for use by selected target genes in different cell 
types (Curran & Franza, 1988).
1 .3  SIGNAL TRANSDUCTION PATHWAYS IMPLICATED IN 
THE CONTROL OF CELLULAR PROLIFERATION
The flow of information upon cell stimulation by a ligand can be traced 
through a cascade of regulatory reactions that involve a number of specific enzymes, 
regulatory proteins and other regulatory factors. Comparison between these 
regulatory cascades reveals a highly sophisticated design underlying the signal 
transduction systems.
Both the adenylyl cyclase and the phospholipase C-based signal cascades 
may be divided into three functional domains: the first, occurring at the plasma 
membrane, functions to convert the external stimulus into an intracellular message; 
the second, which is mainly cytosolic, is responsible for translating the intracellular 
message into regulatory activities; and the third domain contains the regulatory 
activities directed towards various cellular proteins to result in the appropriate cellular 
responses. The transducing factor in the first domain may take the form of a GTP- 
binding protein that couples the receptor to the transducing pathway (Gilman, 1984). 
This contributes to the rigorous control within the system. The minimal essential 
component in the second translatory domain is a second messenger activated protein. 
Upon binding of the second messenger, this protein becomes capable of modulating 
specific cellular responses. For both cAMP and DAG, regulatory activities are
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performed by multifunctional protein kinases, cAMP dependent protein kinase 
(Walsh et al., 1968) and PKC (Nishizuka, 1986).
The mechanisms responsible for terminating signal transduction are as 
important as those involved in activation. Starting from the membrane receptor, at 
least two mechanisms have been suggested that may terminate receptor function. 
Phosphorylation by specific kinases may render the receptor insensitive to stimulation 
by its agonist, or internalisation via endocytosis may cause the same effect (Sibley et 
al., 1987). These mechanisms are the basis of the well-known phenomenon of 
desensitization.
For the coupling G proteins, it has been suggested that the mechanism of 
terminating the coupling activity is intrinsic to these proteins. G proteins are 
heterotrimers, consisting of an a, p and y subunit in its inactive state, a G protein 
contains bound GDP on its a subunit. The exchange of GDP for GTP is part of the 
activation process of the G proteins. Since the proteins also express GTPase activity 
intrinsic to the a  subunit, the active GTP-bound form is converted back to the 
inactive GDP-bound form by the GTPase reaction (Stryer & Bourne, 1986).
The disposal of excess second messengers is often achieved by enzymatic 
degradation. Thus cAMP and cGMP are hydrolysed by cyclic nucleotide 
phosphodiesterases, and IP3 and DAG may be degraded by IP3 phosphatase and 
DAG lipase respectively. DAG may also be cleared from the cell via DAG kinase. 
Examination of the regulation of the basic reactions of the signal cascades has 
revealed various potential means for intrasignal system fine-tuning and intersignal 
system cross-talk, suggesting that the various reactions involved in signal 
transduction form an interacting network.
1 .3 .1  Tyrosine kinase activity
Tyrosinephosphorylation is an important cell regulatory mechanism. The fact 
that many polypeptide growth factor receptors have an intrinsic tyrosine kinase 
activity and several protooncogene products are themselves tyrosine kinases lends
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strong support for a role of tyrosine phosphorylation in cell proliferation (Hunter & 
Cooper, 1985). The finding that the EGF receptor contains as an integral part of its 
structure, a tyrosine-specific protein kinase capable of autophosphorylation (Cohen et 
al., 1980) was followed by similar reports for insulin (Kasuga et al., 1982) and 
PDGF (Ek e ta l ,  1982).
The identification of endogenous tyrosine kinase substrates has recently 
received considerable attention. Studies have shown that the stimulation of PLCyl 
by growth factors may involve tyrosine phosphorylation of the enzyme (Rhee et al., 
1989). In addition, interest has focussed on pp42, a serine/threonine protein kinase 
(MAP kinase see earlier) whose activation leads to phosphorylation of the ribosomal 
protein, S6 (Sturgill & Wu, 1991). More recently, Leeb-Lundberg and Song (1991) 
have suggested that bradykinin and bombesin stimulate tyrosine phosphorylation of a 
120kd group of proteins in Swiss 3T3 cells. This is a PKC-independent signal and 
occurs rapidly (within 0.5min) after peptide stimulation. In contrast to EGF- 
promoted tyrosine phosphorylation, the peptide-promoted phosphorylation via 
cytosolic kinases probably depends on formation of a cellular ’second messenger' 
and may be related to inositol phosphate formation. It is highly likely that growth 
occurs as a result of interaction between the different signalling pathways.
1 .3 .2  Adenylyl cyclase
Another early signal that may be generated within cells in response to 
mitogenic stimulation is cAMP. This occurs via the stimulation of adenylyl cyclase 
activity by a specific G protein (Gs) linked to the receptor (Rozengurt et al., 1981). 
The effect of cAMP on proliferation has been controversial. In 3T3 cells increased 
levels of cAMP have been suggested to reduce the rate of growth and proliferation 
(Kram et al., 1973). However, another group (Rozengurt et al., 1981) has found 
cAMP will act synergistically with growth-promoting agents to stimulate DNA 
synthesis in quiescent cultures of 3T3 cells. In addition, Millar and Rozengurt
(1988) suggest that bombesin causes enhanced cAMP accumulation in Swiss 3T3
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cells. They propose that this may be one mechanism by which bombesin may affect 
mitogenesis. Contrary to this, it has been found that cAMP levels drop when 
quiescent cells are stimulated by mitogens (Otten et al., 1972).
In BALB-C-3T3 cells, raising cAMP levels has been shown to potentiate the 
acquisition of the competence state (O'Keefe & Pledger, 1983), but sustained 
elevation impedes progression into the rest of the pre-replication phase. In some 
3T3 cell lines which are quiescent in the presence of insulin, elevation of cAMP 
initiates the pre-replication development which continues until DNA synthesis 
(Rozengurt & Mendoza, 1985). In other systems such as bronchial epithelial cells, 
c AMP has a major role in the progression into the pre-replicative phase initiated by 
other factors (Willey et al., 1985). It has also been shown by Smets and Van Rooy 
(1987) that cholera toxin-treated 3T3 cells during the G0 to Gi transition, increased 
the fraction of cells responding to serum stimulation, whereas addition during late Gi 
inhibited the onset of DNA synthesis. Cholera toxin causes persistent activation of 
Gs. Thus, the major control points in the pre-replicative phase (initiation and 
progression) can be dependent on cAMP augmentation.
Such opposite effects of the cAMP cascade as mentioned may be explained in 
a number of ways. There may be variation in the optimal concentration of cAMP 
required (Pawelek, 1979). Alternatively, the effect may depend on the differentiation 
state of the cell. Positive and negative regulatory elements have been demonstrated 
in the promoters of cAMP responsive genes. The accessibility of these elements in 
the promoter of a growth related gene could depend on the differentiation state of the 
cell (Dumont et al, 1989). Another explanatory factor may be the existence of two 
isozymes of cAMP dependent protein kinase. Studies have demonstrated changes in 
their levels in a range of human cancer cell lines (Katsaros et al., 1987).
The isozymes differ in their R subunits (Hoffman et al., 1975) and since both 
isozymes have been detected in most cells, selective activation of the enzymes may be 
a function of cAMP in regulating mitosis. Katsaros et al. (1987) have suggested the
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involvement of the type II protein kinase in growth inhibition. A range of cAMP 
analogues were used to demonstrate inhibition of growth of human cancer cell lines. 
This inhibition appeared to be associated with an increase in the cellular levels of the 
RII subunit. Activation of this subunit by site selective analogues has also been 
shown to reverse the transformation of NIH-3T3 cells (Tagliaferri et al., 1988). 
Ridgeway et al. (1988) have also shown that treatment of Kirsten murine sarcoma 
virus transformed Balb/c-3T3 cells with dibutyryl cAMP inhibits the expression of 
transformation related properties such as anchorage independent: growth. This 
strongly implies that a decrease in cellular cAMP levels is associated with the loss of 
controlled proliferation. The importance of cAMP in the regulation of cellular 
proliferation is demonstrated by Vallar et al. (1987) in growth hormone secreting 
pituitary adenomas which exhibit altered Gs and increased adenylyl cyclase.
Recent studies involving mutational analysis have also proved useful in 
identifying the importance of cAMP. Landis et al. (1989) showed that constitutive 
production of cAMP, as a consequence of mutations in as, may contribute to the 
abnormal growth of certain pituitary tumours. More recently, Zachary et al. (1990) 
showed that replacement of glutamine-227 with leucine in the GTP-binding domain 
of as caused increased basal adenylate cyclase activity, cAMP accumulation and 
mitogenic sensitivity in response to forskolin. This supports a role for cAMP in the 
regulation of cell proliferation and suggests that alterations in the G protein can 
directly modify the ability of cells to respond mitogenically to extracellular factors.
1 .3 .3  Phosphoinositide-specific phospholipase C
One of the most widely studied signalling pathways that is activated upon 
mitogenic stimulation is that of phosphoinositide hydrolysis by PLC with the 
resultant second messengers, Ins(l,4,5)P3 and DAG (Berridge, 1987; Whitman & 
Cantley, 1988). The ’bifurcating signal' hypothesis of Berridge (1983) proposes 
that breakdown of phosphatidylinositol (4,5) bisphosphate activates two distinct 
signalling pathways: production of Ins(l,4,5)P3 triggers release of calcium from
16
intracellular stores (Streb et al., 1983), and release of DAG activates PKC 
(Nishizuka, 1986).
Activation of PLC is regulated by a specific G protein (Gp) coupled to the 
receptor. This protein is probably the Gq/Gn species. Taylor et al. (1991) have 
purified an a  subunit that stimulates partially purified PLC and report that this G 
protein specifically activates the pi isozyme, but not the yl and 81 isozymes of PLC. 
This G protein appears to be related to the Gq class of G protein a subunits. This 
observation has also been made by Smrcka et al. (1991).
The extremely rapid activation of PLC in response to agonists such as 
bombesin (Plevin et al., 1990), bradykinin (Slivka & Insel, 1987) and PDGF 
(Blakeley et al., 1989) has been suggested to be the initial signal required for 
activation of other enzymatic pathways such as PLA2 (Axelrod, 1990) and PLD 
(Cook et al., 1991). It is now recognised however, that this is not always true and 
that certainly for PLA2, an independent regulatory mechanism exists (see Section 
1.5). The PLC-stimulated hydrolysis of PtdIns(4,5)P2 is however, essential in 
mitogenesis and this is well demonstrated in experiments where microinjection of 
anti-PIP2 antibodies into NIH-3T3 cells abolished the stimulation of DNA synthesis 
in response to PDGF and bombesin (Matuoka et al., 1988). Both Ins(l,4,5)P3 and 
DAG play important roles in the regulation of proliferation.
1 .3 .1 .( i )  Inositol (1,4,5) trisphosphate
The production of more than 20 inositol phosphate isomers has been 
identified in agonist-stimulated cells (Majerus,d;a>»'?3g)lns(l,4,5)P3 induced calcium 
release occurs within seconds (Hesketh et al., 1985) of agonist addition. This has 
been shown to occur via an Ins(l,4,5)P3 receptor, localised to the endoplasmic 
reticulum (Ross et al., 1989). In addition to the rapid production of Ins(l,4,5)P3, 
induction of a whole cascade of kinases and phosphatases specific for inositol 
phosphates occurs. InsP3 kinase activation leads to Ins(l,3,4,5)P4 production 
which may also be involved in the promotion of calcium-mediated responses in
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several systems (Irvine & Moor, 1986). For long-term processes such as regulation 
of proliferation, changes in the entry of calcium into the cell may be just as important 
as the intracellular release, thereby requiring the involvement of multiple inositol 
phosphate isomers (Whitman & Cantley, 1988).
( ii)  sn-l,2 -d iacy lg lycero!
DAG, the other product of PLC-mediated PtdIns(4,5)P2 hydrolysis, unlike 
Ins(l,4,5)P3, remains associated with the plasma membrane and functions as an 
endogenous activator of PKC. Different isozymes of PKC appear to have different 
regulatory requirements: activation of a, p and y PKC by DAG appears to require 
calcium (Gschwendt et al., 1991) whereas 8 and £ that lack the calcium-binding 
region (Ono et a l, 1988) may be activated by DAG alone. There may even be, at 
least one, isozyme which does not require DAG for activation (Ono et al., 1989).
The importance of PKC has been discussed (see Section 1.2.2) and the existence of a 
variety of isozymes with different regulatory requirements may enhance the 
involvement of the enzyme in proliferation.
The generation of DAG in agonist-stimulated cells has, more recently, been 
shown to occur from alternative sources to PtdIns(4,5)P2. Phosphatidylcholine has 
been identified as a major alternative source (Muir & Murray 1987) which may 
contribute to the second phase of the biphasic DAG response in bombesin-stimulated 
Swiss 3T3 cells (Cook & Wakelam, 1989). This has been proposed to occur as a 
result of PLC- (Muir & Murray, 1987) or PLD- (Cook & Wakelam, 1989) 
stimulated hydrolysis of the phospholipid.
As well as serving as the endogenous activator of PKC, 1-stearoyl 2 - 
arachidonyl diacylglycerol can, when hydrolysed by diglyceride lipase, serve as a 
source of arachidonic acid (AA), although generation of this fatty acid is usually a 
result of PLA2 activation (Axelrod, 1990).
The importance of DAG in the stimulation of cell proliferation is demonstrated 
by the similar actions of tumour promoting phorbol esters (Castagna et al., 1982)
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which mimic the DAG activation of PKC by directly binding to the enzyme, although 
in a sustained manner. These have proved useful in the investigation of the role 
PKC plays in a variety of cellular processes.
1 .3 .4  Receptor mediated phospholipase D activation
Recent evidence has suggested the involvement of PLD in signal transduction 
(Cook et al., 1991; Thomson et al., 1991). The enzyme normally hydrolyses 
phosphatidylcholine producing free choline and phosphatidic acid. Receptor- 
coupled PLD activation was first demonstrated by Billah et al. (1989) in granulocytes
and since then has been observed in a number of cell types (Thomson et al., 1991).
(Martin, and Michaelis, 1989) 
PLD activity may be dependent on both calcium levels (Billah et al., 1989) and PKC
activity (Cook et al., 1991). This may suggest a link between PLD activation and
PIP2 hydrolysis by PLC. However, there are situations in which PLD activation
seems independent of prior PLC activity. In collagen-stimulated platelets (Randall et
al., 1990) and in EGF-stimulated 3T3 fibroblasts (Cook & Wakelam, 1992, in
press). In both situations PLD activation occurs in the absence of significant
PtdIns(4,5)P2 hydrolysis by PLC. It seems likely that PLD is under different
regulation between systems.(Liscovitch 1990,Thomson et al. 1991)
PLD activation gives rise to two potential second messengers, DAG and
phosphatidic acid (PtdOH). The PtdOH produced may be converted to DAG by
phosphatidic acid phosphohydrolase, leading to higher intracellular DAG levels. The
role of DAG generated from phosphatidylcholine is uncertain in terms of PKC
activation. It may activate some forms of PKC. Phosphatidic acid may act as a
mitogenic agent but this is also unclear. Recent observations (Bauldry et al., 1991)
suggest that PLD activity may be induced in virally transformed cells. This may
implicate PLD in the process of transformation. In general though, the main
functional role of PLD remains to be established.
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1 .3 .5  Receptor-mediated phospholipase A2 activation
Mitogenic stimulation of different cell types leads to activation of 
phospholipase A2. This enzyme was initially thought to be regulated by prior 
activation of the phosphoinositide-PLC pathway (Billah, 1987). However, it is now 
well established that in a number of systems, PLA2 may be independently regulated 
through a specific G protein (Ga) linked directly to the receptor (Axelrod et al.,
1988). Activation of PLA2 results in the hydrolysis of major phospholipids 
generating arachidonic acid and the corresponding lysophospholipid. This 
production of arachidonic acid is widely used as a means of measuring PLA2 
activation. Although AA can be formed via other enzymatic pathways, for example 
via DAG lipase, the PLA2 pathway forms, by far, the major route for formation.
AA can be further metabolised intracellularly via a series of enzymes, giving 
rise to prostaglandins, leukotrienes and epoxygenase products (Needleman et al.,
1986). These are discussed in Section 3.1.6. Both A A and its metabolites have 
been suggested to be of importance in mitogenesis. The production of AA in Swiss 
3T3 cells has been proposed to stimulate DNA synthesis in response to various 
ligands (Gil et al., 1991; Takuwa et al., 1991). In addition, the fatty acid has been 
suggested to have a second messenger type role and to release intracellular calcium 
(Wolf et a l, 1986; Chan & Turk, 1987; Chow & Jondal, 1990), induce calcium 
influx (Alonso et al,. 1990) and activate calcium extrusion (Randriamampita & 
Trautmann, 1990) in various cell types. It has also been suggested to activate PKC 
directly (in particular the y and a isoforms) in the absence of calcium (Murakami et 
al., 1985,1986; Shearman et al., 1991) and in a synergistic manner with DAG 
(Lester et al., 1991). Lysophospholipids, the other products of PLA2 hydrolysis 
have also been suggested to regulate PKC (Oishi et a l, 1988) both positively and 
negatively. It was suggested by Oishi et al. (1988) that since PLA2 may generate 
two different second messengers that directly activate PKC, one of which 
(lysoPtdCho) having an activation potency comparable to that of DAG, coupled with
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the high membrane content of PtdCho, it was conceivable that the lysoPtdCho/AA 
system could be at least as functionally important as the DAG system. This 
however, would only be true if the products of PLA2 hydrolysis were generated at a 
high enough concentration. The most potent lysophospholipid in the induction of 
cellular proliferation is lysophosptafidic acid (LPA). Van Corven et al. (1989) have 
shown the ability of LPA to activate three separate signalling cascades and ultimately 
stimulate DNA synthesis. The initial mechanism underlying the action of LPA is 
unknown. However, it is thought to involve, in NG108 cells, regulation of a 
phosphatase which will dephosphorylate certain proteins phosphorylated by tyrosine 
kinase. In NG108 cells, the activation of pp60src (Moolenaar et al., unpublished 
data) is thought to be regulated in this manner.
Activation of PLA2, along with PLC, may constitute one of the very early 
mitogenic signals in stimulated cells, leading to activation of various signalling 
pathways and ultimately cell proliferation. As such, the comprehension of how this 
enzyme is distributed and regulated is of substantial importance in understanding how 
a quiescent cell may enter Gi and become committed to DNA synthesis.
1 .4  PHOSPHOLIPASE Ax  -  A HISTORICAL PERSPECTIVE
PLA2 is a ubiquitous enzyme found in various forms both extracellularly and 
intracellularly. In the gastro-intestinal tract, PLA2 that has been secreted by the 
pancreas breaks down phospholipids for dietary absorption (Verheij et al., 1981). 
However, in other mammalian tissues, AA released by PLA2, serves as the common 
precursor to the leukotrienes and prostaglandins involved in inflammatory diseases 
(Dennis, 1987) and may itself have a messenger-type function.
1 .4 .1  Extracellular and secreted low molecular weight forms
PLA2S are undoubtedly involved in modulation of membrane composition and 
signal transduction and their regulation is key to many aspects of homeostasis. 
Secreted PLA2S have been shown to have a range of pharmacological and higher- 
order digestive actions (Davidson & Dennis, 1990). The vast majority of PLA2S that
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have been structurally characterised so far are extracellular, mainly isolated from the 
venoms of snakes. Snake venom glands are thought to have evolved from digestive 
glands, because of their location and morphology and their secretion of a great variety 
of lytic enzymes. Indeed, there is a high degree of similarity between mammalian 
pancreatic PLA2 and many venom PLA2S.
In general, mammalian extracellular PLA2S are of low molecular weight 
(approximately 14kd) and can be classified into two types, group I (PLA2-I) and 
group II (PLA2-II), based on their primary structures. Several studies have 
implicated the correlation of PLA2-II in the pathogenesis of inflammation (Murakami 
et al., 1990). Glycogen-induced peritonitis in rabbits was found to be associated 
with high levels of soluble PLA2 in peritoneal exudate fluid (Franson et al., 1988). A 
similar PLA2 was found in the ascitic fluid of rodents after intraperitoneal injection of 
casein or zymosan (Gans et al., 1989). PLA2 is vasoactive and proinflammatory. 
Intradermal injection of PLA2 induces sustained hyperemia (Vadas et al., 1981) and 
an acute inflammatory infiltrate (Pruzanski et al., 1986). Several studies have also 
documented the induction of oedema in mouse footpads after injection with PLA2 
(Vishwanath a/., 1988).
Group IIPLA2S also alter the function of phagocytes. Co-incubation of 
human neutrophils and monocytes with PLA2 from synovial fluid results in marked 
superoxide generation and lysosomal enzyme release, but decreased chemostatic 
responsiveness (Pruzanski & Vadas, 1991). Furthermore, group IIPLA2S modulate 
the inflammatory response to microorganisms; PLA2 direcdy, or synergistically with 
bacterial permeability-increasing protein, degrades the membrane phospholipids of 
gram-negative bacteria (Kaplan-Hanis et al., 1980). PLA2 activators such as 
mellitin also enhance the killing of microbes.
High levels of PLA2 activity have been found in synovial fluid from the 
inflamed joints of patients with rheumatoid arthritis,psoriasis and osteoarthritis 
(PruzLanski et al., 1985). Characterisation of this PLA2 shows it is a calcium-
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dependent, neutral active 124 amino acid enzyme which has a molecular weight of 
14kd and is strongly cationic with pi >10.5 (Kramer et al., 1989). More recently, 
the structure of this enzyme has been identified (Wery et al., 1991) and this may be of 
substantial use in future drug design. This enzyme has been suggested to be 
identical to PLA2 purified from human platelets and placenta (Lai & Wada, 1988; 
Kramer et al., 1989).
There is substantial evidence that both local and systematic inflammatory 
reactions may share a common repertoire of soluble mediators. Extracellular Group 
IIPLA2 may serve as a link joining the proximal and distal limbs of the inflammatory 
response. Since the early stages of inflammation are short and the stage of later 
effectors involves various factors, neither is easily amenable to effective therapeutic 
intervention. Therefore, selective inhibition of PLA2-II may become useful to this 
end.
PLA2-I  is mainly secreted from the pancreas as an inactive zymogen, which 
is further converted into the active form by proteases and then has been thought to act 
as a digestive enzyme (de Haas et al., 1968). However, recent studies have shown 
that PLA2-I  is not restricted to the pancreas. It has also be detected in rat stomach 
(Yasuda et al., 1990) and human serum (Nishijima et al., 1983). In addition, the 
existence of isoforms of PLA2 in porcine pancreas has been reported (Diccianni et 
al., 1990). These are distinguished by their sensitivity to heparin. The minor 
isoform is insensitive to changes in pH and calcium concentration and to heparin. In 
tissues, heparin-resistant isoforms of PLA2 may be important when the inhibitor 
heparin is abundant, such as released from mast cells at sites of degranulation. A 
novel effect of PLA2-I  has recently been described in Swiss 3T3 cells (Arita et al., 
1991) where PLA2 was shown to cause increased proliferation, shown by increased 
[3H]thymidine incorporation and 3-0-m ethyl-D-[l^H] glucose transport, via 
specific binding sites of approximately Mr 200,000. Pancreatic-type PLA2, also 
recognised the sites and stimulated DNA synthesis. These same PLA2- I  binding
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sites have also been found in some tissues of several animal species, especially in 
vasculature. These findings may suggest some role of PLA2-I  in vascular function, 
which is now being investigated. This may offer a new viewpoint on the effect of 
mammalian extracellular PLA2 on cellular function.
1 .4 .2  The high molecular weight cytosolic PLA2 S
Owing to their relative abundance, most structural and mechanistic studies 
have focussed on the secreted forms of PLA2. However, there is now good 
evidence that hormonally induced eicosanoid production is mediated through a 
cytosolic PLA2. A number of ligands that couple to GTP-binding proteins exposed 
to the cytosol have been shown to stimulate PLA2 activity (Burch et al., 1986; 
Jelsema & Axelrod, 1987; Gupta et al., 1990). Many of these ligands also mobilise 
calcium. This is of interest since submicromolar concentrations of calcium have been 
shown to cause association of a CPLA2 activity with the membrane fraction (Channon 
& Leslie, 1990). It is unlikely that a secreted PLA2 located in a secretory granule 
could be directly affected by phosphorylation or changes in calcium. In addition, the 
reducing environment of the cytosol would inactivate the disulphide-rich secreted 
PLA2. It therefore seems likely that a cytosolic form would be a likely candidate for 
promotion of the PLA2~linked intracellular signals. Recently, a number of studies 
have reported the existence of a high molecular weight form of the enzyme. Most of 
these studies have been performed on the human monocytic cell line U937. One of 
the earlier reports by Diez and Mong (1990) suggested that the enzyme was calcium 
dependent with a pH optimum of 8.0 and a molecular weight of 56kd. However, 
subsequent work by Kramer et al. (1991) suggests that the 56kd protein was not 
PLA2 but a major contaminating band. Kramer et al. (1991) have purified the CPLA2 
to near homogeneity and found it to be approximately lOOkd. They suggest that this 
form of PLA2 is involved in the release of eicosanoids in response to ligand 
activation. This study was followed by molecular cloning and expression of this 
CPLA2 in order to further understanding of the molecular structure and mechanism of
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the enzyme (Sharp et al., 1991). Interestingly, there was no sequence similarity 
between the human CPLA2 and 68 known secretory PLA2S. Similarly, computer 
analysis for global evolutionary relatedness between CPLA2 and other known proteins 
has shown that none is closely related. It will therefore be of interest to determine 
the mechanism whereby CPLA2 catalyses the same reaction as the secretory PLA2S. 
Studies by Clark et al.(1990,1991) have also suggested the existence of a high 
molecular weight CPLA2 in U937 cells. They have demonstrated that an amino- 
terminal 140 amino acid fragment of CPLA2 translocates to natural membrane vesicles 
in a calcium dependent fashion. This 140 amino acid domain contains a 45 amino 
acid region with homology to PKC, the synaptic vesicle protein p65 which is 
involved in fusion, the GTPase activating protein GAP, and PLC. Clark et al.
(1991) suggest the importance of calcium in promoting the association of CPLA2 with 
its aggregated substrate and postulate that the homology between these proteins 
delineates a calcium-dependent phospholipid binding motif providing a mechanism 
for calcium to translocate and activate cytosolic proteins.
1 .5  REGULATION OF PLA2
A problem in attempting to identify how PLA2 is regulated exists due to the 
multiple forms of the enzyme that are present in mammalian systems. Forms may 
vary between cell types as well as within the same cell. For example, in sheep 
platelets there appear to be at least two isoforms of PLA2 which hydrolyse PtdCho 
and PtdEtn respectively. The isoforms also differ in their sensitivity to calcium, with 
the PtdEtn-specific form being calcium insensitive (Ballou et al., 1986).
In general, cPLA2 may be activated via the second messengers generated by 
the PtdIns(4,5)P2~PLC pathway i.e. calcium, DAG (directly or via PKC activation) 
or it may be activated directly via a specific G protein.
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1 .5 .1  Role of calcium in PLA2 activation
In many cell types, PLA2 activation is closely linked to the occupancy of 
calcium-mobilising receptors (Lapetina, 1984). In rat platelets (Nakashima et al.,
1989) [3H] AA release in response to agonist stimulation was markedly decreased in 
the absence of extracellular calcium or in the presence of the intracellular calcium 
chelator, quin 2. Thus, the rise in intracellular calcium was suggested to play a 
primary role in PLA2 activation. In addition, Whatley et al. (1989) have 
demonstrated that PAF production via PLA2 in endothelial cells is dependent upon 
increases in intracellular calcium that are mediated by hormone-induced activation of 
a calcium channel. The dependence of PLA2 activation on prior 
polyphosphoinositide hydrolysis by PLC has been suggested in a number of reports 
(Meade et al., 1986; Tamiya-Koizumj)and had become a fairly widespread model 
until recently when various groups showed that Ins(l,4,5)P3 production and AA 
release could be dissociated from one another (Slivka & Insel, 1988; Burch & 
Axelrod, 1987) and indeed AA release could occur in the absence of inositol 
phospholipid turnover (Gil et al., 1991; Kanterman et al., 1990).
The possibility that PLA2 activation might also involve calcium-independent 
mechanisms has been raised by several studies. A phosphatidylethanolamine- 
specific PLA2 purified from human platelets does not require calcium for activity 
(Ballou et al., 1986). In addition, in HL60 cell homogenates, a PLA2 has been 
reported which degrades phosphatidylcholine in the absence of free calcium (Billah et 
al., 1986). More recently, Mizuno et al. (1991) have suggested the existence of a 
phosphatidylcholine-specific PLA2 that is calcium independent in rat parotid gland. 
The situation also exists in which both calcium-dependent and -independent 
pathways for PLA2 activation exist in the same cell (Buckley et al., 1991).
Bradykinin was shown to rapidly stimulate AA release in endothelial cells and this 
was closely coupled to changes in calcium concentration. However, it was also 
shown in the same cells that AIF4"-stimulated AA release did not require the presence
PAF; Platelet Activating Factor |
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of extracellular calcium or the mobilisation of intracellular calcium which was in 
distinct contrast to the bradykinin response. This, therefore, suggests the existence 
of multiple pathways of PLA2 activation within the same cell type and the possible 
existence of more than one PLA2 isoform.
1 .5 .2  Role of PKC in PLA2 activation
Many of the calcium-dependent PLA2 activities such as those previously 
described also show a requirement for PKC activation (Whatley et al., 1989; Tao et 
al., 1989). In addition, PLA2 can be activated by a PKC dependent mechanism 
which is not dependent on influx of extracellular calcium (Ho et al., 1987) or the 
mobilisation of intracellular calcium (Carter et al., 1989) and may be due to enhanced 
sensitivity of PLA2 to calcium. The fact that PKC may be a regulatory factor for 
Na+/H+ exchange may be important for its role in AA release (Sweatt et al., 1986; 
Akiba et al., 1989). In rabbit platelets intracellular alkalinisation was important for 
the enhancement of AA release by PKC and when extracellular Na+ was replaced 
with N-methyl-D-glucamine, the enhancement was reduced by approximately 50%. 
PKC has also been suggested to modulate prostaglandin synthesis in mouse 
peritoneal macrophages (Pfannkuche et al., 1989) and this has been proposed to 
occur by modulation of AA reacylation via phosphorylation of a regulatory protein 
linked to acyltransferase activity. It therefore appears that PKC may be involved at 
various levels in the regulation of AA release. Indeed in the alveolar macrophage, 
Spom et al. (1990) have demonstrated the existence of PKC-dependent and -  
independent AA release in response to different stimuli.
There have been some reports suggesting that activators of PKC i.e. 
diacylglycerols, also cause activation of PLA2 but independently of PKC activation 
(Kramer et al., 1987; Burch, 1988). Kramer et al. (1987) showed that DAGs are 
able to stimulate soluble PLA2 with sonicated arachidonyl-PC as substrate. This 
effect appears to be far greater for intracellular PLA2S and may occur directly via 
conformational changes at the level of PLA2 itself (Burch, 1988). The study by
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Burch correlated DAG activation of PLA2 to a biological effect, potentiation of PGE2 
synthesis in response to receptor agonists. This action of DAG may be 
physiologically relevant in that DAG, newly synthesised in response to a variety of 
agonists, may activate or potentiate PLA2 activity.
1 .5 .3  Endogenous PLA2 inhibition by lipocortins
Lipocortins have been proposed to be important in in vivo antiinflammatory 
reactions due to the fact that purified proteins in this family added to prelabelled cells 
appear to decrease the release of [3H]AA or thromboxane in response to stimuli 
(Cirino et al., 1987). Identification of these proteins revealed their similarity to two 
protein tyrosine kinase substrates, p35 and p36, also termed calpactins. The p35 
protein, which is a substrate of the EGF receptor tyrosine kinase (Fava & Cohen,
1984) and is also known as calpactin n, was found to be identical to lipocortin I. 
Furthermore, this protein was 50% identical to the p36 protein, which is a major 
substrate of the viral oncogene protein tyrosine kinase pp60v-src (Gould et al., 1986) 
and is itself the same as lipocortin II and calpactin I. This relatedness appeared to 
link oncogenesis and growth regulation with a protein which was involved in the 
regulation of eicosanoid synthesis. Additional members of this protein family have 
since been found (Pepinsky et al., 1988) and there are now six lipocortins. The 
stimulation of lipocortin synthesis has been shown to occur in response to 
glucocorticoids, causing inhibition of PLA2. However, it has not been concluded 
that these proteins are the primary agents of the antiinflammatory actions observed. 
Problems have arisen in comparing in vitro and in vivo studies. Purified 'lipocortin' 
inhibits stimulated AA release but not basal release (Fradin, 1988) leaving open the 
possible intervention of other mechanisms. There is also controversy over the 
question of whether any of the recombinant lipocortins are actually induced by 
glucocorticoids.
It was proposed that lipocortin action was regulated by phosphorylation and 
inactivation (Davidson & Dennis, 1989). However, the relationship of this
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phosphorylation to eicosanoid biosynthesis has not been proven and is likely to be 
complex if it does exist Experiments claiming to show lipocortin phosphorylation 
and inactivation have often proven inadequate (Hirata et al., 1984) with no added 
calcium present which is necessary for the reactions to proceed. Another type of 
mechanism proposed for lipocortin action involves the 'substrate depletion model' 
(Davidson & Dennis, 1989). This involves binding of lipocortin to the phospholipid 
substrate, preventing access to the phospholipase. Support for this model comes 
from studies in which inhibition was overcome by raising the substrate concentration 
in amounts consistent with overcoming depletion of the substrate by lipocortins used 
in the assays (Aarsman et al., 1987). In addition, no binding of inhibitor protein to 
PLA2 was detected, but extensive binding to substrate was seen. It therefore, seems 
that the action of lipocortins on PLA2 must be studied within a broader perspective 
than previously. They may be connected to growth regulation and oncogenesis, or 
may play a role in inflammation, but there is not sufficient evidence to say they are 
direct regulators of PLA2.
PLA2 is obviously an attractive therapeutic target in the development of
antiinflammatory compounds and constant research goes into the production of
effective PLA2 inhibitors. Compounds which have been identified as inhibitors of
PLA2 include bromophenacylbromide, mepacrine and manoalide. BPB covalently
modifies essential histidine residues associated with the catalytic site on the enzyme
(Kyger et al., 1984). However, it inactivates a wide variety of other enzymes
through similar mechanisms. Mepacrine has been shown to inhibit PLA2 activity in
situ but not in vitro by altering calcium availability to the enzyme and possibly by
modifying the structure of membrane phospholipids (Disc et al., 1982). Manoalide
has been shown to potently inactivate bee and cobra venom PLA2 with IC50 values of
____________  1985
0.05 and 2pM respectively(Lombardo and Dennis, Ulaser et al., 1986), much lower
than that required of BPB and mepacrine. Other work has shown manoalide to
inhibit AA release from polymorphonuclear leukocytes and macrophages in response
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to A23187 stimulation (Meade et al., 1986; Mayer et al,, 1988). The mechanism of
inactivation has been suggested to occur via structural modification of specific lysine
1985)
residues near the active site of the enzyme(Lombardo and D e n n i s , ; -  h o w e v e r ,  again 
this inhibitor appears relatively non-specific since it has been reported to interact with 
other phospholipases. Another potential inhibitor of PLA2 is aristolochic acid 
(Rosenthal et al 1989) which has been reported to interact directly but non-covalently 
with isolated PLA2S, inducing a change in secondary structure as measured by 
alterations in the alpha-helical content of the protein. It has been suggested that the 
lack of attenuated effects of aristolochic acid in biological systems may imply that this 
agent retains its specificity for PLA2 in situ. However, this requires further 
investigation and as yet, a specific inhibitor for PLA2 has not been found.
1 .5 .4  Receptor regulation via specific G proteins
A family of guanine nucleotide binding proteins have been shown to function 
in receptor-linked signal transduction, coupling receptor activation to modulation of 
effector systems such as adenylyl cyclase and phospholipase C. These G proteins 
exhibit sensitivity to certain toxins and this has proved a useful tool in the 
identification procedure. Cholera and pertussis toxins stoichiometrically ADP- 
ribosylate specific G proteins, altering their capacity to function in signal transduction 
(Gilman, 1984). Pertussis toxin interacts with Gai, stabilising its inactive form and 
blocking its function whereas cholera toxin has been shown to stabilise the active 
state of stimulatory G proteins (Gas) and perpetuate their functions. Toxin 
sensitivity has also been shown to exist for G proteins that regulate phospholipase C 
in some but not all cell types and this has proved useful in studies where the 
dissociation of PLC activity from other events has been studied.
The activation of PLA2 by a specific G protein has now been demonstrated in 
a number of systems. Burch and Axelrod (1987) showed that bradykinin receptors 
in Swiss 3T3 cells are coupled by G proteins to both PLC and PLA2. Both AA 
release and Ins(l,4,5)P3 production were affected by addition of non-hydrolysable
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analogues of GTP and GDP to permeabilised cells. It was possible, however, to 
dissociate the pathways through use of phorbol ester pretreatment which inhibited 
Ins(l,4,5)P3 production but was without effect on AA release, and use of 
cycloheximide which inhibited PGE2 synthesis possibly by inhibiting the synthesis of 
a PLA2 activating protein but not Ins(l,4,5)P3 production. The pathways thus seem 
to be independently regulated, possibly via separate G proteins. This phenomenon 
has also been demonstrated in neutrophils (Cockcroft & Stutchfield, 1989), MDCK 
cells (Slivka & Insel, 1988) and human platelets (Nakashima et al., 1987). Further 
support for a direct activation of PLA2 by a G protein has come from work on rod 
outer segments of bovine retina (Jelsema, 1987) in which it was shown that light 
activated PLA2 through the action of the G protein transducin. Additional studies 
(Jelsema & Axelrod, 1987) examined the effect of the a  and Py subunits of transducin 
on PLA2 activity. The a subunit caused a slight increase in enzyme activity. In 
contrast, the py subunit markedly stimulated PLA2. Addition of equimolar amounts 
of a -  and py-subunits caused an inhibition of PLA2 activity in the dark-adapted rod 
outer segments probably due to the reassociation of the apy heterotrimer. It remains 
to be established whether the py-induced increase in PLA2 occurs by direct 
stimulation of the enzyme or by inactivation of a PLA2 inhibitor. Further evidence 
for the involvement of the py subunit in PLA2 activation has come from Kim et al.
(1989) who have shown that py activates the cardiac muscarinic K+ channel by 
stimulating the production of lipoxygenase-derived second messengers. An 
antibody against PLA2 was shown to prevent Py from opening K+ channels. In 
addition, the lipoxygenase-blocking drug, NDGA, prevented K+ channel opening in 
response to both Py and AA. Codina et al. (1987), however, have firmly challenged 
the argument that py can open K+ channels and have strengthened the case that a* is 
responsible by showing that K+ channels are opened by recombinant oq protein made 
in bacteria and that a monoclonal anti-aj antibody blocks G protein-mediated opening 
of the channels.
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The number of p and y subunits identified to date is far fewer than for the a 
subunits (Schmidt & Neer, 1991). Three different ps and three 7s have been 
described, and these different subunits may form dimers with distinct functional 
characteristics. Both transducin py and brain Py have equivalent abilities to couple 
transducin to rhodopsin in a reconstituted system (Kanaho et al., 1984). However, 
the relative ability of these two dimers to inhibit activation of adenylate cyclase is 
different (Casey et al., 1989). Differences have also been noticed in the ability of Py 
dimers to activate PLA2. Brain Py will stimulated PLA2 activity in atrial membranes 
but transducin py is much less effective (Kim et al, 1989). In these studies, the p 
subunit was predominantly pi, therefore, the functional differences may depend on 
the y subunit. The significance of this subunit in the regulation of signalling paths is 
under further investigation (Schmidt & Neer, 1991) but remains highly controversial, 
for several reasons. It remains to be demonstrated in the majority of cases whether 
the py preparations used are at all contaminated with the a subunit. This would 
obviously weaken the argument that py is the active subunit The proposal that Py 
activates PLA2 is also open to criticism since many situations exist in stimulated cells 
where the heterotrimeric G protein has dissociated, and the a  subunit e.g. as activates 
a signalling pathway e.g. adenylyl cyclase/cAMP, leaving free Py subunits that 
should, according to the theory, stimulate PLA2 activity. This is not the case.
The identification of the G protein involved in PLA2 regulation remains 
unknown. However, several possibilities have been suggested. The possibility has 
been considered that the G protein involved is a ras proto-oncogene. The 
mammalian ras genes H-ras, K-ras and N-ras encode small molecular weight G 
proteins normally involved in cellular regulation that are activated by oncogenic 
mutation. Microinjection of the H-ras oncogene into fibroblasts (Bar-Sagi & 
Feramisco, 1986) had no effect on inositol phospholipid metabolism but activated 
PLA2. This finding was consistent with the normal H-ras protein being responsible 
for control of AA production. In contrast to this, Wakelam et al. (1986) have
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suggested that the ras proteins are responsible for activation of inositol phospholipid 
breakdown and could therefore be forms of Gp. These discrepancies have been 
explained by Burgoyne et al. (1987) to be due perhaps to the fact that AA, produced 
by ras activation of PLA2 may stimulate inositol phosphate production (Zeitler & 
Handwerger, 1985). More recently, however, it has become clear that ras proteins 
do not directly control the activity of PLC or PLA2 since the introduction of 
compounds designed to duplicate the enzymic activity could not produce DNA 
synthesis in cells injected with an anti-ray antibody (Yu et al., 1988). It seems more 
likely that any increased PLA2 activity in ray-transformed cells is due to an indirect 
effect of other signalling pathways activated by ray-transformation e.g. increased 
DAG production and increased PtdCho breakdown (Grand & Owen, 1991).
Several recent studies have postulated on the identification of the G protein 
involved in PLA2 activation in certain systems. Gupta et al. (1990) have suggested 
that the stimulation of PLA2 by thrombin and type 2 (P2)-purinergic receptor agonists 
in Chinese hamster ovary cells is mediated by Gj. To decipher a chain regulatory 
regions responsible for control of PLA2, chimeric cDNAs were constructed in which 
different lengths of the a subunit of Gs were replaced with the corresponding 
sequence of the Gja subunit (o^). When a carboxyl-terminal chimera, which has 
the last 38 amino acids of 0^  substituted with the last 36 residues of 0^ 2, was 
expressed in the cells, the receptor-stimulated PLA2 activity was inhibited, although 
the chimera could still activate adenylate cyclase. It was thus proposed that the last 36 
amino acids of 042 are critical for G protein regulation of PLA2. This type of study 
offers distinct advantages over pertussis toxin treatment of cells because of better 
specificity. Specific a  chain sequences may be used to selectively inhibit pathways 
regulated by different G proteins. The inhibition of PLA2 described in this study 
may be due to direct interaction with PLA2 or a regulatory peptide required for Gi 
regulation of the enzyme. If Gi does regulate PLA2 then it would be expected that 
pertussis toxin would inhibit all activation.
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A study by Cantiello et at. (1990) has suggested that activation of Na+ 
channels in epithelial cells is mediated by Ga# stimulation of PLA2 activity. 
Picomolar concentrations of 0^ 3 were capable of stimulating PLA2 activity, and 
allowing lipoxygenase-mediated Na+ channel activation. Further evidence for 
involvement of a Gi in PLA2 regulation has been suggested by Lowndes et al.
(1991). Expression of the GTPase-deficient Gi2 a subunit oncogene gip 2 in 
Chinese hamster ovary cells altered the regulation of PLA2 to different extents 
depending on the agonist used, causing differing degrees of attenuation. This study 
showed additional evidence for involvement of Gi2 in PLA2 activation.
Another suggestion that has been made in G protein regulation of PLA2 is that 
dual regulation may exist. Burch et al. (1987) suggested that PLA2 may be subject 
to regulation by both stimulatory and inhibitory G proteins. This conclusion was 
based on the sensitivity of PGE2 synthesis to both cholera and pertussis toxins. 
Ideally reconstitution experiments will be required to clarify whether Gi, Gc or Gq 
proteins are involved. In addition, experiments using chimeras such as those 
previously described in different cell types would be informative.
1 .6  PATHWAYS OF ARACHIDONIC ACID METABOLISM
Arachidonic acid may be metabolised via three main pathways. These are (i) 
the cyclooxygenase pathway, producing prostanoids, which include non-prostanoic 
derivatives like thromboxanes in addition to true prostaglandins (Smith, 1989), (ii) 
various lipoxygenase products (Needleman et al., 1986) and (iii) NADPH-dependent 
cytochrome p-450 epoxygenase metabolites (Snyder et al., 1983).
1 .6 .1  Cyclooxygenase
Conversion of AA to the prostaglandin endoperoxide PGH2 is mediated by 
PGG/H synthase, an integral membrane protein found in the endoplasmic reticulum 
of prostanoid forming cells (DeWitt et al., 1981). This enzyme has two distinct 
catalytic activities, a bis-oxygenase (cyclooxygenase) involved in PGG2 formation
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and a hydroperoxidase mediating a net two-electron reduction of the 15- 
hydroperoxyl group of PGG2 to yield PGH2 (Ohki et al., 1979). The 
cyclooxygenase is specifically inhibited by aspirin and related non-steroidal anti­
inflammatory drugs. Aspirin causes O-acetylation at a serine residue located 70 
amino acids from the C-terminus (DeWitt & Smith, 1988). Indomethacin, 
meclofenamate and flurbiprofen also cause irreversible inactivation of cyclooxygenase 
activity but apparently without covalent modification of the enzyme (Rome & Lands, 
1975).
The level of PGG/H synthase has been shown to be influenced in various cell 
systems by steroids, growth factors and tumour promoters (Smith, 1989), suggesting 
that regulation of the level of the enzyme is an important factor in regulating 
prostanoid formation. The biologically active eicosanoids, which are considered to 
be PGD2, PGE2, PGF20C PGI2 and TxA2, are synthesised in a cell-specific manner 
from PGH2. In comparison to PGG/H synthase, relatively little is known about the 
enzymes which catalyse PGH2 metabolism. Both PGI2 synthase (DeWitt & Smith, 
19&B) and TxA2 synthase (Shen & Tai, 1986) have been purified to homogeneity 
and both appear to be related membrane-bound haemoproteins with a cytochrome p -  
450 chromophore. It seems likely that these enzymes, along with other PGH2 
metabolising enzymes are regulated coordinately with PGG/H synthase.
PGE2 synthesis requires reduced glutathione. The formation of PGE2 is 
catalysed by several distinct membrane-bound PGH-PGE isomerases which lack 
glutathione S-transferase activity (Smith, 1989), as well as by several subtypes of 
soluble glutathione S-transferase. The question of which of these enzymes is 
important in PGE2 synthesis in vivo is unresolved. Several, but not all, soluble 
proteins with PGH-PGD isomerase activity have been purified (Tachibana et al.,
1987).
Eicosanoids are lipophilic substances and are believed to be easily capable of 
crossing plasma membranes and generating effects in neighbouring cells.
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Prostaglandins are thought to have individual cell surface receptors (Schafer et al., 
1979) through which they exert these effects. A common mechanism of action of 
several prostaglandins like PGD2, PGE2 and PGI2 is to alter cell cAMP via adenylyl 
cyclase stimulation, and to subsequently alter A A release at the PLA2 level, 
depending on the target cell. This has been demonstrated in human platelets 
(Gorman, 1977) and since cAMP is a potent inhibitor of AA release in platelets,
PGD2 and PGI2 will thus inhibit eicosanoid synthesis. The physiological relevance 
of this inhibition by PGD2 is reinforced in considering that this is the main 
cyclooxygenase product of mast cells.
In addition to stimulating cAMP, prostaglandins have also been shown to 
cause an increase in intracellular calcium which may occur via increased 
PtdIns(4,5)P2 turnover (Macphee et al., 1984). Based on measurements of the 
effects of prostaglandins on second messenger levels, Muallem et al. (1989) 
classified the receptors into three classes: a PLC/Ca2+-linked receptor accepting 
PGF2a, PGD2 and TxB2*, a PLC/Ca2+-linked receptor accepting PGE2, PGEi, 
PGA2, PGI2 and 6-oxo-PGFia ; and an adenylyl cyclase-linked receptor accepting 
PGE2, PGEi, PGA2 and PGI2. This classification may however be somewhat 
limited given that other signalling molecules have been shown to be affected by 
prostaglandins in addition to those mentioned. PGF2a and PGB2 have been shown 
to induce a PKC-dependent contraction of rat aorta by a mechanism that does not 
depend on phosphoinositide hydrolysis (Heaslip & Sickels, 1989). It was suggested 
that these prostaglandins may activate a DAG-generating signal-transduction 
pathway independent of phosphoinositide hydrolysis, possibly by stimulating PLC- 
dependent hydrolysis of phosphatidylcholine. Another potential pathway that may 
be regulated by prostaglandins is that of AA mobilisation itself. Rosenthal and 
Franson (1989) have suggested that PGBi is capable of inhibiting agonist-stimulated 
AA release in both human neutrophils and endothelial cells. The effect was rapid, 
dose-dependent and resulted in approximately 95% inhibition of A23187-stimulated
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release. This effect appeared to be at the level of PLA2 itself. However, further 
studies are required to determine whether PA&i also inhibits other paths of receptor- 
mediated signal transduction. The possibility may exist that feed-back loops 
between prostaglandins and PLA2 regulation are present in certain systems.
1 .6 .2  Lipoxygenase
Leukotrienes and related mono- di- and tri-hydroxy fatty acid products are 
formed via lipoxygenase pathways. There are three different mammalian 
lipoxygenases which catalyse the insertion of oxygen into A A at positions 5, 12 or 
15. The initial of these reactions is a hydroperoxyeicosatetraenoic acid (i.e. 5 -  12- 
or 15HPETE) which can then be reduced to the corresponding 
hydroxyeicosatetraenoic acid (i.e. 5 - 12- or 15-HETE). The 12-lipoxygenase is 
present in platelets (Nugteren, 1982) and leukocytes (Yokayama et al., 1986) but the 
physiological function of 12—HETE is unclear. The 15-lipoxygenase is found in 
leukocytes (Narumiya & Salman, 1982) and a variety of other cells but is not always 
expressed. Many biological actions of 15-HETE and other 15-lipoxygenase 
products have been described in vitro. Wallukat et al. (1991) studied the influence of 
lipoxygenase products on the ^-adrenergic receptor of rat heart myocytes and found 
that 15-HETE at 10’10M induced supersensitivity of the receptor to its agonists. In 
pulmonary tissues, 15-HETE is a potent proinflammatory metabolite. In cultured 
human airways, mucus glucoprotein release was stimulated by lpM 15-HETE 
(Marom et al., 1983). 15-HETE at <10gM also stimulates angiogenesis. This 
effect is due to stimulation of both migration and proliferation of endothelial cells. In 
fetal bovine aortic endothelial cells, stimulation of cell proliferation and DNA 
synthesis by 15-HETE has been suggested to occur via inhibition of DAG kinase, 
leading to an increase in cellular DAG (Setty et al., 1987). There appear to be 
regulatory relationships between the various lipoxygenase pathways. For example, 
15-HETE (6pM) is a potent inhibitor of both 5 - and 12-lipoxygenase (Vanderhoek et 
al., 1980). Moreover, 15-lipoxygenase can inactivate the peptidoleukotrienes by
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15-lipoxygenation (Sirois, 1979). Thus, 15-lipoxygenases appear to be involved in 
antiinflammatory as well as proinflammatory reactions.
Another group of 15-lipoxygenase metabolites are the lipoxins (Rokach & 
Fitzsimmons, 1988), which are products of multiple oxygenations of AA. A variety 
of biological effects of lipoxins have been reported such as inhibition of killer cell 
toxicity, modulation of leukocyte chemotoxis, vasodilation, smooth muscle 
contraction in lung tissue, activation of protein kinases and inhibition of the 
phosphatidylinositol cycle (Samuelson, 1987). The large variety of effects of 15- 
lipoxygenase still require considerable investigation but it is thought that these 
enzymes may have a major function in the oxidative modification of lipoproteins as an 
early event in the pathogenesis of inflammatory states such as atherosclerosis.
The 5-lipoxygenase pathway is involved in leukotriene formation. Thus 5 -  
HETE can be converted by removal of water to an acid-labile 5,6-epoxide containing 
a conjugated triene structure, leukotriene A4 (LTA4). This can be converted to LTB4 
by net addition of water via LTB4 hydrolase or to LTC4 by addition of a glutathionyl 
group at C-6  by the action of glutathione 5-transferase. Leukotrienes containing 
peptides or amino acids at C-6  are termed peptidoleukotrienes. LTC4 can be cleaved 
by y-glutamyl-transpeptidase to produce LTD4 which can be further metabolised to 
LTE4 by a dipeptidase (Smith, 1989). Most attention has focussed on LTB4 which 
has been shown to be an important modulator of many immune cell functions either 
as an internal messenger or as an external signal, linking inflammatory cells to 
lymphocytes. LTB4 is one of the most powerful chemokinetic and chemotactic 
agents and it can induce neutrophil aggregation, degranulation and enhanced binding 
to endothelial cells (Rola-Pleszczynski,, 1989). It has also been shown to induce 
cation fluxes and increase cytoplasmic calcium via activation of phosphoinositide 
hydrolysis (Mong et al., 1986). High- and low-affinity LTB4 receptors have been 
identified and signal transduction via the high-affinity form has been suggested to 
involve a G protein (Mong et al., 1986). The mechanism underlying 5-lipoxygenase
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activation has recently been proposed to involve a specific activating protein termed 
5-lipoxygenase activating protein or FLAP (Dixon et al., 1990). This was 
discovered through the use of a compound MK-886 which blocks the synthesis of 
leukotrienes in intact activated leukocytes. The mechanism by which FLAP activates 
5-lipoxygenase is not known. The authors have suggested that since the 
translocation of the enzyme to the membrane after A23187 activation is blocked by 
M K-886, FLAP could be a membrane anchor for 5-lipoxygenase. According to this 
model, a stable complex would be required to form at the membrane between 
activated 5-lipoxygenase, FLAP and possibly other components. The formation of 
this complex could regulate the interaction of 5-lipoxygenase with AA. It has been 
suggested that this type of mechanism may be fairly widespread for regulating 
enzymes that act upon membrane-associated substrates.
The leukotriene LTD4 also appears to act via specific receptors that are 
coupled to at least two separate G proteins with different toxin sensitivities. This 
leukotriene has also been shown to stimulate signalling pathways such as PI-PLC 
and a receptor operated Ca2+ channel (Crooke et al,. 1989). LTD4 has also been 
suggested to indirectly activate PLA2 via production of endogenous activating 
proteins (PLAPs). The LTD4 transduction pathway seems to be regulated at the 
receptor level by both homologous and heterologous desensitization via PLC. There 
appear to be differences in the mechanisms of action and regulation of the different 
leukotrienes and this is an area into which future studies should be directed.
1 .6 .3  Epoxygenase
The cytochrome p450 enzymes are widely distributed in animal tissues, plants 
and microorganisms and appear to be a multigene family whose main function is the 
monooxygenation of lipophilic substances. Oxidation of AA by cytochrome p450 
results in the formation of eicosatetraenoic acids (Needleman et al., 1986). In 
addition both cyclooxygenase and lipoxygenase products can be metabolised via this 
route to form epoxygenase products.
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Various biological effects of these products have been observed. Incubations 
of anterior pituitary cells with synthetically produced epoxygenase metabolites of AA 
caused an increase in the release of luteinising hormone (Needleman, 1986). The 
most potent metabolite was 5(6)epoxyeicosatetranenoic acid with a maximal response 
at IpM. The specificity of this response is however questionable and it may be due 
to the stimulation of the formation of a cyclooxygenase metabolite. In a mouse 
pituitary cell line (AtT-20), inhibitors of cytochrome p450 enzymes were shown to 
suppress secretogogue-induced ACTH release, suggesting a role for epoxides in 
pituitary function. The cytochrome p450 pathway may also have a role in renal 
function. It has been reported that 5(6) epoxyeicosatetraenoic acid or one of its 
metabolites inhibits sodium absorption and potassium secretion in rabbit cortical 
collecting tubule. In addition, vascular Na+/K+ ATPase activity is inhibited by these 
products in the medullary thick ascending limb of loop of Henle (Needleman, 1986). 
More recently, it has been suggested that cytochrome p450 products are endogenous 
modulators of the growth response in rat mesangial cells (Sellmayer et al., 1991). 
Inhibition of cyclooxygenase or lipoxygenase alone had no effect on cell growth 
caused by EGF, PMA and vasopressin. Stimulation with these substances followed 
by GC-MS analysis revealed an epoxyeicosatetraenoic acid-like substance 
suggesting these compounds may be important mediators of the growth response to 
mitogenic agents. This represents a novel role for these products although the 
underlying mechanism has yet to be elucidated.
It seems clear that the eicosanoids from each of the three groups have wide- 
ranging effects upon the intra- and inter-signalling networks. Therefore, in studies 
examining the role of PLA2 in signal transmission, it will be important to consider not 
only the immediate product of phospholipid hydrolysis, AA, but also the potentially 
important metabolites of this fatty acid.
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1 .7  BOMBESIN -  A MITOGENIC PEPTIDE FOR SWISS 3T3 
CELLS
Bombesin is a tetradecapeptide isolated from frog skin and has a wide range 
of biological activities. Bombesin-like peptides such as gastrin release peptide 
(GRP) and neuromedin B (NMB) are widely distributed in mammals and have 
diverse functions including neurotransmission in the central nervous system 
(Minamino et al., 1985) and stimulation of exocrine secretion in the pancreas and gut 
(Knigge et al., 1984). They are potent mitogens in vitro for Swiss 3T3 cells 
(Takuwa et al., 1991) and have been proposed to act as growth factors for human 
fetal lung (Spindel et al., 1987) and human smallcell lung cancer (Cuttitta et al.,
1985).
The effects of bombesin appear to be exerted upon its binding to a single class 
of high affinity cell surface receptors which have now been well characterised 
(Brown e ta l ,  1988; Sinnett-Smith et al., 1988; Battey etal., 1991). This receptor 
is a member of the G protein-coupled receptor superfamily with seven hydrophobic 
transmembrane domains. Evidence for the existence of bombesin receptor subtypes 
was put forward by Schrenck et al. (1989) and Shapiro et al. (1991). There appear 
to be to date three subtypes of the receptor present in distinct tissues. Oesophageal 
smooth muscle expresses an NMB preferring receptor type, while pancreatic acinar 
cells and Swiss 3T3 cells possess a GRP preferring receptor type. The latter two 
subtypes were distinguished by their differences in sensitivity to a specific GRP 
receptor antagonist (Shapiro et al., 1991). As yet,, there is no evidence of bombesin 
receptor subtypes existing within the same cell.
The bombesin receptor in Swiss 3T3 cells is linked to a pertussis toxin 
insensitive G protein which mediates activation of PLC (Fischer & Schonbrunn,
1988), the exact identity of which remains unclear. However, as mentioned earlier, 
it may be a member of the Gq/Gn species.
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Bombesin acts as a typical Ca2+ messenger system hormone. Takuwa et al. 
(1987) have demonstrated that it has three measurable effects on cellular Ca2+ 
metabolism: a transient stimulation of radiocalcium efflux from [45Ca2+]-prelabelled 
cells; a transient rise in the intracellular calcium concentration and a rapid and 
sustained increase in calcium influx rate. These results imply that bombesin 
stimulates the cycling of calcium across the plasma membrane. The transient rise in 
Ins(l,4,5)P3 in response to bombesin has been well characterised (Takuwa et al., 
1987; Cook et al., 1990; Plevin et al., 1990) as has the biphasic DAG response 
(Cook et al., 1990). This increase in DAG leads to activation of PKC in Swiss 3T3 
cells (Erusalimsky et al., 1988). The source of bombesin-stimulated DAG 
formation may comprise more than one phospholipid. It is thought that the initial 
phase of DAG that corresponds with Ins(l,4,5)P3 is generated from PLC-stimulated 
hydrolysis of PtdIns(4,5)P2- However, the second phase has been proposed to 
come from hydrolysis of PtdCho, either via PLC (Muir & Murray, 1987) or PLD 
(Cook & Wakelam, 1989). Thus, bombesin may stimulate the turnover of more than 
one phospholipid type. Activation of PKC by bombesin may be important in the 
peptide's ability to stimulate protein synthesis since PKC has been suggested to 
regulate certain eukaryotic initiation factors via phosphorylation as mentioned in 
Section 1.2.2 (Morley & Trough, 1989). In Swiss 3T3 cells, PKC-a appears to be 
the dominant isoform and is active for a prolonged period of time in the face of 
limited calcium influx as far as the level of DAG remains elevated (Takuwa et al., 
1991). It is possible, however, that other calcium-independent PKC isoforms such 
as 8 and q might be involved in the sustained phase of bombesin action. However, 
this remains to be investigated.
Bombesin has also been shown to cause increased expression of the cellular 
oncogenes c-fos and c-myc (Bravo et al., 1987). Prolonged treatment of the cells 
with PMA, which causes a selective decrease in PKC activity, partially inhibited the
43
induction of c-fos and c-myc expression. This suggests a partial role of PKC in 
protooncogene induction by bombesin.
As mentioned earlier (see Section 1.3.2), the question of whether bombesin 
enhances cAMP accumulation in Swiss 3T3 cells has been one of controversy.
Millar and Rozengurt (1988) suggested that bombesin, in the presence of either 
forskolin or cholera toxin, caused a 4-6 fold enhancement of cAMP. Other groups 
however, (Fischer & Schonbrunn, 1988; Takuwa et al., 1991) have failed to detect 
any increase in cAMP levels in response to the peptide.
The possibility that bombesin may induce an increase in tyrosine 
phosphorylation was suggested in Section 1.3.1. The identity of the phosphorylated 
proteins remains uncertain but since bradykinin and vasopressin also stimulated their 
phosphorylation, they may be important in the cellular signalling for a number of 
agonists. Previous studies examining the effect of bombesin on tyrosine 
phosphorylation include Cirrillo e ta l  (1986) who showed an increase in tyrosine 
phosphorylation of a 115Kd protein species in 3T3 cells. However, Isacke et al. 
(1986) were unable to repeat this effect. The possibility does, however, remain that 
this may represent another, potentially important, signalling event that comprises part 
of the mitogenic effect characteristic of bombesin.
1 .8  AIMS
Previous studies of bombesin-stimulated Swiss 3T3 cells have focussed on 
the activation of PLC, examining Ins(l,4,5)P3 and DAG production. In an effort to 
extend the knowledge of how bombesin exerts its mitogenic effect, this study 
examines the possibility that PLA2 activation may be an important effect of bombesin 
stimulation. The main aims of the study were:-
1. To characterise the kinetics and composition of the PLA2 response,
2. To identify possible regulatory factors for this enzyme,
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3. To determine the mechanism behind initial PLA2 activation and the
relationship between activation of PLA2 and PLC in response to 
bombesin stimulation,
4. To ascertain whether the products of PLA2 hydrolysis have a role to play
within the cell.
CHAPTER 2
MATERIALS AND METHODS
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MATERIALS AND METHODS
2 .1  CELL LINES AND MATERIALS
2 .1 .1  Cell Line
Swiss mouse 3T3 fibroblasts
Kindly donated by Dr. K.D. Brown, A.F.R.C., Institution of Animal 
Physiology, Babraham, Cambridge, CB2 4AT, U.K.
2 .1 .2  Materials
The following is a list of sources of the materials used during the course
of this project.
Amersham International pic, Buckinghamshire, England
[5,6,8,9,11,12,14,15- 311^ 301^ 0^0 acid (214.3Ci/mmol) 
[ l - 14C]arachidonic acid (55mCi/mmol)
[methyl^Hjcholine chloride (75.9Ci/mmol)
[3H] 15-HETE assay kit 
[2-3H]myo-inositol (10-20Ci/mmol)
[20(n)-^H]phorbol dibutyrate (lOCi/mmol)
[5,6(n)^H]prostaglandin E2 (140Ci/mmol)
[U-14C] sucrose (460mCi/mmol)
[methyMH]thymidine (25Ci/mmol)
Beckman RIIC Ltd., High Wycombe, England
Ultrasphere ODS column
BDH Chemical Co., Poole, England
Ammonium formate, EDTA, Gelatin, Hepes, Orthophosphoric acid,
perchloric acid, petroleum ether (60-80°), potassium dihydrogen
phosphate, sodium carbonate, sodium hydrogen orthophosphate, sodium
hydroxide, trichloroacetic acid, Universal indicator.
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Biogenesis Ltd., Bournemouth, England
Epidermal Growth Factor (receptor grade) purified from mouse 
submaxillary glands.
Boehringer (UK) Ltd., Lewes, England
ATP
GDPpS
GTPyS
Cambridge Research Biomedicals, Cambridge, England
Bombesin
DuPont NEN Research Products, Stevenage, England 
[3H]water (ImCi/g)
FSA Lab Supplies, Loughborough, England
Chloroform, diethyl ether, ethanol, ethyl acetate, methanol, sap-pak 
columns
Gibco, Paisley, Scotland
Dulbeccos modified essential medium (DMEM lOx), gentamycin,, 
glutamine (lOOx), penicillin/streptomycin, sodium bicarbonate (7.5%) 
Koch-Light Ltd., Suffolk, England
Calcium chloride, dimethyl sulphoxide (DMSO), magnesium sulphate, 
potassium chloride
May & Baker, Dagenham, England
Acetic acid, formic acid, hydrochloric acid, sodium tetraborate 
Merck, Essex, England 
Lichrosorb C-18 column
National Diagnostics, Aylesbury, England
Ecoscint
Porton Products, Porton Down, Salisbury, England
Pertussis toxin
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Wellcome Diagnostics, Dartford, Kent, England
Streptolysin -  O
Whatman Ltd., Maidstone, England 
t.l.c. plates
All other chemicals were obtained from the Sigma Chemical Co., Poole, 
England.
Soyabean 15-lipoxygenase (Spec.ac.90u/pg) was kindly donated by Dr. 
C.C.Hallam, Fisons Pharmaceuticals.
2 .2  BUFFER COMPOSITION
Phosphate buffered saline (PBS)
146mM sodium chloride, 5.4mM potassium chloride, 9.6mM di-sodium 
hydrogen orthophosphate, 1.5mM potassium di-hydrogen orthophosphate.
When freshly prepared, PBS was adjusted to pH7.2-7.4 if necessary 
with 1M sodium hydroxide and/or 1M hydrochloric acid.
Sterile trypsin solution for cell passage
Trypsin was prepared as a solution of 0.1% (w/v) trypsin, 0.025% (w/v) 
EDTA and lOmM glucose in PBS at pH7.4 and filtered before aliquoting through a 
sterile 0.22pm membrane (Flow pore D).
Hank's buffered saline (Hanks)
1.26mM calcium chloride, 0.5mM magnesium chloride, 0.9mM 
magnesium sulphate, 5.37mM potassium chloride, 137mM sodium chloride, 4.2mM 
sodium hydrogen carbonate, 0.35mM sodium dihydrogen phosphate.
When freshly prepared, the pH was between 12-1  A.
Hank's buffered saline with glucose and BSA (HBG)
Hanks was prepared as above and lOmM D-glucose and 1% (w/v) BSA 
(fraction V) added.
When freshly prepared, the pH was adjusted to 7.4 as for PBS.
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Permeabilisation buffer
20mM Hepes, 120mM potassium chloride, 6mM magnesium chloride, 
2mM potassium di-hydrogen orthophosphate, 0.1 mM EGTA, 61{iM calcium 
chloride (0.5|iM calcium).
When freshly prepared, the pH was adjusted to 7.5 with 1M potassium 
hydroxide. When using, 2.5MM ATP and 1 mg/ml BSA were added.
2 .3  ION EXCHANGE RESIN
Preparation of Dowex formate
Dowex 1 x 8-200 chloride form, strongly basic anion exchange resin, 8% 
cross-linked with a dry mesh of 100-200 was treated as described below to obtain the 
formate form for separation of inositol phosphates. A known packed volume of 
Dowex was washed with distilled water, left to settle and the 'fines' discarded. This 
was repeated twice. The Dowex was transferred to a sintered glass funnel and 
washed with 20 volumes of 2M sodium hydroxide. The Dowex was then washed 
with 10 volumes of water followed by 5 volumes of 1M formic acid. Finally, the 
Dowex was washed with water until the pH of the slurry was constant at ~5.5. 
Following each preparation of Dowex formate, it was characterised by performing ml 
by ml elutions of a mixture of [3H]inositol (1) monophosphate, [3H]inositol (1,4) 
bisphosphate, [3H]inositol (1,4,5) trisphosphate.
2 .4  CULTURE OF SWISS 3T3 MOUSE FIBROBLAST CELLS
Swiss 3T3 cells were routinely maintained in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with glutamine (2mM), penicillin/streptomycin 
(lOOIU/ml) and newborn calf serum (10%). Medium was changed every two days 
as it became acidified and depleted of serum. To prevent selection of resistant strains 
of bacteria, gentamycin was used in rotation with penicillin/streptomycin. Cells were 
kept in a humidified atmosphere of 5% CO2 at 37°C. Except for experimental
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dishes, cells were grown in 25 or 75cm2 culture flasks and were passaged when 80% 
confluent. Cells were checked regularly for their ability to contact inhibit when 
100% confluent. Cells which exhibited transformed morphology, showed reduced 
responsiveness to given agonists or reached passage numbers higher than 40, were 
discarded.
Cell Passage
Cells were passaged at a ratio of 1 to 5 according to the following
protocol:
The medium was aspirated and replaced with 3ml of sterile trypsin 
solution per 75cm2 flask. Flasks were returned to the incubator for 2-3 minutes 
until cells were detached from the flask bottom. Trypsin activity was inhibited by 
addition of 6ml of medium. The cells were then suspended by aspiration to ensure 
maximal dispersal.
After transfer to a sterile tube, the cell suspension was centrifuged at 1000 
rpm for 5 minutes and the supernatant discarded. Cells were then resuspended in 
complete medium and aliquoted into new sterile flasks containing 9ml of fresh 
medium. The flasks were rocked gently to ensure even distribution of the cells 
across the bottom, and then returned to the incubator.
Cryogenic preservation of cell lines
Cell lines were stored in liquid nitrogen according to the following
protocol:
Cells were trypsinised as outlined. They were then resuspended in 
DMEM containing 20% (v/v) newborn calf serum and 8% (v/v) DMSO at a density of 
approximately 106 cells per ml of freezing medium and aliquoted into freezing vials.
Cells were frozen slowly for 24h at -80°C before transfer to a vat of liquid 
nitrogen. To bring cells up from frozen, vials were removed from liquid nitrogen 
and thawed rapidly in a water bath at 37°C. Each aliquot of cells was plated out in
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9ml fresh medium and left to attach overnight. The following day, the medium and 
suspended dead cells were removed and the surviving cells were fed normally.
2 .5  THE RADIOLABELLING AND ANALYSIS OF
PHOSPHOLIPIDS
2 .5 .1  Cell incubation and lipid extraction
Swiss 3T3 cells were seeded onto 6-well plates and grown in DMEM 
containing 10% newborn calf serum for 48h until approximately 90% confluent.
The medium was then changed to one containing lfiCi/ml [5,6,8,9,11,12,14,15 -  
3H]arachidonic acid (150-230Ci/mmol) for 12, 24, 36, 48, 60 and 72h. The plates 
were then transferred to a heated aluminium block plate holder. The incubation 
medium was removed and the monolayers washed three times with 0.5ml HBG for a 
total of 45 minutes. Ice-cold methanol (1ml) was then added to each well 
immediately upon aspiration of the HBG and the contents were scraped with a wax- 
filled pipette tip and transferred to a polypropylene tube. Each well was washed 
further with an additional 0.5ml ice-cold methanol and this was combined with the 
previously scraped samples. Chloroform (0.75ml) was added to each tube, the 
contents thoroughly mixed, and samples allowed to extract for at least 30 minutes at 
4°C Following this, 0.75ml each of chloroform and water were added to every 
sample, tubes vortex-mixed and samples left to stand to allow separation of the 
phases. Finally, 1ml of the lower, organic phase was transferred to a 2ml glass 
trident vial. The samples were then dried under vacuum in a centrifugal evaporator. 
Lipids were dissolved in chloroform:methanol (19:1 v/v) and used for thin layer 
chromatography.
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 . 2 .5.2  Thin layer chromatography
A 20 x 20cm silica gel 60 plate was soaked in ImM EDTA and allowed to 
dry at room temperature. The plate was activated by incubation at 120°C for lh 
before use. Samples, prepared as described, and standard lipids were spotted onto 
the plate in a volume of 30jil. The plates were developed in a solvent of 
chloroform:methanol:glacial acetic acid:water (75:45:3:1 v/v). Plates were then 
allowed to dry in a fume cupboard and the standards located by exposure to iodine 
vapour in an enclosed chamber. By reference to the migration of standards, the 
phospholipids of interest were marked, the silica removed from the plate with a razor 
blade and transferred to a scintillation vial. 3ml of scintillation fluid (optiphase 3) 
was added to each vial, the contents mixed and the radioactivity determined by 
scintillation counting. Standard Rf values on this system were: sphingomyelin -  
0.075; phosphatidylcholine -  0.125; phosphatidylinositol -  0.48; 
phosphatidylethanolamine -  0.56; phosphatidylserine-0.825; phosphatidic acid -  
0.91.
2 .6  MEASUREMENT OF ARACHIDONIC ACID GENERATION
2 .6 .1  Preparation of samples
Cells were seeded onto 24-well plates and grown in DMEM containing 
10% NCS until approximately 90% confluent when the medium was removed, and 
replaced with medium containing 0.5pCi/ml [3H] arachidonic acid for 24h. Plates 
were then transferred to an aluminium plate warmer at 37°C. The labelling medium 
was removed and cells washed three times in 0.5ml HBG for a total of 45 minutes. 
The cells were stimulated by addition of the appropriate agonist in 200|il HBG for the 
required time. To determine basal levels of arachidonic acid, the appropriate wells 
were treated with HBG alone for the equivalent times.
When measuring extracellular arachidonic acid release, the incubation 
medium was removed and transferred to an Eppendorf tube. This was centrifuged
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for 5 minutes at 1000 rpm and an aliquot of 200j l l 1 was counted for radioactivity. 
When examining intracellular liberation, the medium was aspirated and 1ml of ice- 
cold methanol, containing 15jil of glacial acetic acid, was added to each well. The 
plates were left on ice for 20-30 minutes. The cell debris was then scraped from 
each well and transferred to a polypropylene tube. Each well was further washed 
with an additional 0.5ml methanol and transferred to the appropriate tubes. 
Chloroform (0.75ml) was then added to each tube, the samples mixed and left to 
extract at 4°C for at least 30 minutes. Phases were split by the addition of 0.75ml 
each of chloroform and water followed by a vortex mix and short centrifugation (1 
min) at 800g. The upper phase was aspirated and 1ml of the lower phase transferred 
to a glass vial and dried under nitrogen. At this point, samples were prepared for 
either thin layer chromatography or silicic acid column chromatography. For the 
former, samples were dissolved in 30p.l of chloroform:methanol (2:1 v/v). For the 
latter, samples were dissolved in 1ml of petroleum ether (60-80°) containing 4% (v/v) 
diethyl ether.
2 .6 .2  Thin layer chromatography
A 20 x 20cm silica gel 60 plate was activated at 120°C for lh prior to use. 
Samples, prepared as described, and standard arachidonic acid were spotted onto the 
plate and developed with the solvent system obtained from the upper phase of ethyl 
acetate:acetic acid:2,2,4-trimethylpentane:water (45:10:25:50 v/v/v/v). Plates were 
then allowed to air-dry in a fume cupboard and standards located either by 
radioactivity counting (if radiolabelled standard) or exposure to iodine vapour in an 
enclosed chamber (if unlabelled). By reference to the migration of standards, the 
arachidonic acid was marked, scraped from the plate with a razor blade, and 
transferred to a scintillation vial to which was added 4ml of scintillation fluid. The 
contents were mixed and radioactivity determined by scintillation counting.
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2 . 6 . 3  Silicic acid column chromatography
Silicic acid columns were prepared by adding 0.5g silicic acid to glass 
wool plugged Pasteur pipettes. The columns were supported in a metal rack and 
each washed with 10ml petroleum ether (60-80°) before use. The samples, 
dissolved in 1ml petroleum ether/diethyl ether (96/4 v/v) were applied to the columns 
and the solvent allowed to run to waste. The columns were then washed with 3ml 
petroleum ether/diethyl ether (96/4 v/v). The arachidonic acid-containing fraction 
was collected in a scintillation vial by eluting with 3ml diethyl ether. Scintillation 
fluid (10ml) was added to this and the radioactivity determined by liquid scintillation 
spectrometry.
2 .7  MEASUREMENT OF LYSOPHOSPHOLIPID GENERATION
2 .7 .1  Preparation of cells
Swiss 3T3 cells were cultured in 24-well plates and labelled with 2{iCi/ml 
[3H]choline chloride for 48h. The cell density at the onset of labelling was such that 
at the end of the labelling period the cultures were both confluent and quiescent.
Plates were transferred to a heated aluminium block and the monolayers washed, as 
before, with HBG. Cells were then stimulated for the appropriate times by the 
addition of 200fil of agonist in HBG. The medium was aspirated and reactions 
terminated by the immediate addition of 1ml of ice-cold methanol containing carrier 
lysophosphatidylcholine, lysophosphatidylethanolamine and lysophosphatidylinositol 
at 1 mg/ml. Phospholipids and lysophospholipids were extracted as described in 
Section 2.6.1 and the lower phase dried under vacuum. The lipids were dissolved in 
30pl of chloroform:methanol (2:1 v/v), ready for thin layer chromatography.
55
2 . 7 . 2  Thin layer chromatography
An EDTA-treated silica gel 60 plate was activated at 120°C for lh. 
Samples and standard lipids were spotted in 30pl amounts and the plate developed for 
approximately 90 minutes in a tank pre-equilibrated with a solvent system of 
chloroform:methanol:glacial acetic acid:water (50:30:8:3 v/v/v/v). The plate was air- 
dried in a fume cupboard and the standards located by exposure to iodine vapour.
By reference to the migration of standards, lysophosphatidylcholine and other 
lysolipids were scraped from the plate and transferred to a scintillation vial containing 
4ml scintillation fluid. The radioactivity was determined by scintillation counting.
Standard Rf values on this system are: phosphatidylcholine -  0.312; 
phosphatidylethanolamine-0.79; phosphatidylserine-0.8; phosphatidic ac id - 
0.825; lysophosphatidic acid -  0.6; lysophosphatidylcholine -  0.106; 
lysophosphatidylethanolamine -  0.52; lysophosphatidylinositol -  0.4; 
lysophosphatidylserine -  0.306.
2 .8  MEASUREMENT OF ARACHIDONIC ACID METABOLITES
2 .8 .1  Cyclooxygenase products
(i) Preparation of samples
[3H] arachidonate labelled cells were washed and stimulated as previously 
described (see Section 2.6.1). Reactions were terminated by the addition of 1ml of 
methanol containing PGE2, 6-keto PGFia , PGD2 and PGF2a (2|ig carrier/ml 
methanol). The contents of each well were scraped and transferred to small 
centrifuge tubes which were kept on ice for 20-30 minutes and then centrifuged at 
lOOOg for 15 minutes at 4°C. 0.8ml of the supernatant was transferred to a glass vial 
for hplc analysis. This was acidified to pH3.0 by the addition of 0.2ml sodium 
citrate (0.1M)/citric acid (0.1M) solution, pH3.0. An additional 0.2ml 
orthophosphoric acid, pH3.0, was added to maintain the correct aqueous:organic 
ratio for hplc. The total volume for hplc was 1.2ml.
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(ii) High performance liquid chromatography
lml samples were injected onto a 30cm x 0.39cm p-Bondapak C-18 
reverse phase column and eluted with 32% acetonitrile/68% orthophosphoric acid 
pH3.0, at l.Oml/min for 30 minutes. The column was then flushed with 95% 
acetonitrile/5% orthophosphoric acid, pH3.0 at 2.0ml/min for 3.5 minutes and the 
run was completed with 32% acetonitrile/68% orthophosphoric acid, pH3.0, at 
2.0ml/min for 3.5 minutes. Fractions of 0.5ml were collected in scintillation vials to 
which 4.5ml of scintillation fluid was added and the radioactivity determined by 
liquid scintillation spectrometry. Arachidonic acid and prostaglandins were detected 
by comparison with the elution profiles of standards.
Standards were prepared for chromatography by dissolving in acetonitrile 
32%/orthophosphoric acid, pH3.0, 68%. These were detected by U. V. absorption 
at 216nm. The retention times were as follows: PGE2 -  21.35 minutes; PGD2 -  
25.14 minutes; PGF2« -  18.08 minutes; 6-keto PGFia -  25.64 minutes; AA -  
44.10 minutes.
2 .8 .2  Lipoxygenase products
Two different protocols were used for the measurement of these products,
(i) Protocol 1
Preparation of samples
[3H] arachidonate labelled cells were washed and stimulated as previously 
described (see Section 2.6.1). Reactions were terminated by addition of lml 
methanol containing 5-HETE and LTB4 (2|ig canier/ml methanol). The methanol 
content of the stopped reactions was increased to 70% and the samples kept at -20°C 
for at least 20 minutes to precipitate excess protein. After scraping and centrifugation 
at lOOOg for 15 minutes at 4°C, the supernatant was removed for analysis. The 
methanol content of the samples was reduced to 50% with water prior to analysis.
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 High, performance liquid chromatography
Injections of 1ml were made onto a 25cm x 0.39cm Lichrosorb C-18 
column using an autosampler. Products were eluted with methanol 68.7%/(methanol 
20%/ammonium acetate (0.5%) 80%) 31.3% at 2.0ml/min for 12 minutes. This was 
followed by an increase in the methanol fraction to 93.7% at 2.0ml/min for 6.5 
minutes. The mn was completed by decreasing the methanol to 50% at 2.0ml/min 
for 3 minutes. Samples were compared with the elution profiles of standards which 
were run using a radiochemical detector. The retention times were as follows:
LTB4 -  5.2 minutes; 5-HETE -11 .9  minutes and AA -  18.85 minutes.
(ii) Protocol 2
Preparation of samples
[3H] arachidonate labelled cells were washed and stimulated for the 
required times with the appropriate agonists. The supernatant was removed and 
PGB2 (lOOng/ml), prepared in ethanol, was added to each sample as an internal 
standard. This was then acidified to pH3 -  3.5 with 1M hydrochloric acid. At this 
point the sample was ready to apply to C-18 Sep-pak columns. These columns were 
washed with 10ml methanol, 10ml deionised water (pH3.0) and 10ml deionised 
water prior to addition of the sample. This was applied via a syringe attached to the 
top of the column. This was then washed with a further 20ml water and leukotrienes 
were eluted with 10ml ethyl acetate. After removing any residual water from the 
samples, they were dried under a flow of nitrogen and re-dissolved in 100-jJ.l of hplc 
solvent (see below) ready for injection.
High performance liquid chromatography
Samples (25|il) were injected onto a reverse phase 5|im ultrasphere ODS 
column (4.6mm i.d. x 25cm) for separation of products. The solvent system used 
consisted of de-ionised water:methanol:acetonitrile:acetic acid (45:30:25:0.05 v/v/v/v) 
pH5.7 and methanol. Products were eluted by increasing the concentration of 
methanol linearly over a period of 40 minutes until 100% methanol was obtained.
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The flow rate was lml/min and products were detected at 270nm. This concentration 
of methanol was retained for 10 minutes at a flow rate of 1.5ml/min. The 
concentration of methanol was then decreased over a period of 1 minute at 1.5ml/min 
until the starting concentrations were re-achieved. This was retained for 9 minutes at 
a flow rate of 0.6ml/min. Identification of leukotrienes was achieved by reference to 
authentic standards run using the same hplc system.
2 .9  PERMEABILISATION OF SWISS 3T3 CELLS
2 .9 .1  Electroporation
Monolayers of Swiss 3T3 fibroblasts were grown in 75cm2 flasks. Cells 
were prelabelled with either [3H] inositol (5jiCi/ml) for 48h or [3H] arachidonic acid 
(1 pCi/ml) for 24h. After the labelling period, cells were harvested mechanically with 
a cell scraper, incubated for 45 minutes in prelabelling medium, washed twice by 
centrifugation (800g for 2 minutes) and resuspended in a high potassium incubation 
buffer. The final cell suspension (6 x 106 cells/3ml buffer) was then exposed to four 
discharges of a 3pF capacitor with a field strength of 2KV/cm spaced by 2 second 
intervals. Approximately 90-95% of the fibroblasts were found to be permeable to 
ethidium bromide after this procedure.
For arachidonic acid or inositol phosphate measurements, 50|il of 
permeabilised cells (104 cells) were incubated with agonists in incubation buffer in a 
final volume of 250pl. After the appropriate times, the reactions were terminated 
either with 250j l x 1 methanol (for arachidonic acid measurements) or 250jil perchloric 
acid (for inositol phosphate measurements) and the products measured as described 
above.
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2 .9 .2  Streptolysin-0 permeabilisation
(i) Determination of cell permeabilisation
(a) Entry of fluorescent dye
Swiss 3T3 cells were scraped from a 75cm2 flask and transferred to a 
centrifuge tube kept at 37°C for 45 minutes to allow recovery. Cells were then 
washed three times in HBG and finally resuspended in permeabilisation buffer 
containing streptolysin-O (0.6U/ml) and the fluorescent stain bizbenzimide 
(lOpg/ml). After 5 minutes, the cells were transferred to a slide and examined for 
fluorescence.
(b) Assay for lactate dehydrogenase activity
Confluent Swiss 3T3 cells grown on 6 well plates were washed three
times with HBG and then exposed for 5 minutes to various concentrations of
streptolysin-0 prepared in permeabilisation buffer. The incubation medium was 
removed and transferred to Eppendorfs. These were centrifuged for 5 minutes to 
remove any proteins that could interfere with results.
The equilibrium constant of the LDH reaction is K = 2.7 x 10" mol/l 
(30°C); it strongly favours formation of lactate and NAD.
Therefore, the measurement has to be carried out in an alkaline medium 
with relatively high concentrations of lactate and NAD to obtain reasonable reactivity 
velocities for accurate photometric readings.
The readings were carried out on a spectrophotometer under the following 
conditions: Wavelength -  339nm; light path -  10mm; absorbance -  0.1; 
temperature -  30°C.
The following solutions were pipetted successively into a cuvette: 0.10ml 
of p-NAD (172mmol/l) and 2.40ml of Tris/L-lactate (Tris, 112mmol/l, pH9.30, 
25°C; L-lactate 56mmol/l; potassium chloride, 170mmol/l). This was thoroughly 
mixed with a plastic spatula and placed in the spectrophotometer for 5 minutes or until
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the desired temperature was reached. At this point, 150jil of the sample was added 
and mixed. After 30 seconds, the reading was taken over a period of 5 minutes.
(ii) Protocol for permeabilisation
Swiss 3T3 cells were grown on 24-well plates in DMEM containing 10% 
newborn calf serum. Cells were prelabelled with the appropriate radioisotopes for 
the relevant length of time. After labelling, the monolayers were washed in 250|il 
HBG for 45 minutes. Cells were permeabilised by incubation with 500pl 
streptolysin-0 (0.6U/ml) in permeabilisation buffer for 5 minutes. This was 
followed by a further 15 minutes wash in HBG and then stimulation with the 
appropriate agonist in 200|il permeabilisation buffer. Reactions were terminated by 
the addition of 200pi ice-cold methanol (for arachidonic acid measurements) or 200|il 
of 10% perchloric acid (for inositol phosphate measurements) and the products 
measured as described above.
Approximately 90-95% of the fibroblasts were found to be permeable to 
bizbenzimide after treatment with streptolysin-O. In addition, 0.6U/ml of 
streptolysin- 0  gave maximal release of lactate dehydrogenase from these cells.
2 .1 0  MEASUREMENT OF STIMULATED INOSITOL
PHOSPHATE FORMATION
2 .1 0 .1  Incubation of cells with test reagents
After seeding on 24-well plates in DMEM containing 10% NCS for 24-h, 
cells were grown in 0.5ml of inositol-free DMEM containing 1% glutamine and 1% 
dialysed calf serum with 5|iCi/ml of [2-^H]myoinositol for 48h, by which time the 
cells were confluent, quiescent and labelled to isotopic equilibrium. Labelling 
medium was then aspirated and cells washed three times in HBG for 45 minutes.
The cells were next incubated with 200fil of incubation buffer containing the test 
reagent at the required concentration for the appropriate times.
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2 .1 0 .2  Assay of individual inositol phosphate fractions
Incubations were terminated by addition of 200jil of ice-cold 10% 
perchloric acid. Inositol phosphates were extracted on ice for at least 30 minutes, 
followed by scraping and removal of the cell debris into a plastic Eppendorf tube.
The 24-well plates were washed with a further 200pl of perchloric acid for 5 minutes 
at 4°C. The supernatants were removed to a second tube, neutralised by the addition 
of 1.5M potassium hydroxide/60mM Hepes in the presence of universal indicator and 
the precipitated potassium perchlorate removed by centrifugation at 14,000g for 5 
minutes at 4°C. The supernatants were removed and made up to 4ml with 5mM 
sodium tetraborate/0.5mM EDTA, pH6.7.
Individual inositol phosphates were separated by batch elution from 1ml 
Dowex formate columns in glass wool-plugged Pasteur pipettes. Samples were 
loaded onto individual columns and washed with 10ml water. This was followed by 
14ml of 60mM ammonium formate/5 mM sodium tetraborate which removed 
glycerophosphoinositides. Elution of inositol monophosphate (IP) was achieved 
with 16ml of 0.2M ammonium formate/0.1M formic acid. Inositol bisphosphate 
(IP2) was eluted with 16ml of 0.4M ammonium formate/0.1M formic acid and a 
further 16ml of 0.8M ammonium formate/0.1M formic acid was used to elute inositol 
trisphosphate (IP3). To determine the amounts of each inositol phosphate, 3ml from 
the IPi fraction, 4ml from the IP2 fraction and 5ml from the IP3 fraction were added 
to 15ml of scintillation fluid and the radioactivity determined by liquid scintillation 
spectrometry.
2 .1 0 .3  Assay of total inositol phosphates
Total inositol phosphates were assayed by accumulation in the presence of 
lOmM lithium chloride essentially by the method of Berridge et al (1982). Dowex 
formate (1 x 8 20(M00 mesh) 500fil, was added to samples, followed by 3ml of 
distilled water. After the Dowex had settled, the supernatant was aspirated. The 
removal of glycerophosphoinositides was achieved by washing with 3ml of 60mM
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ammonium formate/5mM sodium tetraborate followed by a further 3ml wash with 
water.
Total inositol phosphates (mainly IPi and IP2) were eluted with 1ml of 
1M ammonium formate/0.1M formic acid. 0.8ml of the supernatant was removed 
and added to 5ml of scintillation fluid. The radioactivity was determined by liquid 
scintillation counting.
2 .1 1  QUANTITATION OF THE ARACHIDONIC ACID
CONCENTRATION PRODUCED IN STIMULATED CELLS
The amount of arachidonic acid produced in stimulated cells was 
measured via its conversion to 15-hydroxyeicosatetraenoic acid (15-HETE) using 
soyabean 15-lipoxygenase. This was converted to a concentration by measuring the 
intracellular volume of Swiss 3T3 fibroblasts (see 2.12).
(i) Preparation of samples
Swiss 3T3 cells were seeded onto 6-  or 24-well plates and grown to
quiescence in DMEM containing 10% newborn calf serum. Plates were then washed
in 0.5ml HBG for 45 minutes. This was followed by stimulation with agonists for 
20 seconds (a point at which the intracellular early phase of arachidonic acid release 
should be maximal). The reaction was terminated by the addition of 1ml of 
methanol. Arachidonic acid was extracted and separated on silicic acid columns as 
previously described. Once eluted from the columns in diethyl ether the samples 
were dried down and re-dissolved in 20|il ethanol.
(ii) Enzyme assay with soyabean 15-Iipoxygenase
The stock enzyme (specific activity 90U/|il) was prepared in 1M 
ammonium sulphate/0.05M sodium phosphate, pH8.0. For use in experiments, this 
was diluted to lOpM in 0.1M phosphate buffer, pH7.4.
Reactions were performed in a heated water bath at 37°C. For 
incubation, 5pl of enzyme was added to a polypropylene tube containing 29|il
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phosphate buffer and 6pl of either the sample or standard arachidonic acid (this was 
used in the range 0.08ng/ml -  3.125ng/ml). The reaction was allowed to proceed for 
30 minutes and stopped by the addition of 5pl nordihydroguaiaretic acid (NDGA) 
920pM and 5|il of sodium borohydride (50mg/ml).
(iii)  HPLC for arachidonic acid and 15-HETE detection
It is possible to check the efficiency of the enzyme in converting 
arachidonic acid to 15-HETE by separating these components on hplc.
Samples, containing [3H] arachidonic acid (0.6pCi), were treated as 
above and were prepared in 50% methanol/50% ammonium acetate (0.5%).
Injections of 25{il were made onto a lichrosorb C-18 column (25cm x 
0.39cm). Using a 2ml/min flow rate, products were eluted with methanol 
62.5%/acetonitrile 37.5% for 5 minutes. This was followed by an increase in the 
methanol fraction to 75% for 10 minutes and a further increase to 93.7% for 8.5 min. 
The run was completed by decreasing the methanol to 43.7% for 15 minutes.
Elution profiles of the samples were compared with those of standards 
which were determined using a radiochemical detector. The retention times were: 
15-HETE -  6.2 minutes and AA -  11.4 minutes.
(iv ) 15-HETE assay system
This assay was used as a means of directly measuring the amount of 15- 
HETE formed in samples treated with the 15-lipoxygenase enzyme. The assay was 
based on the competition between unlabelled 15-HETE in the sample or standard and 
a fixed quantity of tritium labelled 15-HETE for binding to a limited quantity of an 
antibody which has high specificity and affinity for 15-HETE. The amount of 
radioactive ligand bound by the antibody was inversely proportional to the 
concentration of added non-radioactive ligand.
Samples were assayed as described using instructions obtained with a 
[3H] 15-HETE assay kit.
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2 .1 2  DETERMINATION OF INTRACELLULAR VOLUME
Swiss 3T3 cells were seeded onto a 24-well plate and grown in DMEM 
containing 10% NCS until confluent and quiescent. The incubation medium was 
then aspirated and cells washed in 1ml of HBG for 30 minutes at 37°C. After this 
period, the medium was aspirated and cells incubated with 0.25ml of HBG 
containing 0.2|iCi/ml [3H] water and 0.04p.Ci/ml [14C] sucrose, for 30 minutes.
The medium was aspirated and 0.5ml of 1M sodium hydroxide added to each well to 
solubilise the cells. A sample of 0.4ml was then taken from each well and 
transferred to a scintillation vial. 12ml of scintillation fluid was added and the 
radioactivity determined by scintillation counting. Essentially, the [14C] sucrose was 
assumed to represent contamination by the extracellular medium and pH] water, after 
correction for contamination by the extracellular medium, was assumed to be 
intracellular.
2 .1 3  DETERMINATION OF THYMIDINE INCORPORATION IN
SWISS 3T3 CELLS
For measurement of DNA synthesis, cells were grown to confluence and 
quiescence in DMEM containing 10% NCS. The medium was then changed to one 
containing 0.5% NCS for 24h. Additions of mitogens were made at the 
concentrations indicated in serum-free DMEM containing ljiCi/ml of [3H] thymidine 
and the cells were incubated for 24h. The medium was then aspirated and the 
monolayers were washed twice with 0.5ml HBG, three times with 0.5ml ice-cold 
5% (v/v) trichloroacetic acid and twice with 0.5ml ice-cold ethanol. The cells were 
then solubilised in 1ml of 0.3M sodium hydroxide and this was transferred to a vial 
containing 0.2ml of 1.5M hydrochloric acid. The radioactivity was determined by 
scintillation counting in 5ml scintillation fluid.
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2 .1 4  PHORBOL DIBUTYRATE BINDING ASSAY
Swiss 3T3 cells were seeded onto 24-well plates and grown to quiescence 
in DMEM containing 10% newborn calf serum. The medium was aspirated and the 
monolayer washed twice with 0.5ml of PBS at 37°C. Cells were then incubated for 
15 minutes with 150pl of assay buffer (PBS + 0.1%(w/v) BSA) containing 10- 
lOOnM [3H] phorbol dibutyrate (specific radioactivity 25Ci/mmol) ± 200-fold excess 
unlabelled phorbol dibutyrate for non-specific binding. Cells were then rapidly 
washed three times with 0.5ml of ice-cold assay buffer and solubilised with 0.5ml of 
0.5M sodium hydroxide/0.1% v/v Triton X-100. the solubilised cells were 
transferred to vials and assayed for radioactivity in 4ml of scintillation fluid.
Three wells were left in each 24—well plate for cell counting.
2 .1 5  INTRACELLULAR CALCIUM MEASUREMENTS
2 .1 5 .1  Preparation of cells
Glass coverslips which had been sterilised were coated on one side with 
0.3% of gelatin. This was allowed to dry under sterile conditions and the coverslips 
were placed in a 9cm petri dish (four coverslips per dish). Swiss 3T3 cells were 
seeded onto the coverslips and were grown in DMEM containing 10% newborn calf 
serum until confluent and quiescent.
2 .1 5 .2  Calcium measurements
The confluent monolayers were washed in HBG and incubated with HBG 
containing 5pM indo-1 AM, 0.125% (w/v) plurionic acid, 0.5% (v/v) DMSO for 45 
minutes at room temperature. Coverslips were placed in a perspex bath which was 
fixed to the stage of a Nikon Diaphot inverted microscope. The cells were perfused 
with HBG with or without additions at 1.5ml/min (35-37°C) and illuminated at 
360nm. Light emitted from the cells with a wave-length greater than 385nm was 
directed at a 460nm dichroic mirror which sent longer wavelength light via a 495nm 
barrier filter to a photomultiplier. Shorter wavelengths were reflected by the dichroic
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mirror and sent via a 405nm barrier filter to a second photomultiplier. The signals 
from the two photomultipliers were divided using analogue circuitry and a signal 
representing the ratio filtered at 3Hz. No correction was made for cell 
autofluorescence which was less than 5% of a typical indo loaded preparation. Due 
to the difficulties associated with absolute calibrations for intracellular calcium 
concentrations from cells loaded with AM esters of calcium indicators (Highsmith et. 
a i, 1986) the experimental records are presented in terms of raw fluorescence data.
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ANALYSIS AND PRESENTATION OF RESULTS
Unless otherwise stated, all experiments were performed at least three 
times and each data point represents the mean ± S.D. of triplicate determinations. 
The statistical significance was estimated by a paired students’t* test on an Apple 
Macintosh stat-works programme and significance was generally taken as values of 
p<0.05. E C 5 0  values were calculated from dose-response curves fitted to a logistic 
equation (non-linear regression analysis) as defined by DeLean et. al., 1980. 
However, for presentation purposes, dose-response curves were shown as simple 
line graphs from the Apple Macintosh Cricket Graph programme.
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CHAPTER 3
THE MECHANISMS OF ARACHIDONIC ACID RELEASE 
IN BOMBESIN-STIMULATED SWISS 3T3 FIBROBLASTS
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INTRODUCTION
The results presented in this chapter form a general introduction and basis for 
subsequent studies within this research project The quintessential features of this 
chapter are firstly, the definition of the profile of the response to bombesin and, 
secondly, a general indication of the regulatory requirements of this response.
Having determined this, subsequent chapters attempt to analyse certain aspects of the 
response in more detail.
Elucidation of the molecular mechanisms leading to cellular proliferation 
requires the identification and characterisation of the signalling pathways that, when 
activated, induce a mitogenic response. In considering the mitogenic action of 
bombesin, various effects attributed to this peptide may play important roles, such as 
the rapid increase in intracellular calcium via Ins(l,4,5)P3 production (Blakely et al. 
1989; Cook et al., 1990), activation of PKC (Erusalimsky et al., 1988), stimulation 
of the Na+/H+ antiport system (Mendoza et al., 1986) and induction of the cellular 
oncogenes c-fos and c-myc (Bravo et al, 1987). Of these effects, probably the best 
characterised is that of the activation of phosphoinositide-specific PLC. The 
consequent production of Ins(l,4,5)P3 and sn-1,2-DAG has been well studied in 
this system and the former has been shown to be a transient process that is rapidly 
desensitised (Brown et al., 1987). Another enzyme suggested to be activated in this 
system in response to bombesin is PLD. Cook and Wakelam (1989) have proposed 
the existence of bombesin-stimulated PtdCho hydrolysis via PLD. They suggest 
that this contributes to the elevation of cellular DAG in the absence of significantly 
amplified Ptdlns (4,5)P2 breakdown, and that this event may be relevant to the 
activation of PKC in long-term cellular responses, since the agonist-stimulated 
Ptdlns (4,5)P2 hydrolysis is rapidly desensitised. Therefore, the interaction of both 
PLC and PLD signalling pathways may be important in bombesin-stimulated 
mitogenesis.
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The possibility that the mitogenic action of bombesin may involve stimulation 
of another pathway, namely AA release via PLA2 activation, has received relatively 
little attention. Recently, evidence has indicated that the liberation of AA and its 
possible conversion to cyclooxygenase metabolites constitutes one of the early 
mitogenic signals induced by bombesin in 3T3 cells (Millar & Rozengurt, 1990). It 
is also noteworthy that the PDGF AA and BB homodimers that stimulate re-initiation 
of DNA synthesis in the absence of other growth promoting factors, induce a large 
and sustained release of AA in Swiss 3T3 cells (Mehmet et al., 1990). Recent 
results obtained with mastoparan (Gil et al., 1990) also support the conclusion that 
AA release contributes to mitogenic signal transduction in this cell line. Mastoparan 
stimulated AA release in the absence of inositol phosphate accumulation or PKC 
activation and the results strongly suggest direct involvement of the AA signalling 
pathway in mastoparan-stimulated DNA synthesis.
Given the potential importance of the pathway in the mitogenic process in this 
system, the present work was undertaken to clarify the regulatory mechanisms 
controlling AA release in bombesin-stimulated 3T3 cells and to potentially identify 
the role played by the pathway in signal transmission. Given the extensive amount 
of work already performed on this system with regard to the bombesin receptor 
(Brown et al., 1988; Battey et al., 1991) and how it couples to different signalling 
pathways within these cells (Brown et al., 1987; Takuwa et al., 1987; Cook & 
Wakelam 1989; Plevin et al., 1990), it may be possible to relate activation of AA 
release to other established effects of bombesin stimulation.
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RESULTS
The incorporation of AA into cellular phospholipids was examined over a 24h 
labelling period. This gave an indication of the optimal labelling time for these cells 
and also, as has been examined in Chapter 4, which phospholipids may be potential 
sources of the AA released in bombesin-stimulated cells. Approximately 70% of the 
radiolabel was incoiporated into cellular phospholipids. Figure 3.1 shows that the 
label incorporated most readily into PtdCho (48%) and PtdEtn (26%) and to a lesser 
extent into Ptdlns (10%) and PtdOH (12%). Little AA was found in PtdSer and 
sphingomyelin (0.7% and 2.4% respectively). The optimal labelling time was 
approximately 20h. In all subsequent experiments, cells were labelled for 24h prior 
to agonist stimulation.
Addition of bombesin to Swiss 3T3 cells caused the release of AA from 
prelabelled cells. Figure 3.2 shows the timecourse of release over 40 min.
Bombesin stimulated a rapid increase in free AA within 1 min (2.7-fold stimulation). 
This was a transient response since AA levels returned to basal by 5 min. However, 
there was evidence for a later, sustained phase of release occurring after 10 min 
stimulation, with levels reaching 11.1-fold after 40 min. This response was dose- 
dependent with an EC50 value of 3.0 ± 0.4nM as shown in Figure 3.3.
To determine whether the initial phase of this response was due to activation 
of PLA2, the formation of lysophospholipids was examined. Since PLA2 hydrolysis 
of phospholipids will result in the formation of both AA and a lysophospholipid, it is 
essential that both products are measured in the same experiment. Measurements 
were therefore conducted in cells double-labelled with [14-C] AA and [3H] choline so 
that formation of both products could be determined over the same timecourse.
Upon bombesin stimulation, there was no apparent formation of LysoPtdEtn, 
LysoPtdlns or LysoPtdOH over a 10 min period (Fig.3.4a). However, a 1.7-fold 
increase in LysoPtdCho levels was observed after 1 min stimulation with bombesin 
(Fig. 3.4b). This was shown to be significant when analysed by a one-tailed t-test.
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For LysoPtdCho p=0.005 whereas for LysoPtdEtn, LysoPtdlns and LysoPtdOH 
p=0.32,0.28 and 0.36 respectively. The levels of LysoPtdCho subsequently 
decreased but values remained above basal for at least 10 min. A more detailed 
profile of this response is shown in Chapter 4 where the initial phase of AA release is 
examined in greater depth.
As previously described, PLA2 activation has been suggested to be under 
regulation by PLC in some systems. However, in other cases, the enzymes are 
independently controlled. In some cell types, such as neutrophils, this can be 
demonstrated through differential susceptibility of the GTP-binding proteins involved 
in each pathway to bacterial toxins (pertussis toxin and cholera toxin) (Cockcroft & 
Stutchfield, 1989). In the present system, the bombesin receptor is known to couple 
to the PLC pathway via a pertussis toxin insensitive G protein (Fischer &
Schonbrunn, 1988). It was therefore decided to examine whether AA release, as 
shown here, was sensitive to toxin treatment This was seen as a potential means of 
discriminating between the PLA2 and PLC pathways. Experiments suggested that 
the putative G protein involved in stimulation of this pathway was also insensitive to 
pertussis toxin, since AA release showed a similar fold increase in toxin-treated and 
untreated cells (2.8-fold and 3-fold respectively). The toxin did, however, appear 
to stimulate the basal release of [3H] AA in control cells (Fig.3.5). Since pertussis 
toxin could not be used as a tool to distinguish between pathways in this system, 
other methods of discrimination were tested.
Short-term pretreatment with PMA can be used to potentially dissociate the 
activation of PLA2 from PLC. A 15 min pretreatment with PMA will abolish 
bombesin-stimulated PLC-catalysed Ptdlns (4,5)P2 hydrolysis by a mechanism 
involving PKC-mediated negative feedback (Brown et al., 1987). However, the 
same treatment in this system caused significant enhancement (p=0.009) of AA 
release by 5 minutes (Fig.3.6). This result suggested that bombesin-stimulated AA release was
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not dependent on prior Ptdlns (4,5)P2 hydrolysis by PLC, since treatment that 
abolished the latter, potentiated the former.
Additional experiments were performed to determine the interrelationships, if 
any, between the PLC- and PLA2~catalysed pathways. Dependence of the AA 
response upon the PKC activity or increased calcium levels may suggest that prior 
activation of phosphoinositide hydrolysis by PLC is required. By studying the 
effects of altering the levels of PKC and extracellular calcium concentration on the AA 
response, the importance of these factors was established.
The Swiss 3T3 cell is fairly unusual in that its levels of PKC can be 
completely down-regulated after a 48h pretreatment with phorbol ester (Adams & 
Gullick, 1989). As a check that this treatment was effective, phorbol dibutyrate 
binding experiments were performed as a means of measuring the levels of PKC in 
PMA-treated and untreated cells (Fig.3.7). This data clearly showed that after long­
term PMA pretreatment there was virtually no PKC activity remaining within the cells 
(PMA pretreated cells contained 3.2 ± 2.8% of the PKC levels found in controls).
The AA response to bombesin was studied in cells that had received a 48h 
pretreatment with 300nM PMA. Figure 3.8 shows that the rate and extent of the 
response are both essentially the same in control and down-regulated cells (3.1-fold 
in control cells c.f. 2.8-fold in PMA-treated cells). Further experiments were 
performed using the PKC inhibitor staurosporine. A 15 min pretreatment of 3T3 
cells with staurosporine had no significant effect on AA release for up to 10 min of 
stimulation with bombesin (3.2-fold in control cells c.f. 3.3-fold in staurosporine- 
treated cells). Taken together, these data suggest that the initial phase of bombesin- 
stimulated AA release is not dependent on PKC activation.
Another potential regulatory factor of PLA2 is calcium. In various cell types, 
calcium mobilising agonists are reported to liberate AA and its metabolites in an 
extracellular calcium-dependent manner (Ho & Klein, 1987; Conklin et al., 1988; 
Felder et al., 1990). However, other studies suggest the existence of a calcium
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independent component (Bonventre & Swidler, 1988; Coyne et al., 1989; Takuwa 
et al., 1991). In the present study, AA release was examined over 40 min under 
conditions where extracellular calcium was buffered to 150nM using 0.3mM EGTA. 
This was compared with the AA response under normal conditions, i.e. extracellular 
calcium concentration of 1.26mM. As shown in Figure 3.10, bombesin-stimulated 
[3H] AA release occurred rapidly and to a similar extent regardless of the extracellular 
calcium concentration (2.7-fold in normal calcium c.f. 2.9-fold in low calcium). 
However, the second sustained phase of release was differently affected. After 10 
min stimulation at 1.26mM calcium, pH] AA release continued to increase with time 
up to at least 40 min. In contrast, when cells were treated with 150nM calcium, this 
increase was abolished. These observations support the conclusion that the effect of 
bombesin on AA release is temporally composed of two distinct phases i.e. the first 
phase (within 10 min) which is largely independent of the extracellular calcium 
concentration and the second sustained phase (after 10 min) which is totally 
dependent on the extracellular calcium concentration.
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Figure 3.1 Incorporation of [3H] arachidonate into membrane 
phospholipids
[3H] arachidonate was added to Swiss 3T3 cells for the times indicated and 
incorporation into individual phospholipids was examined using thin layer 
chromatography as described. Results are presented as the mean ± S.D. from a 
typical experiment where n=3.
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Figure 3.2 Timecourse of bombesin-stimulated arachidonic acid 
release in Swiss 3T3 cells.
Cells were treated as described and stimulated with either HBG (O) or 
617nM bombesin in HBG ( • )  for the times indicated. Total arachidonate release 
was measured as described. Results are representative of means ± S.D. where 
n=3.
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Figure 3.3 Dose response of arachidonic acid release to bombesin 
in Swiss 3T3 cells
Cells were stimulated with increasing concentrations of bombesin for 30 min 
and [3H] arachidonate release measured as described. Results are presented as the 
mean ± S.D. from a single typical experiment where n=3.
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Figure 3.4 Bombesin-stimulated lysophospholipid production in 
Swiss 3T3 cells
Cells were stimulated for the indicated times with 617nM bombesin (©) or HBG (O) 
(a) LyosPtdEtn, LysoPtdlns and LysoPtdOH and (b) LysoPtdCho production were 
measured using thin layer chromatography. Results are presented as the mean ±
S.D. from a single typical experiment where n=3.
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Figure 3.5 Effect of pertussis toxin pretreatment on bombesin- 
stimulated arachidonate release.
Cells were pretreated for 16h with either pertussis toxin (100ng/ml)(p,fs)or 
incubation medium(o,®)prior to stimulation with 617nM bombesin for the indicated 
times. Arachidonate release was measured as previously described. Results are 
presented as the means ± S.D. from a single typical experiment where n=3.
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Figure 3.6 Effect of short-term PMA pretreatment on bombesin- 
stimulated arachidonate release
Cells treated as described were pretreated for 15 min with either 300nM 
PMA (■) or HBG (•). The arachidonate released in response to bombesin 
stimulation was measured as described: and compared with unstimulated values (O). 
Results are presented as the mean ± S.D. from a single typical experiment where n=3. 
N.B. In the presence of PMA,basal values were slightly increased.
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Figure 3.7 Differences in phorbol dibutyrate binding in control 
and PKC down-regulated cells.
Swiss 3T3 cells were treated for 48h with either incubation medium, 300nM 
TPA, p-phorbol, or DMSO. Phorbol dibutyrate binding was measured as 
described. Results are presented as the mean ± S.D. from a single typical 
experiment where n=3.
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Figure 3.8 Effect of long-term PMA pretreatment on bombesin-
stimulated arachidonate release
Swiss 3T3 cells were treated for 48h with either 300nM PMA (■) or 
incubation medium ( • )  Cells were then stimulated with 617nM bombesin for the 
times indicated and values compared with basal levels (O). Results are presented as 
the mean ± S.D. from a ■ typical experiment where n=3.
Figure 3.9 Effect of staurosporine treatment on bombesin-
stimulated arachidonate release
Swiss 3T3 cells were pretreated for 15 min with either lOpM staurosporine
(S) or incubation medium (®). Cells were then stimulated with 617nM bombesin
and arachidonic acid release measured. These values were compared with those
obtained in the presence of HBG alone (O).
Results are presented as the mean ± S.D. from a single typical experiment where n=3.
| N.B. Values obtained after 20 minutes in the presence of PMA or staurosporine are 
significantly different from controls (p < 0.05)
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Figure 3.10 Effect of reducing extracellular calcium on bombesin- 
stimulated arachidonate release
[3H] arachidonate labelled cells were stimulated with 617nM bombesin in 
medium containing ImM calcium (• )  or medium in which the calcium had been 
buffered to 150nM with EGTA (■). Arachidonate was measured as described. 
Results are expressed as means ± S.D. from a typical experiment where n=3.
N.B. Values obtained after 20 minutes in medium containing 150nM calcium are 
significantly different from controls (p < 0.05)
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DISCUSSION
The results presented in this chapter demonstrate that bombesin induces a 
biphasic increase in AA liberation with the initial phase probably regulated by PLA2. 
Since neither the formation of lyso-phospholipids nor the effect of using putative 
PLA2 inhibitors has been studied at later time points, it is difficult to tell whether the 
second phase of release is also due to a PLA2 activity or whether a separate pathway 
(e.g. DAG lipase) is mvolved. Given the elevated levels of DAG at later time points 
in response to bombesin, the latter pathway could potentially be responsible for 
increased AA production. In the recent report by Takuwa et al. (1991), which has 
subsequently shown the existence of a biphasic AA response to bombesin, the 
proposal is made that both phases are mediated by PLA2 since mepacrine inhibits 
each to a similar extent. However, the specificity of mepacrine, as with many 
putative PLA2 inhibitors, is questionable. Is therefore remains possible that an 
additional pathway is involved.
The first transient phase of AA release occurs within 1 min of stimulation with 
bombesin. The precise kinetics of the response have not been characterised in this 
chapter (but see Chapter 4). This may be of importance in determining whether a 
direct receptor-mediated effect is involved i.e. receptor-mediated PLA2 activation.
Since bombesin stimulates the rapid hydrolysis of Ptdlns (4,5)P2 by PLC, it 
seemed possible that the resultant combination of calcium mobilisation and PKC 
activation could regulate the AA released by bombesin. However, experiments using 
PKC down-regulated cells, strongly suggest that PKC activation is not necessary for 
the initial phase of the AA response.
The effect of reducing extracellular calcium showed that the initial phase did 
not require bombesin stimulated entry of extracellular calcium. The response 
occurred to the same extent regardless of the calcium concentration in the medium. 
This, together with the lack of involvement of PKC, suggests that the first phase of 
release may be regulated by a PLA2 that is activated independently of PLC. This
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possibility is strengthened by the data shown in Figure 3.6 for PMA treated cells. 
This effect with PMA has been observed in other systems leading to the theory that 
receptor-mediated phosphoinositide hydrolysis and AA release can occur in a non­
interdependent manner via parallel activation of PLA2 and PLC (Burch & Axelrod, 
1987; Van Corven et al., 1989; Cockcroft & Stutchfield, 1989).
The second, sustained phase of AA release showed completely different 
characteristics to that of the first. It appeared to be absolutely dependent upon 
extracellular calcium as the increase in AA release was completely abolished in 
medium where the calcium had been reduced to 150nM. This effect has 
subsequently also been observed by Takuwa et al. (1991). These authors also 
showed that if the medium calcium was restored to 2mM after 30 min in cultures 
treated with low calcium conditions, [3H] AA release immediately increased at a 
constant rate during the second phase. Thus, the calcium dependent process 
underlying the second phase response may be readily reversible even after a 
prolonged calcium depletion.
These observations may reflect the involvement of a PLA2 with a different 
sensitivity to calcium. Perhaps the second phase is dependent upon stimulated 
calcium entry. Ballou et al. (1986) showed the existence of two different substrate- 
specific forms of the enzyme in platelets: one for PtdCho, which was calcium 
dependent and another for PtdEtn, which was calcium independent In Swiss 3T3 
cells, a small loss of AA from PtdEtn at later times has been observed. However, 
the significance of this is uncertain. Alternatively, a different enzyme such as DAG 
lipase may be involved in the second phase.
The role of PKC was explored up to 30 min stimulation in the second phase 
(c.f. 40 min for Ca2+ effects), An inhibitory effect was detected after 20 min in cells 
where PKC had been down-regulated or inhibited. This may reflect the existence of 
a PLA2 isozyme with a PKC dependency. In addition, these results may suggest 
that PKC activation of PLA2 is dependent on calcium.
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The mechanism behind PKC activation of PLA2 is unclear. It was 
previously proposed that PKC might phosphorylate and inactivate the physiological 
inhibitors of PLA2 known as lipocortins (Hirata et al., 1984). However, this has 
since proved inaccurate. More recently, it was suggested by Altiba et al. (1989) that 
PKC may enhance AA liberation by stimulation of Na+/H+ exchange which may 
modulate PLA2. This type of mechanism may be important in the second phase of 
AA release. Similar observations by Takuwa et al. (1991) concerning PKC, 
strengthen the possibility that the second phase of release is under different regulation 
from the first, and lend further credence to the possible involvement of different 
isoforms of PLA2 in each of the phases. The existence of isoforms that have 
different calcium sensitivities has already been mentioned. Isoforms of PLA2 have 
also been distinguished by differences in substrate specificity (Kramer et al., 1989) 
by the pH optimum of catalytic activity (Ballou et al., 1986) and in electrophoretic 
mobility (Moreno et al., 1988). The physiological relevance of isoforms is not 
known. Potentially different substrate specific forms of PLA2 may provide a rational 
basis for some apparently conflicting observations concerning the phospholipid 
source and pathway involved in AA release in certain cell types. This may certainly 
be true in the present system. Under different stimulatory conditions, the isoforms 
of PLA2 may be differentially regulated providing more potential variability in the AA 
response generated. In addition, the potential for control of AA release may be 
greatly increased under these circumstances where a number of regulatory factors are 
involved.
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CHAPTER 4
BOMBESIN STIMULATES THE RAPID ACTIVATION 
OF PHOSPHOLIPASE A2 CATALYSED PHOSPHATIDYLCHOLINE 
HYDROLYSIS IN SWISS 3T3 CELLS
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INTRODUCTION
Data presented in the previous chapter showed the novel biphasic nature of AA 
generation in response to bombesin in 3T3 cells and indicated the potential for there 
being two separate mechanisms regulating the initial transient phase of release and the 
later sustained phase. The initial phase of AA generation may be regulated by the 
early activation of a PLA2. The work presented in this chapter attempts to strengthen 
the evidence for PLA2 involvement in this response and relate activation of this 
enzyme to that of PLC, dissociating between the likelihood of a receptor-mediated 
process involved in PLA2 activation and the alternative, prior involvement of PLC.
In Chapter 3, the AA measured was total release both within and from the cell, 
i.e. there was no discrimination between intra- and extracellular AA. Many previous 
studies examining agonist induced AA release have often monitored the levels in the 
extracellular medium (Jaffe et al., 1987, Resink et al., 1987). However, changes in 
extracellular levels of AA are unlikely to sensitively and accurately reflect the time 
course of AA changes inside the cell. The AA measured in this chapter comprises 
only intracellular liberation and, as such, clarifies the kinetics and extent of release for 
the initial phase. Previously, the earliest time point measured was 30 sec. This is a 
relatively long period of stimulation by which time the initial intracellular phase could 
be declining or even finished. By examining shorter stimulation times, it is possible 
to clarify the kinetics of release and to dissociate between bombesin-stimulated AA 
release and InsP3 production.
One of the main problems associated with attempting to measure potentially 
rapid yet small changes in AA in stimulated cells is the lack of efficient separation of 
the fatty acid in some thin layer chromatography systems. This was overcome in the 
present chapter by using silicic acid column chromatography (see Chapter 2) in which 
AA can be eluted with a high (approximately 90%) recovery rate from samples with 
greater consistency.
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The question of the phospholipid substrate specificity of the enzyme involved 
in the initial phase of release is also addressed in the present chapter. This gives 
additional information regarding phospholipid turnover involvement in signal 
transmission in this system.
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RESULTS
The method of silicic acid column chromatography was widely used in this 
chapter for measurement of AA liberation. As such, it was important to characterise 
the elution profile of AA from these columns using a solvent system of petroleum 
ether (60-80°) with an increasing concentration (up to 4%) of diethyl ether. A step- 
by-step elution profile is shown in Figure 4.1 with the A A being eluted from the 
column in 4% diethyl ether. Methanol could be added after the diethyl ether to elute 
any phospholipids in the samples. Any remaining free AA was usually associated 
with this eluant. Various attempts were made to increase total AA recovery by using 
different percentages of diethyl ether in methanol before using methanol alone. This, 
however, made little difference and recovery remained approximately 90%. Columns 
were used as described in Chapter 2.
Addition of bombesin to Swiss 3T3 cells caused the rapid release of AA from 
prelabelled cells (Chapter 3). To determine the kinetics of A A liberation in response 
to bombesin, measurements of intracellular AA were made over a timecourse with 
short stimulation periods. AA was significantly elevated after a 2 sec stimulation, 
maximal between 10-30 sec and had returned to basal by 5 min (Fig.4.2). In the 
experiment shown in Figure 4.2, the maximum increase in AA release was 1.3-fold 
after 10 sec; the mean increase in release over 8 independent experiments was 
3.4 ± 0.4-fold. Figure 4.3 shows that the response was dose-dependent with an 
EC50 value of 2.7 ± 0.6nM.
The phospholipid source of the AA was examined by determining release of 
the fatty acid from various phospholipids. Figure 4.4 shows that AA was 
incorporated into PtdCho, Ptdlns, PtdEtn and PtdOH with virtually no label being 
detected in other phospholipids (see Chapter 3). No attempt was made to resolve the 
inositol phospholipids. The timecourse shown in the figure suggests that bombesin 
stimulated the release of [3H]AA only from PtdCho and that this was a very rapid 
event, evident between 2-5 sec and significant after 10 sec (p=0.013). The dpm
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released for PtdCho was approximately equal to the amount of free AA measured. In 
a representative experiment, after a 5 sec stimulation, 4783 dpm was lost from PtdCho 
and 4977 dpm found in free AA. Stimulation with the agonist resulted in a significant 
increase in [3H]AA-labelled PtdOH (p=0.006 after 30 sec). This could be due to 
either bombesin-stimulated PLC catalysed Ptdlns (4,5)P2 hydrolysis followed by the 
phosphorylation of DAG by diacylglycerol kinase, or PLD catalysed PtdCho 
breakdown, both of which have been demonstrated in Swiss 3T3 cells (Cook & 
Wakelam, 1989; Cook er a/., 1990).
To assess whether PLA2 activation might provide the mechanism for 
mobilisation of AA in response to bombesin, it was necessary to show that both AA 
release and lysoPtdCho production occurred over the same timecourse. As described 
in Chapter 3, to achieve this, cells were labelled with both [14C]AA and [3H]choline. 
Bombesin stimulated lysoPtd[3H]Cho as determined by thin layer chromatography 
showed a very rapid increase after 2 sec (almost 3-fold) with peak production after 
5-10 sec (Fig.4.4b). The timecourse of loss of [14C] AA label from PtdCho was the 
same as that for lysoPtdCho generation (Fig.4.5).
The incubation medium in which the above experiments were performed, 
contained calcium at a concentration of 1.26mM. To determine whether bombesin- 
stimulated AA production required the influx of calcium, which then activated PLA2, 
the effect of reducing extracellular calcium to approximately the intracellular 
concentration (150nM) on bombesin-stimulated AA release was examined (Fig.4.6). 
Inclusion of EGTA (0.33mM) in the Hanks buffered saline had no significant effect 
on AA release (2.9-fold stimulation in normal [Ca2+] c.f. 2.8-fold in low [Ca2+] after 
10 sec; values are means obtained from 3 separate experiments). Whilst ruling out a 
role for Ca2+ influx in bombesin-stimulated AA release, these experiments cannot 
address the possibility that bombesin-stimulated release of intracellular stored calcium 
could be involved in activation of PLA2. Swiss 3T3 cells were therefore treated with 
thapsigargin at a concentration reported to rapidly elevate intracellular calcium levels as
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a consequence of inhibition of the endoplasmic reticulum Ca2+-ATPase (Thastrup et 
al., 1990). No effect of the tumour promoter was observed upon A A release in 
control cells. ‘Thapsigargin did potentiate the response to bombesin, but only after a 
total incubation time of greater than one minute (Fig.4.7). Experiments were, 
therefore, performed to check that thapsigargin had indeed stimulated an increase in 
intracellular calcium. Figure 4.8 shows that stimulation of Swiss 3T3 cells with 
bombesin or thapsigargin caused an increase in intracellular calcium. However, there 
were clear differences between the two responses, lOOnM bombesin stimulated an 
almost immediate increase in calcium which reached 10% of peak after 0.42 ± 0.08 
sec and maximum intracellular calcium release was achieved after 6.0 ± 2.6 sec (mean 
of 3 experiments), l|iM  thapsigargin, on the other hand, only stimulated an increase in 
intracellular calcium after 6 sec with 10% of peak being reached after 6.4 ± 1.25 sec 
and maximal after 22 ± 2.6 sec (mean of 3 experiments).
As was shown in Chapter 3, the release of AA in response to bombesin at later 
time points (longer than 10 min) is sensitive to calcium depletion, with the stimulated 
release being reduced by at least 50% after 30 min in low Ca2+. This sensitivity to 
calcium has been seen in previous studies in other cell types (Kanterman et al., 1990), 
which have examined release of AA only at later time points and have only taken 
eicosanoid release from cells into account. As previously mentioned, the possibility 
of different mechanisms of AA release, with different regulatory requirements, 
existing within the same cell is an important consideration that has been ignored in 
many previous studies.
PLA2 has been reported to be regulated by PKC activity in several systems 
(Pfannkuche et al., 1989). To explore the possibility that this very rapid release of 
AA was dependent upon prior activation of PLA2 by PKC, the enzyme was either 
down-regulated by chronic PMA pretreatment, or inhibited by a 15 min pretreatment 
with staurosporine (10~6M). Cells pretreated with PMA, or its inactive analogue
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(T-phorbol, showed no differences in bombesin-stimulated AA release at the early time 
points measured (Fig.4.9). These results are supported by data obtained with cells 
pretreated with the PKC inhibitor, staurosporine (Fig.4.10) where no difference was 
observed in bombesin-stimulated AA release measured between untreated cells and 
cells treated with the inhibitor.
94
Figure 4.1 Arachidonate elution profile from silicic acid columns
[3H]AA (O.lpCi) prepared in 1ml petroleum ether/4% diethyl ether was added 
to petroleum ether-washed columns and eluted in step-by-step additions as shown. 
The results are from a typical experiment where n=3.
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Figure 4.2 Timecourse of bombesin-stimulated arachidonate 
generation
Swiss 3T3 cells, treated as described in the Materials and Methods chapter, 
were radiolabelled and stimulated with 617nM bombesin (• )  or treated with HBG (O) 
for the stated times. AA was measured using silicic acid column chromatography as 
described, the results are expressed as means ± S.D. from a single typical 
experiment where n=3.
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Figure 4.3 Dose-dependence of bombesin-stimulated 
arachidonate generation
[3H]arachidonate labelled Swiss 3T3 cells were stimulated with increasing 
concentrations of bombesin for 20 sec. The results are expressed as means ± S.D. 
from a single typical experiment where n=3.
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Figure 4.4 Bombesin-stimulated changes in the [3H]arachidonate 
labelling of Swiss 3T3 cells 
Swiss 3T3 cells, labelled with [3H]arachidonate, were incubated with either 
HBG (O) or with 617nM bombesin (#) for the required times. Cellular 
phospholipids were extracted as described. Changes in the arachidonate content of 
PtdCho, PtdEtn, Ptdlns and PtdOH in response to this treatment were detected using 
thin layer chromatography. Results are expressed as means ± S.D. of 4 experiments 
in which n=3 in each case.
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Figure 4.5 Bombesin-stimulated arachidonic acid release from
phosphatidylcholine and lysophosphatidylcholine 
formation
Cells were double labelled with [3H]choline and [14C]arachidonate as 
described. PtdCho and LysoPtdCho were detected using thin layer chromatography.
(a) [14C]arachidonate release from Ptd£ho in response to bombesin
617nM ( • ) "
(b) LysoPtd[3H]Cho formation in response to bombesin (617nM) (• )  
orHBG(O).
Results are expressed as means ± S.D. from a typical experiment where n=3.
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Figure 4.6 Effect of depleting extracellular calcium on bombesin- 
stimulated arachidonate release
[3H]arachidonate labelled cells were washed and stimulated with 617nM 
bombesin in medium containing ImM calcium (O) or medium in which the calcium 
had been buffered to 150nM with EGTA (•). Arachidonate was measured as 
described. Results are expressed as means ± S.D. from a typical experiment where 
n=3.
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Figure 4.7 Effect of thapsigargin upon arachidonate release
Swiss 3T3 cells, labelled with [3H]arachidonate, were washed in HBG and 
then the appropriate samples were preincubated with (Q, ®) or without (O,©) 
thapsigargin (lpM) for the indicated times. The cells were then stimulated for 20 sec 
with (• ,■ )  or without (o,D) bombesin (617nM) and arachidonate generation 
determined using silicic acid column chromatography. Results are expressed as 
means ± S.D. from a single typical experiment where n=3.
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Figure 4.8 Stimulation of changes in intracellular calcium by 
bombesin and thapsigargin
Swiss 3T3 cells, grown on gelatin coated coverslips were loaded with Indo- 
1-AM and stimulated with either lOOnM bombesin or lpM thapsigargin. Changes in 
[Ca2+] as indicated by the fluorescence ratio were measured as described in the 
Methods section. The results are from a single experiment typical of three.
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Figure 4.9 Effect of long-term PMA pretreatment upon bombesin- 
stimulated arachidonate release
Swiss 3T3 cells were incubated with 300nM PMA for 48h prior to the 
experiment. Controls involved cells treated with 300nM p-phorbol, DMSO or 
ethanol. Stimulation with bombesin (617nM) was performed as previously. Cells 
treated with PMA (• )  are compared with untreated cells (O). Results are expressed 
as means ± S.D. from a single typical experiment where n=3.
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Figure 4.10 Effect of staurosporine treatment on bombesin- 
stimulated arachidonate release
Swiss 3T3 cells, labelled with [3H]arachidonate, were incubated with 
staurosporine (10~6M) for 15 min prior to stimulation with 617nM bombesin for 20 
sec. Arachidonate release was measured in cells pretreated with staurosporine (•)  
and in untreated cells (O). Results are expressed as means ± S.D. from a single 
typical experiment where n=3.
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DISCUSSION
The results presented in this chapter were mainly derived using silicic acid 
column chromatography. The step-by-step elution profile shown in Figure 4.1 
illustrates that AA is eluted during the addition of diethyl ether. This method was 
improved by using batch elution with the AA-containing fraction collected in 3ml of 
diethyl ether. The 'purity' of this fraction was checked by running it on a thin layer 
chromatography system and scraping the entire lane. This method proved to be more 
sensitive and convenient for detecting free AA than other tested thin layer 
chromatography methods.
Results using this technique demonstrate that bombesin stimulates the rapid 
generation of A A in Swiss 3T3 cells (Fig.4.2). Examination of the cellular 
phospholipids demonstrated that the fatty acid was derived only from PtdCho 
(Figs.4.4 & 4.5) and that there was a corresponding increase in LysoPtdCho which 
paralleled the decrease in pH]AA labelling of PtdCho. These experiments thus 
demonstrate that a phospholipase of the A class, presumably PLA2, with a substrate 
specificity for PtdCho is stimulated in Swiss 3T3 cells by bombesin. A PtdCho- 
specific PLA2 has been reported in human platelets (Ballou et al., 1986), whilst a 
1 lOKd PLA2 which is activated by physiologically relevant increases in intracellular 
calcium (Clark et al., 1990; Gronich et al., 1990) and by PMA or hormonal treatment 
(Gronich et al., 1988) has been suggested to be present in U937 cells. However, this 
enzyme species does not show specificity for PtdCho over PtdEtn. A recent study by 
Clark et al. (1990) has reported the cloning and expression of a cDNA encoding an 
85Kd cytosolic PLA2 from U937 cells. This preferentially hydrolyses AA-containing 
PtdCho rather than PtdCho with other fatty acids in the sn-2 position. Although at 
present it is uncertain whether this PLA2 distinguishes between different classes of 
phospholipids in a natural membrane, it has been suggested that it may be important in 
initiating the synthesis of the inflammatory mediator, Platelet Activating Factor (PAF), 
since studies have shown that the most likely phospholipid precursor for PAF is an
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arachidonyl PtdCho (Suga et al., 1990). Clark et al. (1991) suggest that future 
studies will involve the determination of the head group specificity of this cytosolic 
PLA2 when incubated with natural membranes. The existence of enzymes which 
exhibit different substrate specificities may increase the scope with which a cell can 
respond to stimulation and will thus lead to increased diversity in the overall response.
Whilst the generation of AA was sustained over a 1 min period (Fig.4.2), that 
of LysoPtdCho was more transitory (Fig.4.5). Low levels of LysoPtdCho were also 
observed in Chapter 3 and are not surprising since its detergent properties would be 
harmful to cell membranes. The rapid turnover of the lysophospholipid may be 
mediated through combinations of deacylation, reacylation or transacylation. In some 
cells, lysophospholipase activity has been shown to be greater than phospholipase 
activity, which accounts for a relatively low concentration of lysophospholipid even in 
the presence of a raised PLA2 activity (Meade et al., 1986). In bombesin-stimulated 
Swiss 3T3 cells, there is no detectable increase in glycerophosphocholine (Cook & 
Wakelam, 1989), suggesting LysoPtdCho is not further degraded but, rather, 
reacylated in these cells.
A stimulation of AA release by PLA2 activation has been observed in many 
systems in response to a range of agonists (Axelrod et al., 1988). However, the 
increase in fatty acid release has generally been detected after at least 1 min. As can 
be seen from Figure 4.2, bombesin-stimulated AA release was observed after 2 sec. 
This result would suggest that the activation of PLA2 is closely coupled to receptor 
occupation.
The rapidity of AA release compared to reports in the literature was probably 
due to the work reported here involving the measurement of cell associated rather than 
incubation medium AA. Measurement of the release of AA into the extracellular 
medium, as in Chapter 3, does not give an accurate determination of the kinetics of 
phospholipase activation. For this, it is essential that intracellular, or cell associated 
AA is measured.
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Agonist-stimulated PLA2 activity has been proposed to be a consequence of an 
increase either in intracellular free calcium concentration (Kanterman et.al., 1990) or in 
PKC activity (Pfannkuche et.al., 1989) resulting from prior stimulated Ptdlns (4,5)P2 
breakdown. Whilst the direct relationship between PLC and PLA2 has not been 
investigated in this work, the rapid generation of AA (Fig.4.2) is at least as fast as that 
of sn-1,2-DAG and Ins (1,4,5)P3 formation previously observed in the Swiss 3T3 
cell in response to bombesin stimulation (Cook et.al., 1990). This observation would 
question a role for Ptdlns (4,5)P2 hydrolysis in stimulating PLA2. However,, in 
order to address this possibility in more detail the effects of modulating PKC activity 
and intracellular calcium concentration upon bombesin-stimulated AA generation were 
examined.
Incubation of Swiss 3T3 cells in a Ca2+ EGTA buffer, in which the free 
calcium concentration was maintained at 150nM, was without effect upon bombesin- 
stimulated AA release (Fig.4.6). Consequently, agonist-stimulated entry of the ion is 
not required for the rapid activation of PLA2. In order to examine if a change in 
intracellular calcium levels, as a results of Ins(l,4,5)P3-stimulated release, had a role 
in bombesin-stimulated AA release, the cells were stimulated with thapsigargin. This 
has been shown to raise the intracellular calcium concentration independently of 
phosphoinositide metabolism and PKC activation (Jackson et.al., 1988). This effect 
has been attributed to inhibition of the endoplasmic reticulum Ca2+-ATPase (Thastrup 
et.al., 1990). Thapsigargin increased intracellular calcium in Swiss 3T3 cells 
(Fig.4.8) reaching 10% of peak after about 6 sec. However, as shown in Figure 4.7, 
thapsigargin was unable to stimulate PLA2 activity. The tumour promoter was able to 
potentiate bombesin-stimulated AA release, but only after a total of 80 sec exposure, 
suggesting that an increase in intracellular calcium was not the mechanism whereby 
bombesin stimulated rapid i.e. within 2 sec generation of AA. Additionally, 
experiments where cells were treated with PMA for 15 min prior to agonist addition 
showed inhibition of bombesin-stimulated Ins (1,4,5)P3 formation (Plevin et.al.,
107
1990), yet this treatment resulted in the potentiation of bombesin-stimulated A A 
generation (see Chapter 3, Fig.3.6). Together, these results strongly suggest that an 
Ins (1,4,5)P3 stimulated intracellular increase in calcium concentration is not essential 
for rapid stimulation by bombesin of PLA2 activity.
Experiments performed on cells in which PKC was either down-regulated by 
pretreatment with PMA for 48h, or inhibited by staurosporine, showed no significant 
difference in the bombesin-stimulated rapid release of AA compared with control cells 
(Figs.4.9, 4.10). Thus, there does not appear to be a role for PKC activation in the 
rapid stimulation of PLA2, lending further support to the proposal that initial activation 
of the enzyme is a response to receptor occupation rather than being subject to 
regulation by other signals. This suggestion is supported by the finding that the EC50 
for bombesin-stimulated AA generation, 2.7± 0.6nM (Fig.4.3), is very similar to 
those found for the stimulation of Ins (1,4,5)P3 and DAG production (Cook et.al., 
1990) and choline generation (Cook & Wakelam, 1989) in the same cells.
If the activation of PLA2 is coupled directly to receptor occupation, it is likely 
that a G-protein may mediate this interaction. The bombesin receptor has been 
shown to couple to at least one G-protein which is insensitive to cholera toxin and 
pertussis toxin (Fischer & Schonbrunn, 1988) and to couple the receptor to PLC 
(Plevin et.aH., 1990). G-protein regulation of PLA2 has been suggested in a variety 
of cell types (Cockcroft & Stutchfield, 1989; Burch & Axelrod, 1987) although the 
G-proteins involved have not yet been identified. Since the EC50 values for 
bombesin-stimulated AA release (Fig.4.3), Ins (1,4,5)P3 and DAG production (Cook 
et.al., 1990) and choline generation (Cook & Wakelam, 1989) are almost identical, 
stimulation of all three phospholipases (A2, C and D) may occur through the activation 
of the same receptor. Whether this involves three separate G-proteins coupled to a 
single receptor, or whether isotypes of the bombesin receptor, with identical agonist 
affinities exist is uncertain, though none of these responses are sensitive to pertussis 
or cholera toxins. The identity of the putative G-protein(s) involved remains open to
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speculation. However, the recent evidence suggesting the existence of a novel family 
of G proteins (Gq) increases the potential for involvement in numerous signalling 
pathways. A variety of roles have been suggested for this family including ion 
channel activation, PLA2 activation (Strathmann & Simon, 1990) and PLC -fl 
activation (Taylor et al., 1991). It is possible that one or several of this G-protein 
family could be instrumental in coupling the bombesin receptor to the signalling 
systems mentioned. However, there is, as yet, no direct evidence for this.
The alternative suggestion, that there may be subtypes of the bombesin 
receptor, is also highly speculative. The receptor has been purified and cloned from 
Swiss 3T3 cells (Battey et al., 1991) with no evidence for different subtypes existing 
within the same cell. However, there do appear to be differences in receptor types 
between systems (Van Schrenk et al., 1989 and see Introduction) with different 
binding affinities for gastrin releasing peptide (GRP) and neuromedin B (NMB). 
Whether these subtypes would exhibit different coupling mechanisms to and 
regulatory requirements for the signalling pathways involved remains to be 
established.
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CHAPTER 5
BOMBESIN STIMULATES THE RELEASE OF ARACHIDONATE 
FROM PERMEABILISED CELLS IN A GTP-DEPENDENT
MANNER
110
INTRODUCTION
The ability of neurotransmitters, hormones and growth factors to bind to 
specific cell-surface receptors and elicit their effects via GTP-binding proteins is 
considerably widespread (see Chapter 1). Probably the most widely studied 
system in which involvement of a G protein has been implicated is the regulation of 
phosphoinositide hydrolysis by a Ptdlns (4,5)P2-specific PLC (Cockroft, 1987). 
Some of the most convincing evidence for this involves the capacity of GTP and its 
non-hydrolysable analogues to enhance the agonist-mediated accumulation of the 
products of hydrolysis in permeabilised cells. The ability to block this response in 
some, but not all, cell types by treatment of the cells with pertussis toxin suggests 
that there may be cell-specific G proteins involved.
In 3T3 cells, the bombesin receptor has been suggested to interact with 
specific GTP-binding proteins. In one case, but only when excessively over­
expressed, the product of the N-ras gene (Wakelam et al., 1986) and in another, a 
pertussis toxin substrate (Letteria et al., 1986). More recently, Fischer & 
Schonbrunn (1988) demonstrated that exposure of Swiss 3T3 cells to pertussis 
toxin or cholera toxin did not affect either the affinity of membrane bombesin 
receptors for agonists or guanine nucleotide regulation of receptor binding. There 
appear to be multiple G proteins involved in the coupling of receptors to the 
regulation of PtdInsP2 turnover and the latter report suggests that the G protein 
coupled to the bombesin receptor belongs to the pertussis toxin insensitive group.
That PLC activity in Swiss 3T3 cells is regulated by a specific G protein is 
well established, although the nature of the protein involved remains to be 
absolutely elucidated. A recent study by Taylor et al. (1991) has shown that 
members of the G n class of a subunits are involved in PLC-pl regulation.
Others have also observed stimulation of partially purified PLC activity by purified 
brain Gq in the presence of fluoroaluminate (Smrcka et al., 1991). Both PLC and 
Gq have widespread tissue distribution (Rhee et al., 1989; Strathmann & Simon, 
1990) so the pathway may be common to several eukaryotic tissues and species.
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Indeed the Gq/Gn species has been detected in Swiss 3T3 cells (Kaur & Wakelam, 
unpublished data).
Involvement of G proteins in receptor stimulated PLA2 activity has been 
suggested in a number of cell types (Murayama & Ui, 1985; Burch et al., 1986;
Burch & Axelrod, 1987; Teitelbaum, 1990). Unfortunately, research into this 
area has been hampered by the long-standing dogma that PLA2 was activated only 
as a result of prior PLC activation (Axelrod et al., 1988). Direct G protein 
regulation was thought to intervene only at the site of receptor-linked PLC 
stimulation. However, this has now been questioned. Evidence supporting a role 
for G proteins in PLA2 activation ranges from stimulation of the enzyme by 
guanine nucleotides in 3T3 cells (Burch & Axelrod, 1987) and permeabilised rat 
basophilic leukaemia cells (Narasimhan et al., 1990) to differential susceptibility to 
inhibition by pertussis toxin in neutrophils (Cockroft & Stutchfield, 1989).
Although a range of G proteins have been characterised, the G proteins that are 
coupled to PLA2 remain to be identified. Cholera toxin stimulates Gsa but has 
been shown to either stimulate (Burch et al., 1988) or inhibit (Jelsema, 1987)
PLA2, depending on the receptor or cell type investigated. Pertussis toxin inhibits 
the functioning of G proteins of the i and o, series (Gilman, 1987) and transducin 
(Stryer, 1986) but has been shown to inhibit or to stimulate PLA2 (Burch et al.,
1988). It appears that there are multiple G proteins that are linked to PLA2
activation. There may be several PLA2 isozymes that have different calcium
requirements, pH optima and intracellular locations and may have the ability to
translocate from cytosol to membrane upon activation. (Clark et al., 1991). Some G proteins maj
directly couple a receptor to an effector PLA2. However, others may modulate
PLA2 activity indirectly by stimulating calcium channel opening or by stimulating
Ins (l,4,5)P3-induced release of calcium from intracellular stores. It has even
been suggested that PLA2 may be under dual regulation by inhibitory and
stimulatory G proteins, as for adenylate cyclase (Burch et al., 1988).
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The py subunit of certain G proteins has also been implicated in the 
activation of PLA2 (Jelsema & Axelrod, 19 S 7 ; Kim et al.y 1989). This 
potentially novel mechanism has raised considerable controversy. Whether the jfy 
subunit is active upon dissociation from a  has yet to be convincingly demonstrated. 
However, this does raise the possibility of more extensive variation in the G protein 
regulation of PLA2 and PLC. It also raises the possibility of both phospholipases 
being regulated by the same G protein but different subunits which would explain a 
number of observations concerning phospholipase activation in the same cell type.
Work presented in this chapter attempts to demonstrate the involvement of a 
GTP-binding protein in the initial AA response to bombesin described in Chapter 
4. In addition, the correlation between this putative G protein and that involved in 
bombesin-stimulated PLC activation is also explored, with regard to further 
dissociating between the two pathways.
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RESULTS
In order to examine whether analogues of GTP have an effect on the AA 
response to bombesin, an effective permeabilised cell system had to be established. 
Previous work in Swiss 3T3 cells had shown the effective use of electroporation in 
examining the stimulation of InsP3 formation by bombesin (Plevin et al., 1990). It 
was therefore decided to use this method for examining the generation of AA. 
Figure 5.1 shows a timecourse of AA release in response to bombesin, GTPyS and 
the two agents together. This represents a typical experiment where n=6. No AA 
release was detected in response to any of the stimuli tested over a period of 10 
min, by which time the first phase of release is over in whole cells.
Electroporation involves using cells in suspension whereas all previous 
experiments were performed on a confluent monolayer. This lack of response may 
be due to increased basal rates of AA release in the suspended cells, making 
stimulated levels appear negligible. Conceivably, detaching cells from dishes with 
a calcium-free enzyme-containing medium or by scraping with a rubber policeman 
(both of which were employed here), followed by several cycles of centrifugation 
and suspension of cells may damage the surface of the cells such that non-specific 
leakage of cellular metabolites may occur affecting the coupling between membrane 
receptors and the effector system under study. Thus, employment of the cell 
monolayer may be indispensible for studying the small effects of agonists on AA 
release in permeabilised Swiss 3T3 cells.
Various methods are available for permeabilising cells grown as a 
monolayer, which involve addition of either a detergent (Martin & Michaelis, 1990) 
or a bacterial toxin (Howell & Gomperts, 1987) in a suitable permeabilisation 
buffer to the cells. This eliminates any mechanical disruption and damage to the 
monolayer. It was decided to examine the effects of streptolysin-0 on Swiss 3T3 
cells. This bacterial toxin has been used to permeabilise a variety of cell types 
(Howell & Gomperts, 1987; Stutchfield & Cockroft, 1988) and will generate 
lesions in cholesterol-containing membranes of up to 12nm. These lesions are
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small enough not to allow toxin entry and permeabilisation of intracellular 
membranes but are large enough to allow access of nucleotides for studies such as 
those described here.
Experiments were performed initially to check that streptolysin-O caused 
sufficient permeabilisation of Swiss 3T3 cells. The release of the cytosolic protein 
lactate dehydrogenase (LDH) was monitored in streptolysin-0 treated cells.
Figure 5.2 shows the relationship between increasing concentrations of the toxin 
and the activity of LDH in the medium. Maximal LDH activity was achieved at 
0.6U/ml streptolysin-O. This is slightly higher than the concentration quoted by 
Howell & Gomperts (1987) of 0.4U/ml, and was the concentration used in 
subsequent experiments. This concentration caused approximately 100% 
permeabilisation of 3T3 cells as examined by entry of the fluorescent dye, 
bisbenzimide.
It was then essential to determine the response of the cells to bombesin and 
to different analogues of GTP. Initially, the generation of L1SP3 was examined in 
streptolysin-O permeabilised cells. Figure 5.3 shows a timecourse of L1SP3 
production in response to bombesin and GTPyS. The response to bombesin is 
slow and small as is that to GTPyS alone. The response to GTPyS shows an 
obvious lag time before onset of L1SP3 release. Under normal resting conditions, 
the rate of exchange of GDP for GTP is very slow. This rate is accelerated by the 
addition of an agonist. Thus, when both bombesin and GTPyS were added 
together, there was a significant potentiation of the response. In addition, the 
response \yas maintained at potentiated levels for up to 1 min and possibly longer. 
A similar potentiation was observed for InsP2 formation and for InsPi, although to 
a smaller extent. These results are comparable with those obtained in 
electropermeabilised cells. The fold-stimulation achieved with bombesin alone 
and with bombesin and GTPyS together in streptolysin-O permeabilised cells was 
almost identical to that seen in electropermeabilised Swiss 3T3 cells. Figure 5.4 
provides additional evidence that the inositol phosphate response remains intact in
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streptolysin-O permeabilised cells. Figure 5.4(a) shows a dose-response curve 
demonstrating the effect of GTPyS on inositol phosphate production in bombesin- 
stimulated cells. Significant potentiation (p=0.012) was observed in the presence 
of GTPyS. The EC50 value for bombesin was slightly decreased by the presence 
of GTPyS (control = 1.2 ± 0.3nM;-v-GTPyS = 0.3 ± 0.18nM). The EC50 for the 
peptide decreased only marginally after streptolysin-O treatment (intact cells = 1.65 
± 0.4nM) suggesting receptor integrity had been maintained. In addition, the 
response was significantly (p=0.009) decreased by pre-incubation of the 
permeabilised cells with GDPpS at millimolar concentrations (Fig.5.4b)
Similar experiments were performed to examine the effects of these non- 
hydroly sable analogues of GTP on A A generation. GTPyS, in the presence of 
bombesin, stimulated AA release in this system, whereas bombesin alone 
stimulated negligible release. The small level of release observed was probably 
due to some residual GTP remaining within the cell (Fig.5.5). This finding is 
similar to the results presented for InsP3 and is consistent with a requirement for 
GTP to allow the receptor to transduce its message through G protein coupling to 
PLA2. Figure 5.6a shows a dose-response curve demonstrating the effect of 
GTPyS on AA release. The EC50 value for the peptide in permeabilised cells is 
similar (3.2 ± 0.8nM) to that in whole cells. Figure 5.6b shows that ImM GDPpS 
pretreatment inhibits the AA response and, as shown in Figure 5.7, totally inhibits 
the potentiation of the response achieved with GTPyS. These results are also 
consistent with the previous suggestion that a GTP-binding regulatory protein is 
involved in the coupling of bombesin receptors to PLA2.
In a further effort to discriminate between the regulation of PLC and PLA2
activity, the aminoglycoside antibiotic neomycin was used. In all experiments this
reduced bombesin-stimulated InsP3 production, though to varying extents (12% -
89% of normal levels). Figure 5.8a shows this effect, presented as a mean of five
experiments where inhibition was greater than 50%. In these experiments, A A release was
unaffected (Fig.5.8b). These
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studies indicate that bombesin-stimulated AA release is not a consequence of prior 
phosphoinositide hydrolysis.
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Figure 5.1 Lack of bombesin-stimulated arachidonate release in 
electropermeabilised Swiss 3T3 cells
Swiss 3T3 cells were treated as described in the Materials and Methods section 
and were stimulated with (a) increasing concentrations of bombesin with GTPyS •  
(30pM), (b) HBG (O), bombesin (30nM) (•) , GTPyS (30pM) (■ ) or both (A)  for 
the times indicated. Each point represents the mean ± S.D. of triplicate 
determinations from a single experiment representative of two others.
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Figure 5.2 Release of lactate dehydrogenase from Swiss 3T3 cells 
permeabilised with streptolysin-O
Swiss 3T3 cells were treated with increasing concentrations of streptolysin-O 
and the amount of lactate dehydrogenase released into the medium was measured as 
described. Results are representative of three experiments.
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Figure 5.3 Kinetics of bombesin and GTPyS-stimulated
[3H]inositoI phosphate formation in streptolysin-O  
permeabilised Swiss 3T3 cells
Cells treated as described in the Materials and Methods section were incubated 
with HBG (O), 30nM bombesin (ft),.30pM GTPyS ( f t ) or both ( a )  for the times 
indicated (a) InsP, (b) InsP2 and (c) InsP3 formation was measured. Each point 
represents the means± S.D. from a single typical experiment where n=3.
N.B. The response is significantly potentiated by GTP by 5 seconds stimulation with 
bombesin.
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Figure 5.4 (a) Effect of GTPyS on bombesin-stimulated accumulation 
of total [3H]inositol phosphates in permeabilised 
Swiss 3T3 cells
Cells treated as described were incubated with increasing concentrations of 
bombesin in the absence (O) or presence (• )  of 30pM GTPyS for 30 min at 30°C in 
incubation buffer containing lOmM LiCl. Each point represents the mean ± S.D. of 
triplicate determinations from a single experiment representative of three others.
Figure 5.4(b) GDPpS inhibition of bombesin-stimulated
accumulation of total [3H]inositol phosphates in 
permeabilised Swiss 3T3 cells
[3H]inositol labelled cells were incubated with increasing concentrations of 
bombesin in the absence (O) or presence (• )  of 2mM GDPpS in a buffer containing 
lOmM LiCl. Each point represents the mean ± S.D. from a single typical experiment 
where n=3.
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Figure 5.5 Kinetics of bombesin- and GTPyS-stimulated 
[3H]arachidonate release in streptolysin-O 
permeabilised cells
Cells treated as described were incubated with HBG (O), 30nM bombesin (•) , 
30pM GTPyS ( • )  or both ( a ) for the times indicated and A A release measured. 
Results represent the mean ± S.D. from a single typical experiment where n=3.
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Figure 5.6(a) Effect of GTPyS on bombesin-stimulated
[3H]arachidonate release in permeabilised Swiss 3T3 
cells
Cells treated as described were incubated with increasing concentrations of 
bombesin in the absence (O) or presence ( • )  of GTPyS for 30 sec. Each point 
represents the means ± S.D. from a single typical experiment where n=3.
Figure 5.6(b) GDPpS inhibition of bombesin-stimulated
[3H]arachidonate release in. permeabilised Swiss 3T3 
cells
[3H]arachidonate labelled cells pretreated for 10 min with either 2mM GDPpS 
(© ) or incubation buffer (o )  were incubated with increasing concentrations of 
bombesin for 30 sec. Each point represents the mean ± S.D. from a single typical 
experiment where n=3.
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Figure 5.7 Effect of GDPpS pretreatment on bombesin and GTPyS 
stimulated arachidonate release in permeabilised cells
Cells treated as described were pretreated for 10 min with either 2mM GDPpS 
(©) or incubation buffer ( •)  and then stimulated with either bombesin, GTPyS or both 
for the indicated times. Each point represents the mean ± S.D. from a single typical 
experiment where n=3.
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Figure 5.8 Differential effects of neomycin on bombesin-
stimulated InsP3 production and arachidonate release 
in permeabilised Swiss 3T3 cells
Cells treated as described were pretreated for 10 min with 2mM neomycin ( • )  
or incubation buffer (o). They were then stimulated with increasing concentrations 
of bombesin and either (a) InsP3 production or (b) arachidonate release were 
measured. Results represent means ± S.D. from a single typical experiment where 
n=3.
N.B. For (a) experiments were not used where'inhibition was below 50%.
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DISCUSSION
The results presented in this chapter clearly indicate that rapid bombesin- 
stimulated AA release is totally dependent on the presence of GTP in the system 
and strongly suggest the involvement of a G protein, coupling receptor stimulation 
to PLA2 activation. Previous reports in other systems have suggested a similar 
scenario (Teitelbaum, 1990; Narasimhan et al., 1990; Kajiyama etal., 1990).
The kinetics of AA generation shown in Figure 5.6 are very similar to those of 
InsP3 in Figure 5.4. The lag time observed with GTPyS alone for both InsP3 
production and AA release is significantly decreased in both cases by bombesin 
receptor occupation. In addition, both responses to bombesin are potentiated at the 
early time points tested in the absence of a response to GTPyS alone. These 
observations suggest that the dissociation of bound GDP is the rate-limiting step in 
the activation of the G protein and also that agonist receptor stimulation 
significantly enhances the exchange of GTP for GDP. This phenomenon has been 
described by Plevin et a l . (1990) amongst others for InsP3 production.
In various systems, receptor-mediated PLA2 activity has been distinguished 
from PLC activation through differential susceptibility to pertussis toxin treatment 
(Teitelbaum, 1990; Cockcroft & Stutchfield, 1989; Jelsema 1987). However, 
both the PLC and PLA2 responses in bombesin-stimulated Swiss 3T3 cells are 
pertussis toxin insensitive. In order to distinguish these pathways, alternative 
methods have to be used. One means of discrimination has been described in this 
chapter and involves inhibition of the phosphoinositide-PLC pathway using 
neomycin. These results (Fig.5.9) have demonstrated the apparent independence 
of the PLA2 pathway from prior PLC activation in bombesin-stimulated Swiss 3T3 
cells. This conclusion is strengthened by the results presented in Chapter 3, where 
short-term PMA pretreatment causes inhibition of PLC-mediated InsP3 production 
but stimulation of PLA2-mediated A A release. Overall, these results strongly
implicate the involvement of a G protein in the regulation of PLA2 in this system.
\
In addition, this protein may be distinct from that which regulates phosphoinositide
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specific PLC activity in the same system. No attempt has been made in this study 
to identify the G protein that may regulate PLA2 because of the extreme diversity of 
G proteins.
In systems where G protein-mediated regulation of PLA2 has been 
suggested, the putative G protein has been designated Ga (Burch et al., 1986). 
However, the identity of this putative G protein remains to be determined. This 
particular area of research has encountered considerable controversy, not only 
concerning the identity of the protein but also, which subunit of the G protein is 
involved. Jelsema & Axelrod (1987) and Clapham & Neer (1988) have both 
presented evidence that the Py subunit will activate PLA2 in the systems under 
study. However, various questions have been raised by Bimbaumer (1987) 
concerning the purity of the py's used and the limited range of a subunits tested in 
these studies. These suspicions are apparently well-founded, since Jelsema & 
Axelrod do state that their Py preparations contain a small level of intrinsic PLA2 
activity which is obtained during the purification procedure. However, more 
recent findings by Kim et al. (1989) suggest the existence of a novel G protein 
dependent signalling pathway, mediated by Py, causing stimulation of PLA2 
activity and metabolism of the AA produced via lipoxygenase enzymes. These 
metabolites are suggested to be involved in activation of the cardiac muscarinic K+ 
channel. They suggest that several lipoxygenase products activate the channel 
through a less specific mechanism than receptor coupling, such as release of the G 
protein a subunit or direct channel activation. There is evidence to suggest the 
existence of multiple forms of p and y (Schmidt & Neer, 1991). This may allow 
dimer formation with distinct functional characteristics. Differences have been 
noted in the relative ability of Py dimers to activate PLA2. Brain Py will stimulate 
PLA2 activity in artial membranes, but py from transducin is much less effective 
(Logothetis et al., 1987; Kim et al., 1989). In these studies the p subunit was 
predominantly pi. Therefore, these functional differences may be due to the y 
subunit. Involvement of the Py subunit in Swiss 3T3 PLA2 activity could be
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checked using reconstitution experiments and possibility anti- py antibodies. 
However, these may be hindered by potentially incorrect py combinations and 
impurity of the preparations.
Over the past few years it has been found that the family of genes encoding 
the a subunits of G proteins is larger than previously thought. Strathmann & 
Simon (1990) have proposed the existence of a distinct class of a subunits (Gaq) 
evident in vertebrates and invertebrates. These show less than 50% amino acid 
sequence identity with any of the other a  subunits and are not substrates for 
pertussis toxin modification. It has been suggested that these novel G proteins 
may account for some of the less well understood activities attributed to G proteins. 
One such role may be that of regulating PLA2. A recent report by Smrcka et al. 
(1991) suggests that phosphoinositide-specific PLC is regulated by Gq. In a more 
detailed study by Taylor et al. (1991), the isozymes of PLC were investigated with 
respect to regulation by Gq. They reported that this G protein specifically activates 
the pi isozyme, but not the yl or 81 isozyme of PLC. The possibility is also 
addressed that other phospholipases may be regulated by this family of G proteins. 
As Strathmann & Simon (1990) suggest, the possibility of different combinations 
of a, p and y subunits may allow a cell to 'fine tune' G protein function to the 
specific requirements of a particular signalling pathway. Whether a form of Gaq is 
responsible for regulating PLA2 activity awaits definitive evidence in the form of 
reconstitution experiments of Gq with specific receptors and the development of 
specific antibodies to these proteins.
Other Ga subunits have been proposed to activate PLA2 in different 
systems. Cantiello et al. (1990) suggest Gai_3 regulates epithelial Na+ channels by 
PLA2 activation. Kajiyama et al. (1990) propose the involvement of different G 
proteins, Gj- and G0-like proteins in the coupling of a2-adrenergic and thrombin 
receptors respectively to PLA2 in rabbit platelets. A detailed study by Gupta et al. 
(1990) examined the regulatory regions within the a chains responsible for control
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of PLA2. Different chimaeric cDNAs were constructed in which certain lengths of 
the a  subunit of Gs (as) were replaced with the corresponding sequence of Gi, 
(oq_2). They proposed that the last 36 amino acids of cq_2 are a critical domain for 
G protein regulation of PLA2. However, Gi proteins are substrates for pertussis 
toxin and this cannot be the coupling protein in Swiss 3T3 cells.
It appears likely that the specificity of the G protein regulating PLA2 may 
vary according to the system studied. In Swiss 3T3 cells, G protein regulation of 
PLA2 has already been proposed (Burch & Axelrod, 1987). However, the identity 
of the protein requires more detailed investigation. Expression of the relevant 
cDNAs in Swiss 3T3 cells could resolve which G protein(s) is/are involved. Such 
an approach, involving PLA2 co-expression could show how disruption of this 
signalling pathway, perhaps by constitutive G protein activation or over­
expression, may lead to disruption of cell function. Alternatively, the opposite 
approach of removal of the cytosolic PLA2 and/or specific G proteins using anti­
sense RNA may be more effective in demonstrating the same effect. These types 
of study would help in implicating PLA2 involvement in certain areas of signal 
transduction.
A final consideration that is of equal importance for future investigation, is 
identification of how this signalling pathway is turned off. This is important given 
the transient nature of the initial response. Whether this occurs at the level of the G 
protein (either a separate inhibitory G protein, allowing dual regulation of PLA2, or 
phosphorylation and inhibition of the stimulatory G protein) or at the level of PLA2 
itself is unclear. Preliminary studies by Lowndes et al. (1991) have indicated that 
PLA2 is phosphorylated in Chinese hamster ovary cells. They suggest that this 
may be a mechanism for attenuation of the signal and are currently attempting to 
identify regulatory phosphorylation sites within the PLA2 polypeptide by 
proteolytic phosphopeptide mapping. They predict that the attenuation of PLA2 
stimulation is a compensatory mechanism resulting from constitutive activation of
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certain G protein regulated signalling pathways. However, phosphorylation as a 
desensitization mechanism is an alternative possibility.
Cumulatively, results presented in this chapter, together with data obtained 
in other systems, indicate that G protein-coupled PLA2 and PLC signals are under 
tight control. This feature will allow for distinct responses to be obtained in certain 
systems and will prevent hyperactivation of these second messenger pathways. 
Given the number of G proteins implicated in PLA2 activation, the deviation in 
responses between systems should be considerable. It may even be possible in 
certain systems, contrary to long-standing belief, that PLC activation is dependent 
on prior receptor-mediated PLA2 activation.
CHAPTER 6
BOMBESIN DOES NOT SIGNIFICANTLY STIMULATE 
THE METABOLISM OF ARACHIDONIC ACID VIA 
CYCLOOXYGENASE OR LIPOXYGENASE PATHWAYS
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INTRODUCTION
When examining bombesin-stimulated AA release in Swiss 3T3 cells, it is 
important to consider the actual composition of the response. In mitogen-stimulated 
cells, AA may not necessarily be the final product of PLA2 hydrolysis since it may 
be further metabolised into various biologically active eicosanoids via 
cyclooxygenase and lipoxygenase pathways. In some cases, the determination of 
whether AA is liberated faster than would be expected from its esterified levels is 
complicated because a substantial proportion is further metabolised to eicosanoids. 
For example, Irvine et al. (1982) have shown that in platelets after 10 sec stimulation 
only 20-25% of [3H]AA liberated was still the free acid, the rest having been 
converted to products of cyclooxygenase and lipoxygenase enzymes.
Prostaglandins and leukotrienes, which are products of the cyclooxygenase 
and lipoxygenase pathways respectively, can be considered to be autocrine or 
paracrine hormones which bind to specific receptors. Their actions depend on cell 
type, location, metabolic activity of the cell and the simultaneous actions on the cell 
of other humoral factors. It is clear that the same eicosanoids can trigger opposite 
metabolic or physiological effects in different types of cells (Needleman et al, 1986).
In Swiss 3T3 cells, where prostaglandins are apparently required for 
replication, PGG/H synthase gene expression is induced by serum growth factors 
(DeWitt et al., 1983). Induction is relatively rapid, occurring at the time of 
induction of immediate early response genes such as c-fos and c-myc. Thus, the 
PGG/H synthase gene appears to be an important cell-cycle regulated gene. In 
studies by Burch and Axelrod (1987), PGE2 production was demonstrated in Swiss 
3T3 cells in response to bradykinin stimulation. An immediate effect of this 
stimulus must be an increase in the concentration of free AA in the vicinity of the 
PGG/H synthase, resulting in metabolism of the free fatty acid. Other studies in 
Swiss 3T3 cells have also shown PGE2 production in response to different agonists 
(Burch et al., 1988).
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Evidence for the synthesis of lipoxygenase products in Swiss 3T3 cells is 
much less apparent. Leukotrienes and related mono-, d i- and tri-hydroxy fatty 
acid products are formed via lipoxygenase pathways. The 5-lipoxygenase pathway 
has received most attention since this is the one involved in leukotriene formation. 
These substances, in particular LTB4, appear to be important modulators of many 
immune cell functions and are also known protagonists of numerous inflammatory 
processes. As such, the large majority of studies have been performed on 
inflammatory cells. It was therefore of interest in the present study to examine 
whether bombesin could stimulate the metabolism of AA via either the 
cyclooxygenase or lipoxygenase pathways.
The present chapter focusses on this question and examines the effect of 
bombesin stimulation on the production of a range of eicosanoids which may be 
potential metabolites of the free AA released in response to the peptide.
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RESULTS
The stimulation of AA metabolism via cyclooxygenase enzymes in response 
to challenge with bombesin was studied initially. The range of prostaglandins 
examined in this study included PGE2, PGD2, PGF2« and 6-keto-PGFia. Figure 
6.1 shows an hplc trace comparing the profile of prostaglandin standards with the 
profile of samples that had been stimulated with 617nM bombesin for lh. The only 
product formed in response to stimulation was PGE2. Table 6.1 shows that there is 
no significant production of any other prostaglandins at earlier time points of 
stimulation. Since the samples analysed contained HBG, it seemed possible that 
this might have affected results. The recoveries of standard [3H]prostaglandins 
which were prepared in HBG, were checked accordingly. These were found to be 
between 86% and 90% on a regular basis. Therefore, sample preparation in this 
buffer did not hinder detection of cyclooxygenase products.
Figure 6.2 illustrates the proportion of the AA response that is composed of 
PGE2. The profiles examined at various times over a 2h period, clearly show that 
the majority of the response appeared to be composed of the free fatty acid itself and 
only a very small amount (approximately 4% of total) was metabolised to PGE2. In 
addition, the data in this figure indicate that the AA response reached a maximum 
between 60-90 min then declined. This feature can also be seen in Figure 6.3 
which shows the release of AA and production of PGE2 over a period of 4h 
stimulation with bombesin. PGE2 production appeared to increase very slowly 
over this timecourse and even after 4h, still comprised only approximately 5% of the 
arachidonate response (see Table 6.2).
Since bombesin-stimulated AA generation is composed of two phases, it 
was of interest to check how early PGE2 could be detected upon stimulation with the 
peptide. Figure 6.4 shows that no significant PGE2 production occurred until after 
10 min stimulation with bombesin when it increased to 2.3-fold over basal values, 
this strongly suggests that the first phase of the AA response to bombesin is not
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metabolised via the cyclooxygenase pathway and may imply that it is composed 
entirely of AA itself. However, in order to strengthen this proposal, it was essential 
to examine the possibility that the AA may be metabolised via the lipoxygenase 
pathway.
Two different hplc separation methods were used to measure lipoxygenase 
products (see Chapter 2). Figure 6.5 shows a typical chromatogram of standards 
for LTB4 and 5-HETE at early time points which correspond to the first phase of 
AA release.
In order to determine whether Swiss 3T3 cells were capable of producing 
lipoxygenase metabolites, cells were stimulated with the calcium ionophore, A23187 
in parallel with bombesin and a larger range of lipoxygenase products examined. 
Extraction and subsequent hplc of the lipoxygenase products, after ionophore 
stimulation of the cell monolayer, gave a typical chromatogram as shown in Figure 
6.7 using the water/methanol/acetonitrile/acetic acid solvent system which is changed 
to 100% methanol using a linear gradient over 40 min (see Chapter 2). Whilst 
variations in relative peak size were observed between different samples, ionophore 
stimulation resulted in the production of LTB4 and a 5,6-diHETE. When cells 
were stimulated for the same period (i.e. 10 min) with bombesin, there was no 
obvious production of any of the lipoxygenase metabolites examined (Fig.6.8).
To determine whether any HETES were produced in response to stimulation 
with ionophore or bombesin challenge, a gradient solvent system was used upon the 
hplc (Fig.6.9) since HETES are only eluted with a very long retention time when the 
solvent system is run isocratically. The HETES were eluted with retention times 
only slightly greater than those of the leukotrienes. As can be seen from Figure 
6.9, neither ionophore nor bombesin stimulated 5-, 12- or 15-HETE production.
No examination of the peptido-leukotrienes (LTC, LTD and LTE) was performed in 
this study. However, hplc runs were completed at 280-nm and 310nm, 
wavelengths at which peptido-leukotrienes and conjugated tetraenes, such as the
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lipoxins, would be detected. There were no apparent peaks in response to either 
stimulus at these wavelengths.
Since no lipoxygenase products were detected upon bombesin stimulation, 
cells were challenged with bombesin in the presence of 20jiM AA. This caused a 
slight increase in the production of HETES, in particular 15-HETE, demonstrating 
that these compounds can be derived from this fatty acid and suggesting that 
bombesin alone may not cause a sufficient increase in free AA for HETES to be 
formed in this cell type.
Overall, these results illustrate that the AA response to bombesin is almost 
entirely composed of the free fatty acid itself. No metabolites were detected during 
the first phase of release and only approximately 5% of the second phase was 
metabolised to PGE2. although other undefined routes of metabolism or lipid resynthesis 
may of course occur.
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Figure 6.1 Bombesin-stimulated prostaglandin production in 
Swiss 3T3 cells
A representative hplc chromatogram of (a) prostaglandin standards and (b) 
prostaglandin production after lh  stimulation with 617nM bombesin. Isocratic 
solvent system; 32% acetonitrile/68% orthophosphoric acid, pH3.0. Flow rate;
1 .Oml/min. Detection at 216nm.
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Table 6.1 The effect of bombesin on prostaglandin levels
[3H]AA-labelled Swiss 3T3 cells were stimulated with bombesin (617nM) 
for the times indicated and prostaglandin production determined by counting the 
radioactivity associated with 0.5ml fractions eluted from hplc. Results are expressed 
as means ± S.D. from a single typical experiment where n=3.
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Figure 6.2 Comparison of bombesin-stimulated arachidonate 
release and PGE2  production
A representative hplc trace showing the radioactivity associated with AA and 
PGE2 upon bombesin stimulation for the times indicated.
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Table 6.2 Stimulation of PGE2  production by bombesin
These data numerically depict the fold-stimulation of PGE2 over a 4h period 
in response to 617nM bombesin. Results are from a single typical experiment where 
n=3.
Time(h) dpm in dpm in
AA PGE2
0 1949 ±325 155+ 18
0.5 5506 ±779 314 ±95
1 8267 ±1154 • 496 ± 6 6
1.5 6663 ± 1532 401 ± 37
2 6420 ± 955 408 ± 103
2.5 5968 ± 824 497 ± 52
3 5931 ± 1422 502 ±25
3.5 5998 ± 1012 432 ± 34
4 5552 ±653 503 ±42
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Figure 6.3 Long-term timecourse of arachidonate release and 
PGE2  production in response to bombesin
[3H]AA-labelled Swiss 3T3 cells were stimulated with 617nM bombesin and 
the radioactivity associated with PGE2 and AA was measured in 0.5ml fractions 
eluted from hplc. This is a single typical experiment representative of two others.
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Figure 6.4 Short-term timecourse of arachidonate release and 
PGE 2 production in response to bombesin
Swiss 3T3 cells were stimulated with 617nM bombesin and the release of AA 
and PGE2 production were measured over a period of 40 min. This is a single 
typical experiment representative of two others.
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Figure 6.5 Effect of bombesin stimulation on the levels of LTB4  
and 5-HETE
(a) A representative hplc chromatogram of LTB4 and 5-HETE standards and 
(b) the effect of bombesin stimulation on levels of these products, over a period of 
l^ih. Isocratic solvent system; methanol 68.7%/(methanol 20%/0.5% ammonium 
acetate 80%) 31.3%. Flow rate 2.0ml/fnin. Detection at 270nm.
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Figure 6 . 6  The effect of short-term stimulation with bombesin on 
the levels of LTB4  and 5-HETE
Swiss 3T3 cells were stimulated over a shorter timecourse with 617nM 
bombesin and the production of LTB4 and 5-HETE measured. Results are from a 
typical experiment representative of two others.
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Figure 6.7 Effect of ionophore stimulation on LTB4 production
A typical hplc chromatogram produced by calcium ionophore challenged 
Swiss 3T3 cells (lOpM for 10 min at 37°C) after sep-pak extraction and hplc using a 
linear solvent gradient changing from 100% water/methanol/acetonitrile/acetic acid 
(45:30:25:0.05 v/v, pH5.7) to 100% methanol in 40 min with a flow rate of 
0.6ml/min and detection at 270nm (n=3).
LTB
PGB.
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Figure 6.8 Effect of bombesin stimulation on LTB4 production
A typical chromatogram produced by bombesin challenged Swiss 3T3 cells 
(617nM for 10 min) after sep-pak extraction and hplc using the solvent system 
described for the previous experiment (n=3).
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Figure 6.9 Effect of bombesin and ionophore stimulation on 5-, 
12- and 15-HETE production.
Swiss 3T3 cells were stimulated for 10 min with either (a) bombesin (617nM) 
or (b) ionophore (lOpM). HETE production was determined using the solvent 
system previously described with detection at 235nm.
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Figure 6.10 Effect of arachidonate on bombesin stimulated HETE 
production
Swiss 3T3 cells were stimulated for 10 min with 617nM bombesin with 
20pM AA added. HETE production was determined as described (n=3).
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DISCUSSION
In the Swiss 3T3 cell system, hplc analysis has shown that bombesin does 
not stimulate the metabolism of rapidly generated AA via any of the pathways tested. 
However, a small, slow increase in PGE2 production was detected during the 
second phase of AA liberation. Other methods of measuring metabolites were not 
tested. Gas-liquid chromatography-mass spectrometry (GC-MS) techniques are 
sensitive and reliable but very expensive and therefore, limited.
Radioimmunoassays are lower in cost, rapid and possess the sensitivity and 
specificity to quantitate metabolites derivatised from endogenous AA. However, 
antibodies to all the known AA metabolites are not readily available, limiting the 
technique. The hplc methods used in this study were well established and gave 
highly reliable information.
The metabolism of AA via the cyclooxygenase pathway has previously been 
studied in this system and results have suggested that PGE2 is the main metabolite 
formed (Burch & Axelrod, 1987; Millar & Rozengurt, 1990). However, detailed 
timecourses were not performed and the possibility of other cyclooxygenase 
metabolites or lipoxygenase metabolites being produced was apparently not 
considered. The potential of bombesin to stimulate lipoxygenase activity in Swiss 
3T3 cells has not been examined previously. Results obtained here suggest that the 
peptide does not stimulate activation of either HETE or leukotriene production in this 
system. However, use of a powerful stimulus such as the calcium ionophore 
A23187 provides information about the maximum capacity of these cells to produce 
hydroxy fatty acids and leukotrienes and illustrates that they have the synthetic 
capability. Therefore, the lipoxygenase pathway may be potentially important in the 
action of some agonists on these cells and this may increase the diversity in the 
cellular arachidonate response between different stimuli.
The limited production of PGE2 in response to bombesin illustrated in this 
chapter contrasts with results obtained by Millar & Rozengurt (1988,1990), where
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PGE2 comprises a substantial proportion of the AA response to this stimulus. It 
also questions their theory that bombesin stimulates the accumulation of cAMP via a 
cyclooxygenase-dependent mechanism. They have demonstrated that treatment 
with indomethacin will partially inhibit the cAMP response. However, they also 
suggest that PKC may have an additional involvement in this response. The issue 
remains controversial since other groups have been unable to demonstrate this 
cyclooxygenase-dependent cAMP accumulation (Murayama & Ui, 1985). In the 
present study, although the PGE2 response measured is small, it may still be 
sufficient to exert important effects within the cell either alone or in cooperation with 
other factors. Recent evidence has indicated that the liberation of AA and its 
possible conversion to eicosanoids constitutes one of the early mitogenic signals 
induced by bombesin in 3T3 cells (Takuwa et al.y 1988,1991; Gil et al.y 1991). 
The present study did not measure the concentration of PGE2 formed.
The general lack of metabolism of AA in response to bombesin stimulation 
presents an important feature of the pathway in this system. The question that 
arises from this concerns the turnover of AA during both phases of the response. If 
the fatty acid is not metabolised via either cyclooxygenase or lipoxygenase enzymes, 
how do its levels decline so rapidly during the initial phase? In addition, during the 
second phase, AA is only metabolised to a limited extent -  what eventually causes 
the response to decline? It is also of interest why the AA remains unmetabolised. 
This may indicate that the fatty acid itself plays some important intracellular role, a 
subject which is addressed in detail in Chapter 7.
The possible mechanisms behind turnover of AA in this system deserve 
consideration. One primary route by which fatty acid turnover can occur is via the 
deacylation -  reacylation or Lands pathway. In this, AA is cleaved by PLA2 
creating a lysophospholipid which is rapidly re-esterified with another fatty acid by 
acyl coenzyme Ailysophosphatide acyltransferase. The free AA may be re­
incorporated into phospholipids via an acyltransferase. Questions exist concerning
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the number of different acyltransferase enzymes within cells. For example, in 
platelets Inoue et al. (1984) have suggested the existence of separate 1-acyl GPI and 
1-acyl GPC specific acyltransferases. This may also be true for Swiss 3T3 cells 
and free AA could be re-incorporated into phospholipids in this manner.
Direct transfer of AA between phospholipid subclasses by transacylases has ‘ 
also been shown to occur in a Co-A dependent or independent manner. This has 
been demonstrated between intact phospholipids and lysophospholipids (Malone et 
al., 1985) as well as between two intact phospholipids. The majority of studies 
examining this type of mechanism have been performed on cells of the immune 
system. However, this type of response may also exist in other cell types. In 
Swiss 3T3 cells, this mechanism may not be important in the initial AA response but 
may affect the eventual availability of AA-containing phospholipids for PLA2 
hydrolysis during the secondary phase. Additional work has indicated that AA is 
initially incorporated into the nuclear envelope and then shunted in a time-dependent 
fashion into other cellular compartments thus curtailing its availability for release 
(Caprioti et al., 1988). It is possible that one primary role of the transacylase 
enzymes is to limit the availability of AA for release by moving it from the site of 
hydrolysis to other intracellular locations. This type of mechanism may lead to a 
slow decline in free AA as in the secondary phase of AA observed in this system. It 
is likely that the decrease in AA release in response to bombesin may be due to a 
combination of reacylation and transacylation, particularly during the first phase of 
release. The mechanism behind the decline of the second phase may include other 
factors which will switch off PLA2 activation after a certain period. This may 
involve either a negative feedback mechanism exerted via AA itself or possibly the 
activation of a lipocortin-type factor, causing inhibition of the PLA2 response. This 
does not, however, preclude the concept that reacylation and transacylation may also 
be important in this latter phase. It has previously been shown that bombesin- 
stimulated PLC activation is subject to desensitization which may occur at the level
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of receptor or G-protein (Plevin et al., 1990). This may also occur with bombesin- 
stimulated PLA2 activity and may be responsible for switching off the second phase 
of AA release.
The precise nature behind AA turnover in the absence of its metabolism, as 
seen in this system, is dependent upon a complete understanding of the exact role of 
various pathways involved in the regulation of phospholipid fatty acid remodelling 
and fatty acid relocation. Until then, it is only possible to speculate on how this 
occurs in bombesin-stimulated 3T3 cells.
CHAPTER 7
IS ARACHIDONIC ACID A POTENTIAL SECOND 
MESSENGER IN SWISS 3T3 CELLS?
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INTRODUCTION
Results presented in the previous chapters have indicated that the AA
i
response to bombesin in Swiss 3T3 cells isunusualfor a number of reasons: the 
fatty acid is released rapidly from its phospholipid precursor with a timecourse 
comparable to that observed for Ins(l,4,5)P3 generation; the biphasic nature of the 
response provokes questions concerning the mechanism(s) behind release; and the ■ 
lack of metabolism of AA while in the free liberated fatty acid' state presents the 
possibility that AA itself may have some important role within the cell. With 
regard to this, it has been proposed that AA can act as a second messenger 
(Abramson et al., 1991) because it can exert direct effects on signal transduction. 
These responses are elicited by AA itself and not its metabolites.
Second messengers may exert their effects by activating an appropriate 
protein kinase. Previous reports have suggested that AA can activate certain forms 
of PKC (Murakami & Routtenberg, 1985; Nishizuka, 1988 and Shearman et al., 
1989). It also appears that AA can exert important effects on intracellular calcium 
in a variety of systems (Chan & Turk, 1987; Chow & Jondal, 1990 and 
Randriamampita & Trautmann, 1990) and that this may occur independently of 
PKC activation (Alonso et al., 1990). This points to the possibility of AA having a 
similar role to Ins(l,4,5)P3 in stimulating intracellular calcium release. Chow and 
Jondal (1990) have suggested that AA stimulates an increase in cytosolic calcium in 
T cells by mobilising the Ins(l,4,5)P3-sensitive pool through a mechanism 
independent of phosphoinositide turnover. This may suggest a separate yet 
cooperative pathway with Ins(l,4,5)P3 in the regulation of calcium release.
If AA is to be assigned a second messenger role, it must exert biological 
effects at appropriate concentrations. In this chapter, where the potential role of the 
first phase of AA released upon bombesin stimulation was examined, the ^  
concentration of AA produced during this initial phase of release had to be 
determined. Since the amount of AA liberated from phospholipids is quite small, 
in order to accurately quantitate the mass of AA released from cells using standard
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extraction techniques followed by gas liquid chromatography, large numbers of 
cells would be required. For this reason, an alternative method was used (see 
Results).
The work presented in this chapter examines the possibility that the AA 
released in response to bombesin stimulation may be involved in regulating both 
short- and long-term signalling events in Swiss 3T3 cells. The possible 
importance of this pathway as a separate entity and also its potential to interact with 
other transduction pathways is considered.
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RESULTS
The amount of free AA generated in response to bombesin stimulation was 
measured using the 15-HETE assay system described in Chapter 2. This involves 
synthetically converting the AA to 15-HETE using soyabean 15-lipoxygenase and 
measuring the 15-HETE produced with a radioimmunoassay kit. The original 
amount of AA was calculated based on the efficiency of conversion of the enzyme. 
An effective separation system was required for identification of both A A and 15- 
HETE. The methods tested involved bond-elut columns with a solvent system of 
petroleum ether/diethyl ether (9:1 v/v) and methanol for recovery of A A and 15- 
HETE respectively, and also sep-pak C-18 columns using a range of ethanol 
concentrations for elution. Neither of these methods gave satisfactory recovery of 
15-HETE. Therefore, hplc was used with a lichrosorb C -l 8 column and a solvent 
system comprising an increasing gradient of methanol against ammonium acetate 
(0.5%). This proved reliable for separation and identification of both AA and 15- 
HETE. It was also possible, from hplc traces, to calculate the percentage 
conversion of A A to 15-HETE by the 15-lipoxygenase in the relevant experiments. 
Using this system, the retention times for AA and 15-HETE were 11.4 min and 6.2 
min respectively. This is shown in Figure 7.1 (a).
Soyabean 15-lipoxygenase was used to convert the AA produced by 
bombesin stimulation to 15-HETE for radioimmunoassay. Preliminary 
experiments were conducted prior to this to obtain the optimal conditions for 
conversion. These were performed using standard [3H]AA (spec.ac.
200Ci/mmol). 0.6pCi of this was used for reaction with various concentrations of 
the enzyme ranging from lpM to InM in 0.1M borate buffer, pH9.0 for 90 min. 
The reducing agent sodium borohydride was included to prevent HPETE 
formation. A concentration of lOpM gave an optimum conversion rate -  89% of 
AA was converted to 15-HETE over the time tested. Variations in time and 
concentrations did not improve on this. In addition, antibody binding in the 
radioimmunoassay was not affected at this concentration of enzyme whereas at
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concentrations between 50pM and InM, it was substantially reduced. Hplc traces 
demonstrating the enzyme catalysed conversion of A A to 15-HETE are shown in 
Figures 7.1(b) and (c). Higher enzyme concentrations (>100pM) resulted in the 
formation of two DHPETES -  15,15 DHPETE and 8,15 DHPETE with no 15- 
HETE production and were therefore, unsuitable for this assay.
Having established the conditions for the enzyme reaction using standards, 
experimental samples that had been stimulated with bombesin for 30 sec were 
prepared as described in Chapter 2. Since the experiment involved an overnight 
incubation, standards using [3H]AA were prepared alongside samples to control for 
the conversion to 15-HETE. The hplc trace shown in Figure 7.2 is for the 
conversion achieved during this experiment (approx. 85% of AA converted).
Figure 7.3 shows the standard curves obtained with 15-HETE from the 
radioimmunoassay kit and with that from the samples tested. The actual values for 
AA are shown in the table that forms part of Figure 7.3. These show that the 
resting level of A A was approximately 340pg/104 cells and this increased to 
approximately l.ting/lO4 cells in bombesin-stimulated samples.
In order to calculate the concentration of AA produced upon stimulation, it 
is necessary to determine the cell volume. This was achieved using the method 
described in Chapter 2. The mean cell volume obtained from 18 samples was 
155pl/106 cells. Using this value, basal concentrations of AA were calculated to be 
0.85 ± 0.32pM and stimulated values were 4.1 ± 2.8pM. This is an increase of 
4.7-fold upon agonist stimulation which correlates well with results obtained in 
Chapter 4. It is worth noting that these concentrations are very similar to those 
obtained for the second messenger Ins(l,4,5)P3 in a study by Cook et al (1990). 
These values relate to the first phase of AA release in response to bombesin 
stimulation. .The second phase of release appears to be of greater magnitude and, 
as a result, will probably induce a greater increase in AA concentration.
As previously mentioned, AA may be involved in both long-term and 
short-term intracellular effects. The present study has examined both of these
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possibilities. AA may play a role in mitogenesis, therefore, the effect of the fatty 
acid on DNA synthesis was examined. This may reflect its importance in long­
term cellular events. In addition, its involvement in short-term responses was 
studied by examining the effect of exogenously added AA on intracellular calcium 
levels.
Initially, the ability of AA to act as a co-mitogen was studied. AA has 
previously been shown to stimulate DNA synthesis in Swiss 3T3 cells (Takuwa et 
al., 1988) and this has been suggested to occur via PKC activation. In the present 
study, the effect of exogenously added AA oh both insulin-stimulated and EGF- 
stimulated [3H]thymidine incorporation was examined. As shown in Figure 7.4, 
treatment of cells with 30pM A A alone had no effect. Insulin (0.2pM) and EGF 
(lOnM) also promoted little thymidine incorporation. However, addition of 30pM 
AA together with these agonists, enhanced the incorporation of [3H]thymidine 
achieved. Figure 7.5 shows the effect of increasing concentrations of AA on 
EGF-stimulated thymidine incorporation. The increase in response is evident at 
IOjjM AA and maximal between 30-1 OOgM AA, concentrations which may 
correspond to those obtained in the second phase of bombesin-stimulated AA 
release. It has previously been shown by Takuwa et a l  (1988) that other 
polyunsaturated fatty acids such as oleic acid and linoleic acid are ineffective in 
stimulating thymidine incorporation. Therefore, this effect may be specific for AA.
To examine a role for A A in a short-term response, the effect of 
exogenously added AA on intracellular calcium levels was investigated. Cells were 
loaded with the calcium indicator dye, Indo-l-AM, as described and stimulated 
with various concentrations of AA ranging from 10|iM to lOOpM, the lower value 
being very close to that generated during the first phase of release in response to 
bombesin stimulation (see previously). Figure 7.6(a) shows that 10pM AA is
j
capable of generating an increase in the intracellular calcium concentration and may 
imply that the initial phase of bombesin-stimulated AA release plays such a role.
The responses obtained were very variable between experiments as illustrated in
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Figure 7.6(b) where a single dose of 50gM AA was added to different cell 
populations. The time taken for calcium to peak ranged from 5 sec to 3 min after 
addition of AA. This may illustrate differences in the sensitivity of calcium stores 
to AA between populations or may reflect differences in the time of entry of the 
fatty acid. The duration of the response varied between that of a transient peak, 
similar to the bombesin-stimulated changes in calcium, and a more sustained 
increase. The effect on intracellular calcium due to AA was dose-dependent as 
shown in Figure 7.7. An obvious problem with these experiments is the inability 
to mimic exactly the changes in the intracellular concentration of AA induced by an 
agonist. The increase in calcium levels in response to A A within Swiss 3T3 cells 
may not be dependent on the steady state concentration of AA within the cells, but 
rather on the rate of rise of the intracellular AA concentration which is rapid as 
illustrated in Chapter 4. This is a problem when using exogenous AA which 
would enter the cell more slowly than required and may be metabolised quickly. 
Figure 7.8 illustrates (a) the effect of AA (30pM) pretreatment on bombesin- 
stimulated increases in calcium and (b) the effect of bombesin (lOnM) pretreatment 
on AA-stimulated increases in intracellular calcium. Addition of 100/iM AA for 2 
min prior to bombesin stimulation caused a slight decrease in the bombesin- 
stimulated increase in calcium levels. This could be due to A A causing calcium 
release from Ins(l,4,5)P3 regulated stores, which would be reflected in the 
bombesin response, making it slightly smaller. It may even be possible that AA -  
induced calcium release from an Ins(l,4,5)P3-insensitive store affects the 
bombesin response in some manner. The effect of bombesin pretreatment 
followed by AA is shown in Figure 7.8(b). The AA-stimulated change in 
intracellular calcium concentration is almost completely abolished in cells that have
already received bombesin treatment, (although in view of the marked variability ’
of AA responses alone,this should be inteipreted with caution). This may reflect
the fact that the intracellular AA levels) generated by bombesin have already promoted
an increase in the intracellular calcium concentration and are still sufficiently high that
further treatment with AA has no effect. Alternatively,the AA-sensitive stores may not
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have been given sufficient time to refill after the challenge with bombesin. It is not 
possible to tell from these experiments whether AA releases calcium from 
Ins(l,4,5)P3-sensitive stores, or from completely separate stores. More sensitive 
measurements, involving single cell studies, would be required to answer this.
Since increases in the intracellular calcium concentration are usually 
associated with formation of the second messenger Ins(l,4,5)P3, it was important 
to consider in the present study whether exogenously added AA caused an increase 
in phosphoinositide hydrolysis, leading to Ins(l,4,5)P3 formation. This could 
explain the observations achieved. The effect of increasing concentrations of AA 
on total inositol phosphate production was therefore examined (Fig.7.9) and it was 
found that concentrations of 30pM and above caused stimulation of inositol 
phosphate production, although even at IOOjiM AA there was only a 1.6-fold 
increase.
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Figure 7.1 Conversion of arachidonate to 15-HETE using 
soyabean 15-Iipoxygenase
(a) a representative hplc chromatogram of AA and 15-HETE standards, (b) a 
chromatogram of AA before enzyme treatment and (c) the same sample after a 90 
min treatment with lOpM 15-lipoxygenase in 0.1M phosphate buffer, pH7.4. 
Isocratic solvent system; methanol 68.7% (methanol 20%/0.5% ammonium acetate 
80%) 31.3%. Flow rate 2ml/min.
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Figure 7.2 Conversion of the arachidonate produced in 
bombesin-stimulated 3T3 cells to 15-HETE
A typical hplc chromatogram of AA and 15-HETE present in samples 
stimulated with 617nM bombesin for 30 sec and treated with 15-lipoxygenase as 
described in Materials and Methods section. Results are from a single typical 
experiment where n=3.
15-HETE AA
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Figure 7.3 Standard curve for 15-HETE produced in 15- 
lipoxygenase treated samples
A typical standard curve for 15-HETE standards (8-312.5pg/tube) ( • )  and 
15-HETE produced in lipoxygenase treated samples (*>) as measured using a 15- 
HETE radioimmunoassay. Results are from a single typical experiment where n=3.
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Table 7.1 Differences in 15-HETE production between 
bombesin-stimulated and control samples
Values obtained from the standard curve are shown for samples diluted 2 - 
fold to 16-fold in both control and bombesin-stimulated cells. Values are 
expressed as ng/104 cells. These values have been corrected to allow for the 
percentage conversion achieved. This is a single typical experiment representative 
of two others.
Sample %B0/TC %B/B0 pg/tube ng/10^cells
TC
NSB
B0 35.4
control
bombesin
control(~2)
bombesin(~2) -
control(~4) 27.1 72 0.28
bombesin(~4) 1.5 600 2.4
control(~8) 37.2 45 0.36
bombesin(~8) 5.9 250 2.0
control(~16) 71.0 23 0.37
bombesin(~16) 23.3 75 0.9
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Figure 7.4 Effect of arachidonate on EGF-stimuiated and 
insulin-stimulated [3H]thymidine incorporation
Confluent? Swiss 3T3 cells were incubated with 0.5pCi/ml [3H]thymidine 
and the indicated agonist for 24h. The effect on thymidine incorporation is shown. 
Results are expressed as means ± S.D. from a single typical experiment where n=3.
EGF+AA
CONTROL
300000200000100000
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Figure 7.5 Dose-dependence of the effect of arachidonate on 
EGF-stimulated [3H]thymidine incorporation
[3H]thymidine labelled cells were incubated with EGF(lOnM) and increasing 
concentrations of AA for 24h. The results are expressed as means ± S.D. from a 
single typical experiment where n=3.
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Figure 7.6 Variations in arachidonate-stimulated increases in 
intracellular calcium concentration
Swiss 3T3 cells, grown on glass coverslips, were loaded with 5gM Indo-1- 
AM and stimulated with (a) IOjiM, (b) 50pM AA. changes in calcium, as indicated 
by the fluorescence ratio, were measured as described in the Methods section. 
Results are from single experiments typical of three.
N.B. The limited solubility in aqueous solutions towards the higher range of AA 
concentrations tested suggests that results with such concentrations should be 
interpreted with caution.
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Figure 7.7 Dose-dependence of arachidonate-stimulated changes 
in intracellular calcium
3T3 cells, loaded with 5jiM Indo-1 were stimulated with increasing 
concentrations of AA. Changes in calcium were monitored as described in the 
Methods section. Results are from single experiments typical of three.
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Figure 7.8(a) Effect of arachidonate pretreatment on bombesin- 
stimulated calcium release
Swiss 3T3 cells, loaded with 5|iM Indo-1, were stimulated with lOOpM AA 
then washed in HBG for 3 min and stimulated with lOOnM bombesin. Changes in 
intracellular calcium were measured as described in the Methods section. Results 
are from single experiments typical of three.
Figure 7.8(b) Effect of bombesin pretreatment on arachidonate- 
stimulated calcium release
Swiss 3T3 cells, loaded with 5pM Indo-l-AM, were stimulated with 
lOOnM bombesin then washed for 3 min in HBG. This was followed by 
stimulation with lOOpM AA. Changes in intracellular calcium were measured as 
described. Results are from single experiments typical of three.
1 
m
in
o>
O l
001 3
3
COOl3
3
IDc
J3 9
a  $o
CD 
3  O 
CD
N>
OO
3
COo
3cr
CD0)
5*
2 
m
in
169
Figure 7.9 Effect of increasing concentrations of arachidonate 
on total inositol phosphate production
[3H]inositol labelled cells were incubated with increasing concentrations of 
AA in a buffer containing lOmM LiCl. Each point represents the mean ± S.D. of 
triplicate determinations from a single typical experiment where n=3.
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DISCU SSIO N
It is becoming increasingly obvious that the term 'second messenger' may 
encompass a wider range of substances than previously thought. Results 
presented in this chapter suggest that AA, produced in response to bombesin 
stimulation, may play such a role in Swiss 3T3 cells. The concentration of AA 
produced during the first phase of release is in the low micromolar range. This is 
similar to the concentration of Ins (1,4,5)P3 required to stimulate an increase in the 
intracellular calcium concentration in Swiss 3T3 cells.
AA can be formed at an 'upstream' or 'downstream' site. The first site is 
directly linked to a ligand-receptor -  G protein complex as described by Burch et 
al. (1986). The second site is distal to the receptor complex and requires elevation 
of intracellular calcium and activation of PKC (Irvine, 1982). Both types of A A 
release are evident in the bombesin-stimulated Swiss 3T3 cell and may contribute to 
A A playing the role of a multifunctional compound. In this context, AA appears to 
be involved in exerting both long- and short-term cellular responses, namely DNA 
synthesis and intracellular calcium mobilisation. The apparent concentration of AA 
produced in response to bombesin during both phases may be sufficient for each of 
these responses to occur.
From results obtained in the present study (Figs. 7.4 & 7.5), it appears that 
the mitogenic action of bombesin is partly due to the release of AA which may 
stimulate DNA synthesis in a cooperative manner with other intracellular signalling 
pathways. This has been suggested in other studies on Swiss 3T3 cells (Gil et al., 
1991; Takuwa et al., 1991) and indicates the potential importance of this pathway 
in cell proliferation. However, it is difficult to directly relate results obtained with 
exogenously added AA to those achieved with intracellularly-generated AA. 
Addition of AA to the cells may cause general membrane perturbation and increased 
permeability which may affect the interpretation of results. Although this factor 
was not examined in the present study, previous work by Chow & Jondal (1990)
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has shown that concentrations of up to 50jiM AA did not affect membrane integrity 
of T cells as judged by 51Cr release.
The ability of A A to cause intracellular calcium mobilisation (Fig.7.6) may 
be a more general phenomenon than initially thought since similar effects have been 
reported in other systems (Wolf et al., 1986; Chow & Jondal, 1990). The calcium 
mobilisation observed here may be an intrinsic activity of the fatty acid itself. 
However, to rule out the possibility that AA metabolites are involved, inclusion of a 
cyclooxygenase inhibitor such as indomethacin would be useful. Hokin (1985) 
has suggested that AA itself stimulates an increase in intracellular calcium based on 
the large amounts of unmetabolised AA and the relatively small amounts of AA 
metabolites released by other stimuli in other systems. The possibility exists, 
however, that the increase in intracellular calcium observed is due to entry of 
exogenous AA rather than mobilisation of intracellular AA. As stated previously, 
this is a problem when attempting to mimic intracellular events with exogenously 
added substances.
The mechanism by which AA induces an increase in the intracellular calcium 
concentration in 3T3 cells is unclear. Various possibilities exist, AA may interact 
directly with the endoplasmic reticulum membrane and induce calcium permeability. 
Alternatively, it may act on the calcium sequestration or release mechanism, thus 
disrupting the balance between the rates of uptake and leakage of calcium across the 
endoplasmic reticulum membrane. This cycling of calcium is a rapid process and 
disturbing the equilibrium via inhibition of the calcium pump could elevate 
intracellular calcium. Whether the calcium released in this system by AA is from 
an Ins(l,4,5)P3-sensitive pool is not known, although this possibility has been 
suggested by Chow and Jondal (1990) in T cells. An obvious possibility is that 
AA causes calcium release indirectly by stimulating production of Ins(l,4,5)P3. 
Although exogenously added AA causes a slight increase in phosphoinositide 
hydrolysis (Fig.7.9), it is possible to dissociate this from involvement in A A - 
induced increases in intracellular calcium by stating two important observations
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from the present studies. At concentrations which do not stimulate 
phosphoinositide hydrolysis i.e. <30pM, an increase in intracellular calcium is still 
observed with AA. Furthermore, the maximum degree of stimulation of 
phosphoinositide hydrolysis achieved with AA is smaller than that achieved with 
2nM bombesin which stimulates a smaller increase in intracellular calcium levels 
than that achieved with 50pM AA.
It is conceivable that AA may promote calcium release from, as yet, 
unidentified stores. The possibility exists that different types of rapidly 
exchanging calcium stores exist with different release mechanisms and possibly 
different molecular components. In PC 12 cells, two different mechanisms have 
been suggested to co-exist in the same store (Meldolesi et al., 1991). Use of 
antibodies against the Ins(l,4,5)P3 receptor has indicated the existence of novel 
structures termed calciosomes which exclude certain components of the 
endoplasmic reticulum and may be an important source of alternative calcium 
stores. Two situations may exist, one in which there are areas of the cell 
containing calcium stores that could respond exclusively to AA and act 
independently or cooperatively with the Ins(l,4,5)P3-sensitive stores in response 
to particular stimuli; the other in which one type of store responds to both AA and 
Ins(l,4,5)P3 depending on the stimulus. This theory lends credence to the 
possibility that different agonists may promote calcium release via different 
mechanisms and may not depend entirely on Ins(l,4,5)P3 production. A situation 
may then be envisaged in which a ligand will induce AA release without enhancing 
phosphoinositide turnover and still activate similar intracellular pathways (calcium 
release and PKC activation). This has already been demonstrated in neutrophils 
stimulated with LTB4 (Volpi et al., 1984) and in Swiss 3T3 cells stimulated with 
mastoparan (Gil eta l., 1991).
In releasing calcium, AA may have a positive effect on the biochemical 
pathway responsible for its own formation. The second phase of AA release is 
calcium-dependent and may be sensitive to the calcium released during the first
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phase. This type of mechanism may allow AA to propagate the initial bombesin 
signal and highlights the possibility of an AA cycle' existing in the cell.
The possibility that AA may activate PKC in Swiss 3T3 cells has not been 
examined in the present study. It is known that Swiss 3T3 cells contain the a-iso 
form of PKC although the existence of other isoforms is uncertain. A major 
obstacle to assignments of a physiological role for AA in PKC activation is the very 
high concentration needed for enzyme activation (Naor, 1991). However, the p 
and y isoforms at least, may be activated by more physiological concentrations of 
the fatty acid. The possibility exists that AA may act independently or in 
cooperation with DAG in promoting PKC activation in 3T3 cells. This has been 
suggested in other systems (Shearman et al., 1991; Lester et al., 1991) and may be 
accomplished either via modification of the DAG binding site or by alteration of the 
physical properties of the membrane such that more of the enzyme is activated. 
These studies indicate that PKC is under more widespread regulation than 
previously recognised.
The inclusion of AA as a second messenger in Swiss 3T3 cells may have 
certain advantages for the cell. It will increase the cells options in the way it 
responds to a particular agonist and will also allow an increased potential for control 
over a particular response. Both of these facts may be of extreme importance not 
only in the normal functioning of the cell but also in the behaviour of the cell in 
abnormal or diseased states.
CHAPTER 8 
CONCLUSIONS
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CONCLUSIONS
Contrary to long-standing belief, the present study demonstrates that PLA2 
activation may occur independently and in parallel with PLC and may be a 
signalling pathway generating the ’second messenger’ AA. This may act 
independently or in cooperation with the more well established messengers 
Ins(l,4,5)P3 and DAG to promote, for example, mitogenesis. Results presented in 
Chapter 7 suggest that AA is present in micromolar levels in stimulated cells. This 
is sufficient to promote an increase in the intracellular calcium concentration and 
may possibly exert other intracellular effects yet to be examined. The iack of 
metabolism of AA at early time points of bombesin stimulation in 3T3 cells 
suggests that any rapid intracellular effects will be due to the fatty acid itself. Many 
previous studies have shown little scope when examining this pathway and have 
avoided detailed studies on the timing of AA release and the potential for 
metabolism in agonist-stimulated cells (Burch & Axelrod, 1987; Slivka & Insel, 
1988; Miller & Rozengurt, 1990). The studies presented here suggest that in 
response to bombesin, free AA can be generated intracellularly at least as fast as 
Ins(l,4,5)P3 and DAG. In addition, this AA is not metabolised. Information 
presented in Chapter 6 addresses the capacity of 3T3 cells to metabolise AA.
PGE2 can be produced after longer (>10 min) stimulation with bombesin and may 
therefore play a role at later stages of the response. No lipoxygenase products are 
formed in response to bombesin. However, this may be due to limitations of the 
agonist rather than of the cell since information presented in Chapter 6 suggests 3T3 
cells possess lipoxygenase enzymes which are, nevertheless,, substantially less 
active than those in inflammatoiy cell types. It is highly possible though that these 
enzymes can be activated in 3T3 cells via certain agonists whose physiological 
effects may require stimulation of this metabolism. The potential of the PLA2/AA 
pathway to generate an array of different metabolites offers huge scope for different 
intracellular actions in various cell types. In 3T3 cells this may even be extended to
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differences in metabolite production between phases of release within the same cell, 
perhaps to different agonists.
This diversity of actions offered by the PLA2/AA pathway may be further 
increased when considering the potential for interaction with other transduction 
pathways stimulated by bombesin. The pattern and timing of these early signals 
may be important in the generation of later events. The degree of interdependence 
between PLA2, PLC and PLD may vary between cell types and agonists and may 
indicate important differences in long-term responses. A hierarchy of importance 
in the timing of activation of certain pathways may exist. For example, in some 
situations PLC would have to be activated first, leading to subsequent PLA2 and 
PLD activation. In contrast, some agonists may activate PLA2, PLC and PLD 
independently yet in parallel. This may require increased regulation in the coupling 
mechanism between the receptor and effector systems. Another scenario exists 
whereby PLA2 may be activated initially, possibly leading to PLC and/or PLD 
activation. Systems are now being identified in which particular agonists stimulate 
AA release but not Ins(l,4,5)P3 production and still generate a mitogenic response 
(Kaya etal., 1987; Gil et al., 1991; Stewart & Wakelam, unpublished data). It 
therefore appears that different degrees of emphasis may be placed on PLA2 
activation depending on the situation. The regulatory factors important in 
activation may also differ between agonist and/or cell type. Chapters 3,4 and 5 
examined several of these factors in 3T3 cells.
The biphasic nature of the AA response discussed in Chapter 3 generates 
questions regarding the underlying mechanism and relative importance of each 
phase. The initial phase appears to depend on activation of a PtdCho-specific 
PLA2 which may be under direct receptor-mediated activation via a specific G 
protein (see Chapters 4 and 5). The identity of the PLA2 and G protein involved is 
not known, but it is possible to speculate on the existence of a high molecular 
weight cytosolic form of the enzyme such as that reported by Clark et al. (1991) 
and Kramer et al. (1991). The unavailability of antibodies to this enzyme until
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recently has prevented identification of CPLA2 in this study. However, this would 
be of high priority in future work. On this note, Leslie(unpublished data) has 
identified at least one form of CPLA2 in Swiss 3T3 cells. Whether the enzyme is 
purely cytosolic or whether it may interact with the cytoskeleton remains to be 
confirmed.
Studies described in Chapter 5 performed on permeabilised 3T3 cells 
suggest the involvement of a G protein in PLA2 activation. As previously 
mentioned, the identity of this protein and its relationship to the G protein coupled 
to PLC in this system remains unknown. Experiments using antibodies to Gp may 
provide information regarding the latter. This type of experiment would be of 
importance in strengthening the argument that PLA2 and PLC are independently 
regulated in bombesin-stimulated 3T3 cells. The lack of effect of calcium on the 
initial phase of AA release suggests an enhanced sensitivity of the PLA2 involved to 
calcium. This is an important observation since PLA2 has been characterised as a 
calcium-dependent enzyme. Perhaps direct regulation via a specific G protein, as 
in the first phase of bombesin-stimulated AA release, confers an increase in 
sensitivity upon PLA2, making it less dependent on, or independent of regulatory 
factors that may be more important at later stages of the response. Certain 
regulatory factors, such as calcium in this case, may be necessary for prolonging or 
sustaining the response rather than for its initiation. This may be analogous to the 
activation of PKC whereby DAG increases the affinity of the enzyme for calcium 
and PtdSer.
The strikingly different regulatory requirements of the two phases of AA 
release as described in this study, raises the possibility that isoforms of PLA2 may 
exist in Swiss 3T3 cells. This has already been suggested in other systems (see 
Chapter 3) where differences in substrate specificity and regulatory requirements 
exist In Swiss 3T3 cells, it is not certain whether different phospholipid 
substrates are required for the two phases. Detailed examination of the changes in
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A A content of all the major phospholipids after bombesin stimulation would be 
required for the second phase of release before drawing any conclusions.
In the present system, it would be of interest to investigate the effect of 
abolishing one of the phases of release (the first phase) to provide an insight into 
how the two phases interact and whether there is any degree of interdependence.
On this note, if isoforms of PLA2 are present, a complete understanding of their 
respective biological functions is contingent on the development of isoform-specific 
inhibitors and rapid methods of separation. The ability to control which forms of 
the enzyme are activated would enable a better understanding of the importance of 
different phases of AA release, such as those described here. It is interesting to 
consider why the cell produces this biphasic response, possibly with the 
involvement of different PLA2 isozymes. It is possible, as mentioned earlier, that 
the pattern of early signals is important in leading to later cellular effects i.e. the 
early AA response to bombesin may be essential for the secondary phase to occur. 
In addition, the different phases may regulate separate events within the cell or 
perhaps the secondary phase is simply an amplification of the first, leading to a 
higher, sustained level of free AA available to the cell. Multiple pathways of PLA2 
activation within a cell which may operate in a parallel or sequential manner may 
prove to be a more widely-used mechanism important in cellular proliferation.
Perhaps the normal functioning as well as the potency of a mitogen depends 
on its ability to stimulate both PLA2 and PLC activities -  two potentially 
independent pathways which, in this system, may or may not only act to amplify 
one another but may also be capable of a less potent effect individually. In this 
context, the 'messenger’ type responses induced by AA in the Swiss 3T3 cell are 
subject to extensive cross-talk from other transduction pathways. For example, 
bombesin-stimulated calcium mobilisation may occur via products of both PLA2 
and PLC activation, promoting release from similar or separate pools. It is also 
possible that bombesin-stimulated PKC activation may be subject to regulation by 
products of PLA2, PLC and PLD hydrolysis. The effect of AA on PKC activity in
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3T3 cells has yet to be demonstrated. However, it is possible that DAG, produced 
from different phospholipid substrates via PLC and PLD, may act in synergy with 
AA as previously described (see Introduction and Chapter 7) to regulate the activity 
of different isoforms of PKC.
The mechanism underlying agonist activation of PLA2 obviously varies 
between cell types. However, the possibility must be considered that ligand 
stimulation of certain receptors may be linked directly to PLA2 activation causing 
generation of the 'second messenger' AA. This may prove to be a multi-faceted 
messenger and could perhaps even be involved in regulation of PLA2 activity itself. 
For example, in the bombesin-stimulated 3T3 cell, AA released in the first phase 
may be involved in regulation of the second phase of release. These suggestions 
may also be relevant to other cellular systems since the increased importance of the 
PLA2/AA pathway in mitogenesis, as suggested here, could prove to be more 
widespread. As such, the present emphasis on PLC as the major effector in 
generation of intracellular signals could shift and lead to a re-evaluation of the 
importance attached to other signalling pathways in regulating cellular proliferation.
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